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The surgical treatment of peripheral arterial disease has progressed
significantly over the past 40 years. Newer non-invasive methods of treatment have
augmented traditional open surgical procedures, and in recent years blood
rheology, thrombotic mediators, and white blood cell activation have all been
associated with peripheral arterial disease.
This thesis was undertaken in an attempt to define more clearly the role of
some of these variables in peripheral arterial occlusive disease. In particular I
aimed to determine if alterations in blood rheology and potential thrombotic
mediators were related to the severity of arterial disease; and whether or not they
were affected by therapeutic intervention in the form of infra-inguinal bypass
grafting. The ability to readily determine the patency of these grafts by a variety of
non-invasive techniques has enabled accurate determination of the outcome of
infra-inguinal grafting. Therefore baseline levels and serial changes in blood
rheology and thrombotic mediators following revascularisation were related to the
outcome following surgery in a large number of patients.
In addition I was interested in the effects of percutaneous angioplasty on
these variables, as this procedure is now the main treatment in patients with an
appropriate distribution of disease, and the response of the blood to angioplasty,
which causes endothelial injury, may offer clues to the aetiology of arterial lesions
in peripheral arterial disease.
It is to be hoped that a greater understanding of the biochemistry of
peripheral arterial disease, both prior to and following revascularisation
procedures, may lead to new therapeutic approaches offering a means of improving
the results of such procedures.
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ABSTRACT
Rheological parameters and levels of plasma fibrinogen, cross-linked fibrin
degradation products (FDP's), von Willebrand Factor antigen (vWF), factor VII,
and Plasminogen Activator Inhibitor (P.A.I.), were found to be altered in 219
patients with occlusive arterial disease undergoing revascularisation procedures,
when compared with an age-matched random population sample. Elevated levels of
some of these potential thrombotic mediators were associated with the angiographic
severity of arterial disease on univariate analysis, while multivariate analysis
indicated that log(FDP) was independently related to disease severity, while other
thrombotic mediators showed a non-significant trend towards independent
association.
Surgical relief of critical limb ischaemia in 82 of these patients returned the
alterations in blood rheology to control levels, but plasma fibrinogen, vWF,
P.A.I., and FDP levels remained significantly higher than in the population
controls.
Percutaneous angioplasty in 40 cases was associated with transient
alterations in vWF and Tissue Plasminogen Activator (t.P.A.) levels in arterial
blood that may be a consequence of endothelial injury, and with a significant
elevation in cross-linked FDP levels 3 months after successful angioplasty. This
alteration in fibrin turnover may be related to restenosis following angioplasty.
Elevated pre-operative plasma fibrinogen, vWF, and FDP's, were
associated with graft occlusion and patient death on univariate analysis of 186
consecutive infra-inguinal bypass grafts. Multivariate analysis indicated that pre¬
operative plasma von Willebrand Factor levels (p < 0.001), systolic ankle
pressure (p < 0.01), female sex (p = 0.03), and limb sepsis (p = 0.01), were all
independently predictive of graft occlusion and patient death within 1 year
following surgery.
The studies undertaken in this thesis indicate that altered levels of potential
thrombotic mediators found in peripheral arterial disease are not reversed by limb
revascularisation, and that more marked alterations are associated with a poor
outcome following surgery. The results suggest that alterations in levels of potential
thrombotic mediators are not a consequence of tissue ischaemia, and may be
directly involved in the pathogenesis of arterial occlusion. Pre-operative
determination of these mediators may assist in patient selection for infra-inguinal
revascularisation surgery, while adjunctive therapy aimed at correcting these






Peripheral vascular disease encompasses the clinical conditions that arise as
a consequence of the thickening and hardening, or "arteriosclerosis", of major
peripheral arteries. There are a number of pathological processes that lead to
arteriosclerosis, but the commonest is atheroma, which can give rise either to
narrowing and eventual occlusion of vessels, or to dilatation and aneurysm
formation (Walter & Israel, 1987B). It is this narrowing of major peripheral vessels
by atheroma that leads to the development of peripheral arterial occlusive disease
(PAOD).
A significant number of the population with objectively defined peripheral
arterial occlusive disease are asymptomatic, or fail to consult a medical practitioner
with their symptoms (Hughson et al, 1978, Fowkes et al, 1991). Those patients
who present with symptomatic occlusive arterial disease, usually present with the
symptoms of chronic ischaemia, ranging from intermittent claudication through rest
pain to tissue necrosis and gangrene.
Most patients with PAOD who consult a medical practitioner, present with
a history of leg pain on exertion that is relieved immediately on stopping walking
(intermittent claudication) (Hertzer, 1991). This pain characteristically recurs at
a similar distance each time walking is resumed (Clain, 1986). The distance walked
to the onset of pain (the claudication distance) can be used as a rough guide to the
severity of the arterial disease.
Intermittent claudication commonly occurs in the calf, but can also occur in
the thigh or buttock, depending on the distribution of the arterial occlusive lesions,
which have been shown to be in the superficial femoral or popliteal segments in up
to 70% of patients (Bloor, 1961). The pain in claudicants reflects the inability of a
diseased peripheral arterial tree to meet the increased blood flow requirements of
exercising muscles, resulting in the accumulation of metabolites, possibly kinins,
that stimulate pain receptors in the muscles (Cotton, 1983).
More advanced occlusive arterial disease presents with more advanced
features of tissue ischaemia, which ultimately lead to tissue necrosis and gangrene
(Figure 1.1). These patients often give a history of prior intermittent claudication
before presenting with calf and foot pain at rest, typically more severe at night as a
consequence of the decreased cardiac output during sleep, and the increased
metabolic demands of tissues that have been warmed under the blankets (Clain,
1986). This rest pain may be temporarily relieved by adopting the dependent
posture, but these symptoms of chronic pain in patients with occlusive arterial
23
Figure 1.1: Gangrenous foot resulting from peripheral arterial occlusive disease.
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disease herald the onset of critical limb ischaemia (European Working Group on
Critical Limb Ischaemia, 1990), which if untreated will progress to tissue necrosis
and gangrene.
A small number of patients present with an acutely ischaemic limb: a
painful white leg associated with absence of peripheral pulses and diminished skin
sensation in the limb. These patients have sustained an acute occlusion of a major
limb vessel in the absence of the adequate collateral flow, which commonly
develops in chronic occlusions (Krupski & Effeney, 1988). In these situations,
prompt revascularisation is required to salvage the limb.
Patients with acute arterial occlusion have either occluded a relatively
healthy vessel with embolic material from a distant source such as atrial thrombi in
patients in atrial fibrillation (Cotton, 1983), sustained a haemorrhagic dissection
beneath a pre-existing plaque (Krupski & Effeney, 1988), or have developed
further thrombosis on pre-existing atheroma (Walter & Israel, 1987B).
The first group of patients, who account for up to 75% of patients
presenting with acute lower limb ischaemia (Clason et al, 1989), can be
revascularised by early Fogarty embolectomy, with few long-term sequelae. The
remaining patients however, have significant underlying occlusive arterial disease,
and the development of acute critical limb ischaemia makes early revascularisation
surgery mandatory if the limb is to be saved.
EPIDEMIOLOGY OF PERIPHERAL ARTERIAL DISEASE
Incidence and prevalence
The true prevalence of peripheral arterial disease in the community is
poorly documented, although recent population studies suggest a prevalence rate
for intermittent claudication of between 2% and 14% depending on the population
studied and the age of the study group (Fowkes, 1988, Fowkes, 1990, Gillum,
1990). The Edinburgh Artery Study (Fowkes et al, 1991) found a prevalence rate
for intermittent claudication of 4.5% in a cross section of the Edinburgh population
aged 55 to 74 years. In addition the study found that 8% of the population had
evidence of major asymptomatic disease, as determined by resting ankle brachial
pressure indices (ABPI) of less than 0.9, together with a negative response to the
W.H.O. questionnaire on intermittent claudication. This combined figure of 12.5%
of the population with a haemodynamically significant impairment of peripheral
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circulation represents the only currently available estimation of the disease
prevalence in a Scottish population.
These figures are comparable to the prevalence rate for peripheral arterial
disease of 11.7% reported in a geographically defined white population in Southern
California (Criqui et al, 1985). The prevalence of symptomatic disease as manifest
by intermittent claudication, was however lower at 2.2% for men and 1.7% for
women, and a similar incidence of claudication was reported in an English study
(Hughson et al, 1978) in which the diagnosis was based on a history of leg pain on
exertion, and a resting ABPI of less than 0.75. However a resting ABPI of less
than 0.9 has been shown to be 95% sensitive in detecting disease (Laing &
Greenhalgh, 1983), suggesting that this study underestimated the incidence of
intermittent claudication in the population examined.
All the population studies that have examined the incidence and prevalence
of peripheral arterial disease have noted that both symptomatic and asymptomatic
disease increase with age, and that, although the prevalence of disease in younger
people is higher in men, the prevalence rate is similar for both sexes in older
populations (Rose, 1991).
Aetiological factors
Epidemiological and population studies have identified a number of factors
that appear to be related to the development of peripheral vascular disease. A high
level of cigarette smoking is the most consistent finding amongst patients with
peripheral arterial disease, and the relative risk of disease in smokers compared
with non-smokers ranges from 1.4 to 7.5 (Fowkes, 1988). Persistent smoking has
also been associated with graft failure following reconstructive surgery (Wiseman
et al, 1989).
Diabetes mellitus is associated with an increased risk of developing arterial
disease (Walter & Israel. 1987B), but additionally, some studies have suggested
that patients with glucose intolerance are at increased risk of developing
peripheral arterial disease (Fowkes, 1988), however there are conflicting results
from other studies (Hughson et al, 1978).
Elevated serum cholesterol and triglyceride levels in patients with
peripheral arterial disease, have been demonstrated in some studies, although there
are conflicting results (Greenhalgh et al, 1971, Kakkar & Stringer, 1990, Leng and
Fowkes, 199IB), despite evidence that lowering serum lipid levels leads to
regression in peripheral atherosclerosis (Barndt et al, 1977, Duffield et al, 1983).
There is stronger evidence that low HDL cholesterol levels are an important risk
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factor (Meerloo & Billimoria, 1979, Leng & Fowkes, 1991B), and also evidence
that lipid peroxides are elevated in patients with arterial occlusive disease
(Stringer et al, 1989). Some of the changes in the lipid profiles of patients with
peripheral vascular disease may however be related to cigarette smoking (Craig et
al, 1989).
There are some studies that suggest a role for hypertension in the aetiology
of peripheral arterial disease (Hughson et al, 1978), however this has not been a
uniform finding (Fowkes, 1988). The potential aetiological roles of fibrinogen and
other haemostatic and rheological factors are covered in more detail elsewhere
in this chapter.
NATURAL HISTORY OF PERIPHERAL VASCULAR DISEASE
The natural history of asymptomatic peripheral arterial disease is poorly
documented, although there is some evidence from small studies to suggest that
between 30 and 47% of asymptomatic patients will develop intermittent
claudication within 4 years of the disease being detected (Strandness 1966, Laing &
Greenhalgh, 1983). The natural history of intermittent claudication, and the fate of
claudicants is however, more fully documented.
Mortality
The finding common to all studies of the natural history of intermittent
claudication, is the greatly increased mortality in claudicants (Table 1.1), as a
consequence of myocardial ischaemia and cerebrovascular events, and claudicants
have a mortality rate twice that of the normal population (Kannel et al, 1970,
O'Riordan & O'Donnell, 1991). The 5 year survival for the claudicant aged 65-74
appears to be around 60%, dropping to 20% at 10 years (Bloor, 1961), and the
overall mortality rate for any group of claudicants is 30-35% at 5 years
(Rosenbloom et al, 1988, O'Riordan & O'Donnell, 1991), and 50% at ten years
(Dormandy, 1991). The mortality rate for patients presenting with more advanced
disease in the form of critical limb ischaemia is higher than that for claudicants,
with a 5 year mortality rate of 50% (Norgren, 1990).
Disease progression
A patient with intermittent claudication surviving 5 years, has a 25 % chance
of developing a further "clinically detectable" arterial occlusion (Bloor, 1961) and
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STUDY No. of patients Mortality rate
Bloor (1961)
Singer & Rob (1960)
Kannel et al (1970)
Rosenbloom et al (1988)
Dormandy (1991)
O'Riordan (1991)
1,476 46% at 10 yrs.
322 23% at 5yrs.
125 x2 over 14 yrs
378 50% at 8 yrs.
1,969 4.3% per annum
112 33%at5yrs.
Table 1.1: Crude mortality rates in patients with intermittent claudication.
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a 7% chance of requiring above-knee amputation. In the same study over 50% of
surviving claudicants noticed an improvement in their symptoms, while over a 3
year period, 56% of claudicants in one study improved or remained static (Singer
& Rob, 1960).
Other reports of the fate of patients with symptomatic occlusive arterial
disease show a similar pattern of events (McDaniel & Cronenwett, 1989), while a
recent prospective study found a major amputation rate of 1.6%, and an
intervention rate of 5.6%, in 1969 claudicants over 1 year (Dormandy & Murray,
1991). Over a longer time period approximately 1 in 5 claudicants will suffer from
worsening claudication, while 1 in 8 may develop critical ischaemia (O'Riordan &
O'Donnell, 1991). A higher rate (41% over 8 years) for the development of critical
limb ischaemia has however been reported in a series with an unusually high (34%)
percentage of diabetics (Rosenbloom et al, 1988). Overall however the figures
from a number of series suggest that in a 5 year period only 29% of claudicants
will require surgery, including 4% who will require an amputation.
Site of disease
The natural history of peripheral arterial disease at different anatomical sites
is poorly documented, although in a study of superficial femoral disease (Walsh et
al, 1991), 28% of asymptomatic and mildly symptomatic superficial femoral artery
stenoses progressed over a 3 year period, with 17% occluding. This was a small
study in a rather atypical population however, with no objective assessment of the
peripheral circulation following disease progression, and until further larger studies
are carried out, accurate data on the rate of progression of arterial disease at
different sites remains unavailable. Current treatment plans for patients with
intermittent claudication have therefore to be based on the data already described,
and on the preference of the individual clinician.
Summary
Based on the data currently available, in a typical group of 100 symptomatic
claudicants aged 55-65 years, 30 of these patients would be expected to die in the 5
years following presentation (Figure 1.2), while of the remaining 70 patients,
around 50 will have improved or stable claudication distances. This leaves 35
patients whose symptoms will deteriorate, although only 10 patients are liable to
develop critical limb ischaemia, with 2 or 3 coming to amputation in the 5 years
following presentation, and the remainder undergoing surgery for limb salvage.
There remain 25 of the original 100 patients whose symptoms will have
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Figure 1.2: The typical 5 year outcome in 100 patients presenting with
intermittent claudication.
30
deteriorated to a point short of critical ischaemia. Surgery in this group will be
determined by the distribution of their disease, the severity of their symptoms, and
their (and their surgeon's) attitude to operation. However at the current time, there
are no means of accurately predicting which group any individual patient will fall
into when they first present with symptomatic peripheral arterial disease.
Alternatively, if the surgeon operates on all 100 claudicants presenting to
his clinic, he will operate on 35 patients whose symptoms would have improved
without operation, and on 30 patients in whom the period of benefit, if any, would
have been short lived, due to co-existing, and ultimately fatal, cardiac or
cerebrovascular disease. This, together with the not insignificant failure rate of
reconstructive surgery for infra-inguinal disease (Bell 1990), makes patient
selection important, with the emphasis on identifying those patients who will
achieve most benefit from surgery, with the least risk of mortality, and the lowest
graft failure rate.
INVESTIGATION OF PERIPHERAL VASCULAR DISEASE
Most patients with symptomatic peripheral arterial occlusive disease can be
diagnosed on the basis of a history of intermittent claudication, the characteristic
findings of the absence of one or more peripheral pulses, and the presence of thrills
or bruits associated with turbulent flow in certain cases (Clain, 1986). These
findings, together with the more obvious features of limb ischaemia found in more
advanced cases (Figure 1.1), enable a confident diagnosis of arterial insufficiency
to be made in most cases, however there are a number of additional investigative
techniques that are usually undertaken:
Ankle-Brachial Pressure Indices
The use of ultrasonic flow detectors to determine the systolic pressure in
ankle vessels was described by Yao in 1968 (Yao et al, 1968), and subsequent to
this it was reported that a pressure index obtained from the ratio of ankle systolic
pressure to brachial systolic pressure, correlated well with arterial stenosis and
occlusion, the ratio in normal patients being greater than 1.0, and in patients with
peripheral arterial occlusive disease, less than 1.0 (Yao et al, 1969).
This ratio, which has come to be known as the Ankle-Brachial Pressure
Index (ABPI), remains the simplest and most effective means of determining the
presence of occlusive arterial disease, with a ratio of 0.9 or less diagnostic of
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arterial insufficiency (Laing & Greenhalgh, 1983). The ABPI has a low coefficient
of variation (Horrocks & Scott, 1991), and can be used to monitor the progress of
the disease. The ABPI value may however be misleading in patients with arterial
wall calcification, as found in diabetes mellitus and end-stage renal disease (Barnes,
1991). The addition of an exercise test, with measurement of the ABPI after a
standard exercise regime further improves the diagnostic sensitivity of the test
(Nicolaides, 1991), with a drop in the ABPI following exercise confirming the
presence of occlusive disease. In patients unable to carry out an exercise test, this
effect can be reproduced using an occlusive cuff hyperaemia test (McShane et al,
1988), which has been found to correlate well with the response to a standard
exercise test (Wyatt et al, 1990).
Doppler blood velocity tracings
A number of authors have investigated methods of analysing the Doppler
velocity waveform. Simple analysis of the waveform (Yao, 1970) can help in the
localisation of significant stenoses, and more detailed mathematical analysis of the
same waveform may detect aorto-iliac disease (Nicolaides et al, 1976). Pulsatility
index (PI) calculations (Gosling et al, 1971), Laplace transform of the peak
velocity waveforms (Baird et al, 1980), and principal component analysis of
spectrum analysed continuous wave Doppler (MacPherson et al, 1984) have also
been suggested as means of assessing the extent of arterial occlusion, but all these
techniques require a skilled technician, and often the use of sophisticated
computers. As a result most of these techniques have remained as research tools,
and play little part in the routine evaluation of the vascular patient.
Duplex scanning
In the early 1970s ultrasonic imaging techniques were developed and
subsequently combined with Doppler ultrasonic devices to create the Duplex
scanner, which provided both anatomical and functional information about the
peripheral circulation. Real-time B-mode imaging of vessels enables identification
of anatomical lesions, and also ensures that the Doppler signal that is being
analysed is from the desired vessel, as the point of sampling for the signal is
selected by the operator. More recent versions of these machines are able to display
some of the Doppler data as a colour display of flow superimposed on the real-time
image (Allan, 1991).
Colour flow duplex devices enable visualisation of some arterial lesions
together with assessment of their functional significance, in terms of velocity,
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diameter, and flow (Renton & Nicolaides, 1991). There is now some evidence that
duplex is as effective as arteriography in the detection of haemodynamically
significant lesions in both aorto-iliac and femoro-popliteal segments (Jager et al,
1985, Legemate et al, 1991). However the role of colour flow duplex in the
investigation of occlusive arterial disease is not yet clearly established, although it
would appear to have a role in graft surveillance (Fig. 1.3) (Grigg et al, 1988B,
Harris, 1992). The main disadvantages of the technique are that visualisation and
acquisition of Doppler information from some segments is difficult to obtain (in
particular from iliac and calf vessels), and that information obtained often
represents a compromise between image quality and Doppler information (Allan,
1991).
Arteriography
Since 1924, when Brooks (1924) described the radiological imaging of
peripheral arteries using intra-arterial injection of sodium iodide, the technique of
arteriography has been the accepted "gold standard" for investigation of peripheral
vascular disease. However it was not until 1953 that relatively safe percutaneous
catheterisation of the arterial tree became available (Seldinger, 1953), and the
technique of percutaneous catheterisation introduced by Seldinger remains the
method of choice for obtaining angiography.
Intra-arterial injection of radiopaque contrast material enables the entire
vascular anatomy of the lower limbs to be visualised in a single examination, while
serial arteriography enables the clinician to monitor the progress of specific lesions.
Newer computerised imaging techniques such as digital subtraction angiography
(DSA) have improved the quality of images available, and reduced the need for
large doses of intra-arterial contrast media (Sutton, 1990), however arteriography
remains an invasive technique that is not devoid of complications (Sutton, 1990).
The major disadvantage of arteriography in clinical practice is that the
routinely performed uniplanar views may fail to demonstrate some significant
lesions, in particular in the aorto-iliac segments, where lesions that are only
affecting the lumen in an antero-posterior plane will not be visualised. In addition,
arteriography gives no functional information about the lesions demonstrated.
Summary
History and clinical examination alone are often sufficient to determine the
presence of significant arterial occlusive disease, but further information is usually
sought before a plan of management is devised for any given patient. This usually
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Figure 1.3: Duplex scans of left femoropopliteal graft showing groin vessels and
popliteal anastomosis.
consists of semi-quantitative assessment of disease severity (ABPI), and
radiological imaging of the arterial tree by conventional arteriography or DSA.
Duplex ultrasonography now offers a non-invasive means of obtaining similar
information in some situations, but has yet to gain widespread acceptance, and has
limitations that will ensure that arteriography remains an important diagnostic tool
in the foreseeable future.
TREATMENT OF PERIPHERAL VASCULAR DISEASE
Until the middle of the 20th century treatment of symptomatic arterial
occlusive disease was confined to amputation of the affected limb when gangrene
had developed. Since then a number of different methods of treating the patient
with symptomatic arterial occlusion have been developed, although amputation may
well still be required in some cases.
Medical therapies
Medical therapies for peripheral arterial occlusive disease are aimed at
reducing risk factors, improving collateral circulation, and avoiding foot trauma
(Krupski & Effeney, 1988). In many cases these measures are enough to enable the
patient with PAOD to lead a symptom-free existence, with as many as 50% of
claudicants remaining stable or improving in the 5 years following presentation
(Singer & Robb, 1960, Bloor, 1961, McDaniel & Cronenwett, 1989), and most
claudicants can be treated initially with this simple advice on lifestyle modification
(Housley, 1988).
Risk factors such as smoking, hypertension, hyperlipidaemia and
polycythaemia should all be treated, and good diabetic control encouraged.
Smoking however is the only risk factor that has been consistently related to
intermittent claudication in most studies (Davey-Smith et al, 1991), and the
benefits of altering other risk factors associated with occlusive arterial disease
remain to be proven.
Despite the lack of controlled studies, walking exercise is thought to
stimulate the development of collateral flow, with a consequent increase in the
claudication distance (Krupski & Effeney, 1988). There is some evidence to
suggest that there is a link between low physical activity in middle-age, and the
subsequent prevalence of PAOD (Housley, 1991), while a significant improvement
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in maximal and pain-free walking distances in stable claudicants following 2
months of treadmill exercising has been reported (Ernst & Matrai, 1987).
These simple measures are often enough to produce symptomatic relief in
many patients with occlusive arterial disease, but in patients whose claudication is
significantly interfering with their lifestyle, or in whom there is evidence of limb
threatening ischaemia, additional measures are required (Housley, 1988).
Pharmacological therapies
A number of different drug therapies have been evaluated in peripheral
vascular disease, either in an attempt to alter the course of the disease, or to reduce
the associated cardiac and cerebrovascular mortality and morbidity in patients with
peripheral vascular disease. However the evaluation of the benefits of drug therapy
in intermittent claudication is complicated by the 50% rate of spontaneous
improvement shown in claudicants over a period of time (McDaniel & Cronenwett,
1989), and by effects of any associated reduction in smoking and increase in
exercise.
The two drugs most commonly prescribed in arterial occlusive disease,
naftidofuryl oxalate (Praxilene, Lipha) and pentoxifylline (Trental, Hoescht),
have both shown a small improvement in the walking distance of patients with
claudication in some studies (Triibestein et al, 1984, Rossner & Miiller, 1987), but
the small numbers studied create difficulties in interpreting the results (Bollinger &
Frei, 1977), and meta-analysis has been required to produce statistically significant
results (Lowe, 1990B). The mechanisms by which both these drugs produce their
therapeutic effects are somewhat unclear, although some possible mechanisms of
action have been demonstrated for pentoxifylline (Currie et al, 1991).
Vasodilator drugs which either act directly on vascular smooth muscle or
indirectly by actions on the sympathetic nervous system, may theoretically be of
benefit in arterial occlusive disease: drugs acting on the sympathetic nervous
system may increase skin blood flow, but will not increase blood supply to
ischaemic muscle (Coffman, 1979), while drugs that directly relax vascular smooth
muscle have not been shown to improve the blood supply to ischaemic tissue
despite an increase in calf blood flow (Coffman, 1979, Morgan et al, 1987).
Antiplatelet therapy has been shown to be protective in patients with
cerebrovascular and coronary artery disease, (Antiplatelet trialists collaboration,
1988), and also to reduce the rate of occlusion of coronary artery grafts (Petch,
1991). Although the role of platelets in peripheral arterial disease is still unclear,
there have been studies of antiplatelet therapy in PAOD that have suggested that a
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similar beneficial effect may exist (Bounameaux et al, 1986). In a prospective
double-blind arteriographically controlled trial of both aspirin and dipyridamole
(Hess et al, 1985), a beneficial effect in terms of reduced disease progression was
shown for antiplatelet therapy in smokers and hypertensives, while the anti-platelet
agent ticlopidine (an inhibitor of ADP-induced platelet aggregation), has been
shown to improve walking distance, walking speed, and ABPI, in patients with
symptomatic occlusive arterial disease, as well as reducing cardiac and
cerebrovascular events in claudicants (Janzon et al, 1990, McTavish et al, 1990).
Aspirin and dipyridamole in combination have also been shown to reduce
myocardial infarction and stroke rate following reconstructive vascular surgery
(McCollum et al, 1991A).
Arterial thrombosis is often the final step in PAOD, and it may be that
anticoagulant therapy can influence the course of the disease, although the
evidence is inconclusive (Bounameaux et al, 1986). A small study in patients with
advanced arterial disease suggested that the reduction in plasma fibrinogen, plasma
viscosity, and blood viscosity, following treatment with subcutaneous ancrod, was
associated with increased nutritional skin blood flow, however large clinical trials
have not been performed (Lowe et al, 1979). The use of minidose warfarin in
claudicants merits further evaluation (Reid, 1991). The use of full dose
anticoagulants in patients with occlusive arterial disease is restricted to patients in
whom there is a clear clinical indication for anticoagulant therapy.
Administration of prostacyclin (PGI2) by either the intra-arterial or
intravenous route, which results in vasodilatation, dispersion of circulating platelet
aggregates, and inhibition of platelet aggregation, has been shown to reduce levels
of ischaemic rest pain in advanced occlusive arterial disease and improve the
healing of ischaemic ulcers (Szczeklik et al, 1979, Belch et al, 1983), while
intravenous infusion of the prostacyclin analog Iloprost (Schering A.G.) has been
shown to have similar beneficial effects in patients with advanced non-
reconstructible arterial disease, with a significant improvement in clinical status and
reduction in amputation rate (UK Severe Limb Ischaemia Study Group, 1991).
Intravenous Iloprost is also of value in patients with thrombangitis obliterans
(Fiessinger & Schafer, 1990), but the exact role of prostaglandins in the treatment
of peripheral arterial occlusive disease has yet to be determined.
Drug treatment of occlusive arterial disease is therefore only an option for a
limited number of patients with limb threat, who may gain some benefit from
intravenous prostaglandin therapy. There are no drug therapies that have
convincingly shown a clear benefit in intermittent claudication, although
37
antiplatelet agents may be of value in reducing the cardiovascular morbidity and
mortality associated with PAOD (McTavish et al, 1989, McCollum et al, 1991A).
Percutaneous arterial recanalisation
Since the advent of the Seldinger technique to place intravascular devices
(Seldinger, 1953), the potential has existed to effect percutaneous treatment of
arterial stenoses and occlusions. Early methods of dilating arterial stenoses
involved the passage of increasing sizes of dilating catheters over an appropriately
placed guidewire, thus enlarging the arterial lumen (Dotter & Judkins, 1964).
However it was not until the development of a catheter with an inflatable balloon,
that successful percutaneous dilatation could be achieved through a small arterial
puncture with good results and a low complication rate (Gruntzig & Kumpe, 1979).
Since then balloon angioplasty has become the mainstay of percutaneous
treatment for peripheral arterial occlusive disease, and it is now being used to treat
patients in whom the risks of surgery would not normally be justified (Campbell,
1986, Michaels, 1990, Whyman et al, 1991).
The results of balloon angioplasty are variable (Michaels, 1990) and are
greatly influenced by the nature of the lesion being treated. Lesions involving the
iliac arteries have an initial technical success rate of over 90%, angioplasty of
femoral lesions is successful in between 70 and 85% of cases (Gruntzig & Kumpe,
1979, Freiman et al, 1979, Spence et al, 1981, Waltman et al, 1982, Johnston et
al, 1987) and the 1-year patency rate following angioplasty of the popliteal artery
and tibial stem is somewhat lower at 57% (Tamura et al, 1982). Long-term results
are less encouraging, with 5-year patency rates of around 64% for iliac lesions and
40% for femoro-popliteal lesions (Johnston et al, 1987), in contrast to cumulative
patency rates for aortic bifurcation grafts of up to 99% at 5 years (Reid & Pollock,
1991), and a 3 year patency of between 55 and 80% for femoro-popliteal grafts
(Cheshire & Wolfe, 1992).
Intermediate patency rates at 2 and 3 years of 80-90% for iliac lesions, and 60-
70% for femoro-popliteal lesions are quoted in a number of series (Gruntzig &
Kumpe, 1979, Freiman et al, 1981, Waltman et al, 1982), but comparison between
studies is complicated by the wide variations in the patient population, and
definition of success (Cambria et al, 1987, Rutherford & Becker, 1991), although
it is accepted that patency declines for a number of years following successful
angioplasty (Johnston et al, 1987). Failure rates for angioplasty of the
femoropopliteal segment however appear to be highest within the first year (Martin
et al, 1981, Mosley et al, 1985).
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A number of factors that influence the outcome of angioplasty have been
identified: any stenoses or occlusions longer than 10cm have a poorer outcome, as
do patients in whom the procedure is carried out for limb-threat, or with a poor
run-off (Spence et al, 1981, Mosley et al, 1985, Cambria et al, 1987, Johnston et
al, 1987, Murray et al, 1987). Recently it has been suggested that infusion of a
thrombolytic agent into the isolated arterial segment following angioplasty, reduces
the rate of early occlusion (Tonneson et al, 1991).
There is now little doubt that successful angioplasty is a cost-effective
alternative to surgical treatment (Doubilet & Abrahams, 1984, Jeans et al, 1986),
and although the procedure has an overall complication rate of 5%-15% (Al-
Kutoubi, 1992), the need for surgical intervention as a consequence of failed
angioplasty is only around 3% (Health and Public Policy Committee. American
College of Physicians, 1983). The availability of angioplasty has not however
reduced the number of patients undergoing surgery for PAOD (Michaels, 1990),
partly because the pattern of diffuse disease that usually leads to surgery is the
pattern of disease that gives the poorest result in angioplasty (Al-Kutoubi, 1992),
although some patients with limb threat considered unsuitable for reconstructive
surgery may obtain a satisfactory result from angioplasty (Lu et al, 1982, European
Working Group on Critical Limb Ischaemia, 1990).
Percutaneous angioplasty represents a suitable alternative to surgery for
selected patients with occlusive arterial disease, but unfortunately the medium to
long term results in the femoropopliteal segments (the commonest site of
symptomatic disease) are disappointing, with early recurrence of symptomatic
stenoses in a large number of these patients (Morin et al, 1986). As a result
angioplasty tends to be reserved for the treatment of the claudicant with the discrete
stenosis, and the patient with limb-threat who represents a significant operative risk
(Al-Kutoubi, 1992).
Attempts to overcome early post-angioplasty restenosis and occlusion have
involved the use of intravascular stents (DiMassa et al, 1986, Sigwart et al, 1987,
Palmaz, 1988), to oppose recoil of elastic vascular stenoses following angioplasty,
and to provide a supporting framework for lesions that are liable to dissect or
embolise after angioplasty, but these have no clear role in the percutaneous
treatment of femoropopliteal lesions (Zollikofer et al, 1991). Additional
percutaneous devices such as the flexible rotating tip catheter (Kensey et al,
1987) have been devised to liquefy atheroma and recanalise occluded vessels, and
although early results have been acceptable (Ginsberg et al, 1988, Vallbracht et al,
1988, Polnitz et al, 1988), the 12 month patency rate is only around 38%. (Triller
39
et al, 1992). Percutaneous laser devices have also been utilised to recanalise
occluded vessels (Nordstrom et al, 1988, Leon et al, 1988, Litvack et al, 1988,
Michaels, 1990), but the initial enthusiasm for laser recanalisation has not been
maintained, as the results appear little better than conventional angioplasty (Bonn
1991, Ginsberg et al, 1985, Sanborn et al, 1988, Nordstrom et al, 1991).
In summary, percutaneous transluminal angioplasty offers an alternative
non-operative means of treating selected symptomatic arterial lesions but the long
term results of this technique are less satisfactory than those of surgery, particularly
in femoral artery disease.
SURGICAL TREATMENT OF PERIPHERAL VASCULAR DISEASE
Development of peripheral vascular surgery
Until the end of the 19th century surgical treatment for peripheral arterial
disease was confined to the amputation of gangrenous limbs. The subsequent
emergence of techniques of vascular anastomosis (Jassinowsky, 1891, Murphy,
1897, Dorfler, 1899, Carrel, 1902) led to the development of a technique of
anastomosis that remains relevant to vascular surgery today (Carrel, 1908), and a
number of procedures were performed using vein grafts to bridge arterial defects
created by axillary and popliteal aneurysm excision (Lexer, 1907, 1912, 1913),
including 2 cases carried out at Glasgow Royal Infirmary (Pringle, 1913).
Further major advances in treatment of occlusive peripheral arterial disease
did not take place until vein bypass grafts were introduced in 1951 (Kunlin, 1951).
Kunlin and his colleagues described 17 cases of vein bypass of superficial femoral
artery occlusions, using autologous saphenous vein in all but one case; 10 grafts
were successful, although 3 subsequently occluded in the following 18 months.
Freeze-dried arterial homografts were also used to replace occluded segments in
iliac and femoral arteries, with similar results (Eastcott, 1953).
With the introduction of prosthetic material for arterial grafts in the 1950's,
the range of arterial pathology that could be treated by bypass surgery increased
greatly. Initial grafts were manufactured from Vinyl N Cloth (Voorhees et al,
1952), but this has subsequently been followed by Nylon, Teflon (PTFE), and
Dacron. Dacron is currently the material of choice for proximal aorto-femoral
reconstruction, and patency rates of up to 99% are possible (Reid & Pollock,
1991). Results of femoro-popliteal and femoro-distal grafting are less encouraging,
with patency rates of 35-85% being reported (McCollum et al, 1991B), and the
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vein bypass graft described by Kunlin (1951), remains the best method of treating
femoropopliteal occlusions.
Current status of surgery in peripheral vascular disease
The high patency rates attainable for aorto-femoral reconstruction (Reid &
Pollock, 1991), suggest that further major improvements in outcome following
such surgery are unlikely. However, surgery for femoropopliteal and infra-
popliteal disease has at best a 5 year patency of 80-85% (Mannick et al, 1991,
Taylor & Porter, 1991), with significant differences in patency between series from
different centres (Tables 1.2, 1.3, 1.4). Infra-inguinal bypass grafts tend to suffer
from rapid deterioration in graft patency in the year after surgery, followed by a
much lower annual occlusion rate thereafter.
Both graft material and the site of the distal anastomosis have a significant
bearing on the outcome of infra-inguinal bypass grafting, with autologous vein
giving the best results in all situations, little difference being demonstrated between
in-situ and reversed vein (Harris et al, 1987). Prosthetic material, in the form of
expanded polytetrafluoroethylene (PTFE) gives similar results to vein above the
knee, although the success of PTFE grafts below the knee deteriorates significantly
the further distal the anastomosis. In situations where autologous vein is not
available, it appears possible to improve the long-term patency of PTFE grafts to
calf vessels, by the interposition of a vein collar or patch between the distal end of
the graft and the recipient artery (Wolfe & Tyrell, 1991, Cheshire et al, 1992,
Taylor et al, 1992).
Indications for surgery
Despite the fact that femoropopliteal disease is the commonest form of
occlusive arterial disease (Bloor, 1961), the results of infra-inguinal grafting are
such that the operation is often reserved for situations of limb threat, when failure
to revascularise the limb would result in tissue loss and ultimately amputation, and
for short-distance claudication where the patient is severely impaired by their
symptoms. Less severe unilateral, and occasionally bilateral, claudication is a
relative indication for surgery, depending on the views of the individual surgeon
and the patients' expectations, although few surgeons in the United Kingdom would
carry out either below-knee popliteal, or femorocrural grafts, for claudication
alone.
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1 yr. late site
No. cumulative cumulative popliteal





















































indicates that cumulative patency was not defined in terms of primary or
secondary patency.
^ r.v indicates use of reversed saphenous vein, i.s indicates use of in-situ vein,
where the outcome for the 2 different techniques was specified.
n.s. indicates that the site of distal anastomosis was not specified. ( A.K. indicates
a proximal popliteal anastomosis, and B.K. a distal popliteal anastomosis. I.P.S.
indicates that the anastomosis was to an isolated popliteal segment.).
Table 1.2: Outcome in femoropopliteal vein bypass grafts.
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1 yr. late site
No. cumulative cumulative popliteal






































































indicates that cumulative patency was not defined in terms of primary or
secondary patency.
® in this series all PTFE grafts had a distal vein patch.
n.s. indicates that the site of distal anastomosis was not specified. ( A.K. indicates
a proximal popliteal anastomosis, and B.K. a distal popliteal anastomosis. I.P.S.
indicates that the anastomosis was to an isolated popliteal segment.).
PTFE: polytetrafluoroethylene.
HUV: Human umbilical vein.
Table 1.3: Outcome in synthetic femoropopliteal bypass grafts.
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No. cumulative cumulative site
























































51 71% 41 %(5yr) tibial 86% limb
salvage
indicates that cumulative patency was not defined in terms of primary or
secondary patency.
@ in these series all PTFE grafts had either a distal vein collar or vein patch.
PTFE: polytetrafluoroethylene.
Table 1.4: Outcome for femoro-distal bypass grafts (all types).
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Graft failure
Factors that have been associated with poor outcome (occlusion) of infra-
inguinal bypass grafts are; 1) undetected proximal disease (Charlesworth et al,
1975, Bergamini et al, 1991), 2) poor quality of distal outflow (Buda et al, 1976,
DeWeese & Rob, 1977), which may be reflected intra-operatively as a low velocity
of flow in the graft (Bandyk et al, 1985) or as increased peripheral resistance
(Parvin et al, 1985, Brennan et al, 1991), 3) elevated plasma fibrinogen levels
(Harris et al, 1978, Wiseman et al, 1989), 4) continued cigarette smoking
(Greenhalgh et al, 1981, Wiseman et al, 1989), and in particular 5) the use of
prosthetic graft materials (Weisel et al, 1981, Hobson et al, 1985, Rutherford et al,
1988, Londrey et al, 1991).
The use of prosthetic materials for limb salvage procedures in the absence of
suitable quality vein however, is still justified, as even with relatively poor results
the overall amputation rate in this group of patients can be reduced (Wolfe &
Tyrell, 1991), mortality from amputation is higher than that following
reconstructive surgery (Ouriel et al, 1988, Cheshire & Wolfe, 1992), and the
economic costs of attempting limb salvage, are less than those of adopting a policy
of primary amputation for all such patients in whom adequate vein is not available
(Cheshire et al, 1992).
Although the outcome of infra-inguinal vein grafting is better than for
prosthetic materials, there remains a 1 year failure rate of 7-50% (Tables 1.2, 1.4),
and when surgery has been carried out for limb threat, graft failure leads to
amputation in many cases (Brewster et al, 1983). Early post-operative failure (up to
30 days) is the cause of up to 25% of graft occlusions, and in both prosthetic and
vein grafts is due to a number of factors including poor anastomotic technique,
selection of patients with inappropriate severity and pattern of occlusive lesions,
systemic hypotension, patient mortality, and intrinsic hypercoagulability (LiCalzi et
al, 1981, Rutherford, 1990). Early failure of autogenous vein grafts may also be
associated with poor vein quality and injury during the preparation of the vein,
particularly injury associated with the use of a valvulotome in the in-situ technique
(Donaldson et al, 1992). A number of pre- and intra-operative investigations have
been proposed in an attempt to reduce this "technical error" and improve the results
of femoro-distal grafting (Parvin et al, 1985, Beard et al, 1989, Bell, 1991,
Thompson et al, 1992), but the only technique that is widely available, is that of
completion angiography, which should be carried out to assess all femoro-distal
grafts following completion of the anastomoses (Gruss, 1989).
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Graft occlusions occurring beyond the early post-operative period may be
related to some of the factors outlined above, but there are additional features
associated with the use of autogenous vein grafts, that are thought to contribute to
vein graft occlusion. The belief that vein graft stenoses were related to endothelial
injury as a consequence of stripping of venous valves and the application of clamps
during surgery, has not been confirmed in prospective studies (Moody et al, 1992),
but the process of neointimal hyperplasia or intimal thickening (Szilagyi et al,
1973) (Fig. 1.4), the proliferation of smooth muscle and deposition of connective
tissue in the intima of the graft, is undoubtedly a major factor in vein graft
occlusions (Rutter & Wolfe, 1992). This appears most marked at sites of
anastomoses, and may be related to excessive fibrin deposition at these sites
(Walton et al, 1985), or to wall tension in the graft causing deformation of the
vessel wall (Schwartz et al, 1992). This results in graft stenoses at the sites of
intimal thickening which can lead to occlusion in 23-42% of cases, compared with
an occlusion rate of 7% in non-stenosed vein grafts (Grigg et al, 1988A, Moody et
al, 1989), although up to 65% of strictures may remain asymptomatic.
Late occlusions (more than 2 years post-operatively) of both vein and
synthetic grafts are usually a result of progression of atheromatous disease in the
native vessels (Rutter & Wolfe, 1992), but atherosclerotic changes can occur in
both vein grafts (Walton et al, 1985), and synthetic grafts (Walton et al, 1986),
with intramural deposition of lipoprotein and fibrinogen-related antigens
contributing to late graft occlusion.
Graft surveillance
The recognition of asymptomatic vein graft stenoses as a precursor of graft
occlusion, and the ability to treat stenoses prior to occlusion, with either
angioplasty (Berkowitz et al, 1981, Whittemore et al, 1991, Berkowitz et al,
1992), or operative patch angioplasty (Cohen et al, 1986), has emphasised the need
for regular surveillance of infra-inguinal vein grafts (Harris, 1992) in the first post¬
operative year, with a similar, although less intense, surveillance of synthetic grafts
(Harris, 1991).
Simple serial ankle-brachial pressure indices were initially thought to be
adequate for graft surveillance (Taylor & Fox, 1977, Berkowitz et al, 1981), but
subsequent comparison of this with intravenous digital subtraction angiography
(DSA) has shown that the use of ABPI alone will fail to detect 50% of stenoses
narrowing the graft lumen by more than 50% (Wolfe et al, 1987), although the
addition of a "stress test" may improve the accuracy of ABPIs (Wyatt et al, 1990).
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Figure 1.4: Neointimal hyperplasia in an in-situ vein graft. This graft occluded 4
months after surgery.
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More sophisticated techniques such as DSA are required to detect asymptomatic
strictures (Moody et al, 1989, Harris, 1991), but such invasive and expensive
techniques cannot be utilised to follow up a vein graft at regular intervals over a
period of years.
Duplex scanning offers a less invasive means of visualising both the anatomical
and functional (peak systolic velocities and volume flow) arrangement of the graft
(Fig. 1.3), and appears to offer an effective means of graft surveillance (Grigg et
al, 1988A, Grigg et al, 1988B). An alternative to duplex scanning may be the use
of computer-assisted impedance analysis (Wyatt et al, 1991, Davies et al, 1993).
Summary
Surgical treatment of peripheral arterial disease has advanced considerably
since Kunlin (1951) first described vein bypass grafting, and excellent results are
now obtained with synthetic aorto-femoral grafts. Infra-inguinal grafts continue to
have a poorer outcome, with consequent reservations about their use in many
situations. A number of factors are responsible for these poor results, including
elevated fibrinogen and continued smoking, although more emphasis has been
placed on graft material, site of anastomosis, and post-operative vein graft stenosis.
In view of the high early occlusion rates of infra-inguinal grafting, graft
surveillance is required, but the ideal technique of identifying what are often
asymptomatic stenoses has not yet been identified.
PATHOGENESIS OF ATHEROSCLEROSIS
Atherosclerosis is a focal disease of the arterial intima which ultimately
leads to stenosis and occlusion of affected vessels. There are 3 classical lesions
described: the fatty streak, the fibrous plaque, and the complicated lesion (Ross &
Glomset, 1976). The fatty streak represents a focal accumulation of intimal
smooth-muscle cells containing lipid deposits in the form of cholesterol and
cholesterol esters, and is found in up to 50% of the aortic intimal surface by the
age of 25 years, regardless of race, sex or environment (Ross & Glomset, 1976).
These lesions cause no obstruction to arterial flow, and no clinical symptoms.
The fibrous plaque is the typical lesion of advancing atherosclerosis, and
its accumulation of lipids and collagen (Barker & Baskerville, 1991) produces a
lesion that protrudes into the arterial lumen, although simple fibrous plaques rarely
cause clinical symptoms. The relationship between fatty streaks and fibrous plaques
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remains unclear, although the former are often found in early life at the same sites
as fibrous plaques at older ages (Ross & Glomset, 1976). It has been postulated
that some fatty streaks at branches and bifurcations will progress to fibrous plaques
(Ross, 1986), while others appear to regress spontaneously (Lindop, 1985). These
fibrous plaques are often referred to as atheromatous plaques.
The complicated lesion represents a fibrous plaque that has been altered by
haemorrhage, calcification, cell necrosis and mural thrombus (Ross & Glomset,
1976), and in these lesions there is typically involvement of all 3 layers of the
arterial wall (Schwartz et al, 1989). These complicated lesions are the source of
clinical symptoms of occlusive arterial disease. Large plaques can partially or
completely occlude the arterial lumen, leading to gradually developing arterial
insufficiency. Haemorrhage into the plaque, and/or thrombus formation on the
plaque can produce acute arterial occlusion and insufficiency. Ulceration of plaques
may be associated with distal embolisation and formation of occlusive thrombi, and
thinning of the arterial media in association with plaque formation can lead to
aneurysm formation (Lindop, 1985).
Microscopic appearance
Microscopic examination of the lesions of atherosclerosis reveals early
accumulation of lipids within smooth muscle cells that are derived from the medial
smooth muscle cells. This is accompanied by accumulation of lipids within the
connective tissue of the arterial intima, and the proliferation of fibrous connective
tissue in the sub-endothelial region. Subsequent necrosis within the deeper layers of
the lesion leads to the typical appearance of a structureless accumulation of lipids
and cell debris. Lesions are often infiltrated by neutrophils, and lipid-laden
macrophages or "foamy cells" (containing cholesterol crystals) are seen within the
lipid rich areas of the vessel wall. The process can extend into the media following
disruption of the internal elastic lamina, and in all cases the underlying media
becomes thin and atrophic (Lindop, 1985).
This represents the usual course of development of atherosclerotic lesions
although the lipid component of atherosclerotic plaques seems to be variable, with
some occlusive lesions containing relatively little lipid, being more
fibroproliferative in nature (Ross et al, 1984).
Aetiology of lesions
Atherosclerotic lesions are presumed to represent the response of arterial
intima to injury, as postulated by Virchow, who suggested that atheroma was a
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response to vascular "irritation" (Lindop, 1985). The initiating event in the
development of atheroma is thought to be endothelial disruption (Ross & Glomset,
1976, Ross, 1986).
The aetiology of this endothelial disruption remains unclear, but a number
of apparent "risk factors" have been identified, including hypercholesterolaemia
and hyperlipidaemia (Walter & Israel, 1987C, Steinberg et al, 1989), and products
of platelet activation (Weiss, 1975, Vermylen et al, 1986, Ross, 1986), which lead
to migration and proliferation of smooth muscle cells which lay down an intimal
connective-tissue matrix into which plasma-derived lipid is deposited. The process
is thought to be halted when endothelial integrity is restored, and the lesions may
then regress (Walter & Israel, 1987A). However in situations of repeated or
continuous endothelial injury, progressive lesions will develop. Thus platelets and
other factors may initiate atheroma, as a response to endothelial injury, and the
lesions then grow as a result of smooth muscle proliferation and superimposed
thrombus (Walter & Israel, 1987B).
The mechanisms by which elevated plasma lipids and cholesterol levels
contribute to atheroma are unclear but may involve alteration of the
cholesterol:phospholipid ratio of endothelial cell membranes resulting in endothelial
cell retraction at branches and bifurcations (Ross, 1986). Alternatively the
oxidation of the low density lipoproteins that accumulate in the arterial wall by
macrophage generated free radicals (Carpenter et al, 1991) produces endothelial
toxins such as lipid peroxides (Hennig & Chow, 1988). Lipid peroxide levels are
elevated in patients with atherosclerosis, and in addition to their toxic effect on
vascular endothelium, they appear to increase platelet aggregation (Goto, 1982).
Rheological factors such as altered shear stress at arterial branchings, may
also contribute to the development of atherosclerotic lesions and may help to
explain the variable distribution of arterial atheromatous lesions (Schwartz et al,
1989).
Cigarette smoking is strongly associated with increased atheroma formation
(Powell, 1991). Elevated levels of von Willebrand Factor antigen, which is a
marker of endothelial damage, are elevated in smokers, and rise immediately
following smoking (Blann, 1992), although the mechanism by which smoking
induces endothelial injury is unclear. Smokers also have elevated fibrinogen levels
(Meade et al, 1987, Yarnell et al, 1991), and fibrin deposition is seen within
atheromatous plaques (Duguid, 1949, Smith & Staples, 1981).
The aetiology of atherosclerosis is therefore multifactorial, with a number
of factors contributing to the development of arterial lesions by their effects on
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endothelial cells, lipid metabolism, and the mediators of platelet aggregation and
thrombosis.
RHEOLOGY AND PERIPHERAL VASCULAR DISEASE
Rheology is the study of flow and deformation of matter and the principles
of rheology can be applied to the study of the flow of blood in the arterial tree:
Blood viscosity and red cell aggregation
Viscosity is the intrinsic resistance to flow of a bulk liquid and represents
the frictional flow resistance between the theoretical concentric layers that slide
telescopically ("shear") over each other in the classical model of laminar flow. This
resistance must be overcome by a driving force to cause shearing and subsequent
flow (Lowe, 1986), and it falls as increasing temperature reduces the molecular
interactions within the fluid that are responsible for it. Blood viscosity is therefore
measured at a standard temperature of 37°C (Lowe, 1992).
In situations of laminar flow viscosity is defined as;
Shear stress (mPa)
VISCOSITY (mPa.s) = Shear rate (s'1)
where the shear stress is the force applied to a unit area of a fluid layer which
causes it to move relative to its adjacent layer, and the shear rate is the difference
in velocity between two adjacent layers. In situations of laminar flow, the velocity
profile is parabolic, with maximal velocity in the central axis of the tube, while
shear stress and shear rates are maximal at the vessel wall (Lowe, 1992). From this
equation it is apparent that as the viscosity of a liquid increases, a greater shear
stress is required to achieve the same shear rate, and hence flow rate (Lowe, 1986).
Blood viscosity is a consequence of frictional interactions between
molecules, proteins and cells; whole blood viscosity is determined by the plasma
viscosity, which is related to the concentration, molecular size and asymmetry of
plasma molecules (Lowe, 1991), with large molecules such as fibrinogen,
contributing more than the smaller molecules such as albumin (despite their lower
concentrations), and by the haematocrit, and the deformation and aggregation of
red blood cells in bulk flow, known as the relative blood viscosity (Lowe, 1991).
Blood viscosity is increased at high haematocrit (Lowe et al, 1986) when the
ratio of cells to plasma is increased. An indication of red cell deformability is
obtained by calculating the relative high-shear blood viscosity, that is, blood
viscosity corrected for the effects of haematocrit and plasma viscosity (Lowe,
1992). Red cell deformation is however increased at high haematocrit and plasma
viscosity, and increases with higher shear rates as aggregates are disrupted, so that
at high shear rates this offsets the tendency of an elevated haematocrit or plasma
viscosity to increase whole blood viscosity. High-shear blood viscosity is therefore
reported at native haematocrit, and also after correction for haematocrit (corrected
blood viscosity), and this practice has been adhered to in this thesis, where blood
viscosity refers to the haematocrit-corrected blood viscosity, measured at a standard
temperature of 37 °C.
The flow rate of blood within arteries can be defined in similar terms to the
flow of a Newtonian fluid along a rigid tube, using the Hagen-Poiseuille equation;
Pressure gradient x tube radius"^
MEAN VELOCITY = 8 x tube length x fluid viscosity
Blood flow in arteries is therefore related to the blood viscosity, in addition to the
structural characteristics of the vessels, and the driving pressure. From this
equation it is apparent that a 50% decrease in the vessel radius, such as may result
from an atherosclerotic plaque, will produce a fourfold decrease in the mean
velocity, and in these circumstances, the effect of any changes in blood viscosity
will be more marked than in vessels of normal calibre.
In a simple Newtonian fluid such as water or plasma, the fluid viscosity
remains constant because the shear rate is directly proportional to the shear stress.
Blood on the other hand only displays these Newtonian characteristics at higher
shear rates, because at low shear rates, red cell aggregation occurs, leading to
increased blood viscosity. These aggregates are dispersed at high shear rates, with
the red cells assuming ellipsoid shapes in the centre of the laminar flow, and for
shear rates of over 200 mPa.s blood viscosity reaches a constant minimum value
(Dormandy, 1981), and high-shear viscosity is the most appropriate measure of
blood flow resistance under normal conditions in wide-bore vessels (Lowe, 1991).
Blood Viscosity in Peripheral Arterial Disease
Patients with peripheral arterial disease have elevated blood viscosity at
both low and high-shear rates (Dormandy et al, 1973A), and this has prognostic
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implications, with a high blood viscosity indicating a more rapid progression of
symptomatic occlusive arterial disease (Dormandy et al, 1973B).
Plasma viscosity and haematocrit are also elevated in peripheral arterial
disease (Dormandy et al, 1973A, Lowe et al 1986, Ernst & Matrai, 1987), and
there is a strong correlation between plasma viscosity and fibrinogen levels in such
patients (Dormandy et al, 1973B), with similar correlations observed in population
studies (Yarnell et al, 1991). More recently, red cell aggregation has been found to
be elevated in patients with peripheral vascular disease (Ernst & Matrai, 1987,
Reid, 1991). Although this rise in red cell aggregation could be due to elevated
fibrinogen levels bridging erythrocytes to form aggregates (Lowe 1986), this has
not been confirmed in clinical studies (Reid, 1991).
Thus plasma viscosity and red cell aggregation would appear to be elevated
independently of each other in patients with peripheral arterial disease. The
resulting increase in whole blood viscosity could either be an effect of the vascular
disease, or a direct causal factor, with a significant aetiological role in PAOD. In
the Edinburgh Artery Study the elevation in blood viscosity found in peripheral
arterial occlusive disease was related to the severity of the disease, and due partly
to increased haematocrit, and partly to increased plasma viscosity and fibrinogen
(Lowe et al, 1993).
The rheological changes that have been demonstrated in peripheral arterial
occlusive disease may have direct effects on blood flow: an increase in blood
viscosity significantly decreases blood flow to limbs and the magnitude of flow
changes in response to alterations in blood viscosity are such that a small change in
blood viscosity could have significant effects on limb blood flow (Dormandy,
1971), and consequently tissue viability. In the Edinburgh Artery Study,
claudication was related to plasma viscosity as well as arterial stenosis (diagnosed
by a low ABPI) (Lowe et al, 1993). This observation has implications in graft
surgery where flow through the graft is a critical determinant of patency, and in
grafts performed for limb salvage this is often only just adequate to maintain
patency. Any means of lowering blood viscosity might produce a large enough
increase in blood flow to increase the margin of safety, allowing the minor
variations in flow that undoubtedly occur in the normal course of events, to pass
without flow falling to levels that result in graft occlusion.
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WHITE BLOOD CELLS IN PERIPHERAL VASCULAR DISEASE
Neutrophil granulocytes make up between 50 and 70% of the normal white
cell population, with around half of their number circulating, and half marginated
in the lungs, from where they can be rapidly mobilised in response to certain
stimuli. Both the neutrophil count and activation are increased in vascular disease
(Jackson et al, 1992) and this may be related to the pathogenesis of occlusive
arterial disease.
Rheological effects
Although the absolute number of circulating neutrophils is too small to
influence the flow properties of the circulation in larger vessels, the
microcirculation is readily influenced by the presence of circulating neutrophils
(Lowe, 1986). These large poorly deformable white cells make a significant
contribution to microvascular resistance with their ability to block nutritive
capillaries (Chien et al, 1987), especially in situations where the perfusion pressure
is reduced as a consequence of an upstream occlusion. This results in increased
neutrophil transit times through capillaries, with a reduction in flow that enhances
neutrophil margination and adhesion to the endothelium (Nash & Shearman, 1992).
Whole blood filterability in peripheral arterial disease is affected by the
leucocyte count, with an increased leucocyte count being associated with decreased
blood filterability (Alderman et al 1981, Ciuffetti et al 1988), suggesting an
increased transit time through the microcirculation. This may lead to local
stimulation of neutrophils, resulting in their adhesion to endothelium with release
of various mediators that are chemoattractant to other neutrophils. The subsequent
recruitment and activation of further neutrophils with their migration through vessel
walls may lead to further tissue and endothelial damage (Nash & Shearman, 1992).
In patients with intermittent claudication the absolute neutrophil count and
the percentage of activated neutrophils are increased after exercise (Neumann et al,
1990, Hickey et al, 1990), while white blood cells from patients with severe limb
ischaemia show impaired filtration through 8/xm. and 5/zm. pore filters, the
filtration properties of the white blood cells returning to normal after amputation of
the ischaemic limb (Nash et al, 1988).
It is therefore apparent that neutrophils can have a significant effect on
blood flow in the microcirculation, in both their passive and activated forms, and
that the rheological effects of these cells may contribute to tissue damage in
PAOD.
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Consequences of neutrophil activation
Activated neutrophils produce a number of mediators that have the potential
to cause significant tissue damage, and the production of activated complement
fragment C5a by ischaemic tissue (Bengtson et al, 1987) may be a trigger for
neutrophil activation in PAOD (Nash & Shearman, 1992). Tissue ischaemia is
present in patients with critical limb ischaemia (Howd et al, 1988), and also occurs
following exercise in claudicants (Holdich et al, 1986), and this may lead to
leucocyte activation in patients with occlusive arterial disease. Endothelial damage
leads to release of platelet activating factor (PAF) which induces platelet
aggregation and the platelet release reaction, further contributing to locally
increased microvascular permeability and endothelial damage (Anderson, 1985).
Following activation, superoxide anions and proteolytic enzymes are
produced by the neutrophil (Lowe, 1990A), and these are capable of inducing
endothelial cell damage, leading to the release of arachadonic acid, which is
metabolised to thromboxane and prostanoids (via cyclo-oxygenase) and also to
leukotrienes (via lipoxygenase). Thromboxanes and leukotrienes are capable of
attracting and activating further neutrophils (Nash & Shearman, 1992) thus
exacerbating the tissue damage.
Following reperfusion of ischaemic tissue, activated neutrophils transform
molecular oxygen into the highly reactive superoxide anion and hydroxyl radical
(Weissman et al, 1980). These compounds have the potential to increase
microvascular permeability via their toxic effects on endothelial cells, and this
increase in microvascular permeability associated with oxygen derived free radicals
has been observed following exercise in claudicants (Shearman et al, 1988),
although it can be prevented by the prior administration of free radical scavengers
(Welbourn et al, 1991).
It has been suggested that both increased white cell numbers and activation
are related to smoking habit (Ernst et al, 1987), but there is evidence that some of
the association between leucocyte count and arterial disease is independent of
smoking (Friedman et al, 1974, Zalokar et al, 1981, Reid, 1991). Although
leucocytes may be a marker of smoking habit, their deformability is impaired in
response to cigarette smoke (Drost et al, 1992) and they would therefore appear to
have an additional role in the pathophysiology of arterial disease.
Studies in patients with ischaemic heart disease suggest that white cell count
predicts the risk of myocardial infarction (Friedman et al, 1974, Zalokar et al,
1981), and recurrent coronary events following myocardial infarction (Lowe et al,
1985), while depletion of neutrophil numbers prior to myocardial ischaemia has
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been shown to reduce the extent of ischaemic injury in an experimental model
(Romson et al, 1983).
Both neutrophil count and activation are increased in patients with an
increased risk of vascular disease (Jackson et al, 1992), and a study of 1969
patients with intermittent claudication indicated that an elevated white cell count
was a significant predictor of myocardial infarction, stroke and vascular death in
these patients (Dormandy & Murray, 1991), while further work has shown that the
elevation in white cell count in patients with peripheral vascular disease is related
to the severity of occlusive arterial disease, as determined by clinical examination
(Reid, 1991).
Whether or not increased numbers of leucocytes are directly contributing to the
pathogenesis of occlusive arterial disease, or are merely acting as markers for
other, as yet unidentified, aetiological factors, is unclear, and further studies are
required.
COAGULATION AND THROMBOSIS IN VASCULAR DISEASE
The recognition that thrombosis is a major component of atherosclerotic
arterial disease (Duguid, 1949) has led to a number of studies into the role of the
mediators of coagulation and thrombosis. These thrombotic mediators have been
studied in patients with various manifestations of atherosclerosis, including
peripheral vascular disease, and a number of them have been implicated as risk
factors in the development and progression of arterial disease:
Fibrin turnover and fibrinogen
The formation of insoluble fibrin from fibrinogen as a result of the
production of thrombin by the coagulation system is fundamental to that system,
although there exists a dynamic equilibrium between the processes of coagulation
and thrombolysis, including both the formation of fibrin and its' subsequent lysis
(Astrup, 1956). The measurement of fibrinogen and of cross-linked fibrin
degradation products (FDP's) offers a means of measuring this aspect of the
coagulation system in-vivo.
The association between fibrinogen and peripheral arterial disease was
demonstrated in 1973 when elevated blood viscosity and fibrinogen levels were
reported in patients with occlusive arterial disease (Dormandy et al 1973A).
Follow-up studies on this group of patients indicated that a high plasma fibrinogen
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level was associated with a poorer prognosis, and likely disease progression
(Dormandy et al 1973B).
The Northwick Park Heart Study, a prospective study of the thrombotic
component of ischaemic heart disease, showed that major ischaemic cardiac events
were increased in men with an elevated plasma fibrinogen level at entry into the
study (Meade et al, 1986), and demonstrated a strong correlation between
fibrinogen levels and cigarette consumption. It was therefore postulated that the
association between smoking and'ischaemic heart disease was in part mediated via
fibrinogen (Meade et al 1987). The same may well hold true for patients with
peripheral vascular disease, and the elevated fibrinogen levels noted by Dormandy
(1973A) were a reflection of cigarette consumption in the population studied.
Subsequently fibrinogen has been linked to an increased risk of
cardiovascular and cerebrovascular events (Kannel et al, 1987, Yarnell et al, 1991,
Qizilbash et al 1991), as well as the prediction of death in patients with stable
intermittent claudication (Bannerjee et al, 1992). In addition fibrinogen has
emerged as an independent risk factor for stroke and myocardial infarction (Ernst,
1991), while the elevated levels of fibrinogen encountered in occlusive arterial
disease and ischaemic heart disease have been shown to be due to more than just
the effects of cigarette smoking (Yarnell et al 1991, Lowe et al 1991, Reid 1991).
The Edinburgh Artery Study has shown a strong relationship between the
presence of peripheral arterial disease in a population study, and fibrinogen levels
(Lowe et al, 1993), confirming the findings of other studies (reviewed by Leng &
Fowkes, 1991A). In addition, in a recent study of 157 patients with femoro-
popliteal vein grafts, plasma fibrinogen was the strongest predictor of graft
occlusion (Wiseman et al 1989), while it was previously reported in a small study
that post-operative elevation in fibrinogen levels is of prognostic value (Hamer et
al, 1973), although this effect was only observed on subgroup analysis, making
interpretation of the results difficult.
The measurement of fibrin degradation products (FDP's) offers a specific
means of assessing the level of fibrin turnover, and elevated levels of fibrin
degradation products have been found in association with occlusive arterial disease
(Al-Zahrani et al, 1992, Peltonen et al, 1992), while the Edinburgh Artery study
found a strong inverse correlation between levels of FDP's and the ABPI in a case
control study, suggesting a relationship with the severity of the ischaemia (Smith et
al, 1993). A similar correlation between FDP's and severity of ischaemia in
hospital patients with peripheral arterial disease has also recently been reported
(Reid, 1991).
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It now seems clear that both fibrinogen and fibrin degradation products are
raised in patients with occlusive arterial disease. At least some of the elevation is
related to cigarette usage, and may in fact be one of the mechanisms by which
smoking exerts its deleterious effects (Meade et al 1987, Yarnell et al 1991, Reid,
1991, Smith et al, 1993). The high levels of fibrinogen seen in PAOD may be a
response to the underlying atheroma of the vessel wall, in the manner of an acute
phase response (Meade, 1991), however the magnitude of the fall in fibrinogen
levels on stopping smoking is too great to be explained by the minimal regression
in atheroma that is seen on stopping smoking, and this tends to confirm that a large
part of the elevation in fibrinogen is directly related to cigarette consumption.
Pathological evidence of fibrin deposition within atherosclerotic plaques
supports the theory that fibrinogen is converted into fibrin within atherosclerotic
plaques (Smith & Staples, 1981). It also seems likely that fibrin is capable of
binding plasma lipoprotein fractions within plaques, providing an explanation for
the high concentration of lipoproteins observed in atheromatous plaques (Thompson
& Smith, 1989).
There is in addition to any affect of smoking on fibrinogen levels, a genetic
component contributing up to 15% of the variability in fibrinogen levels
(Humphries et al, 1987), and a recent case-control study concluded that variation at
the B fibrinogen locus was associated with an increased risk of arterial disease, but
that this was not mediated merely by an increase in plasma fibrinogen concentration
(Fowkes et al, 1992). Other studies of the genetic contribution to variations in
fibrinogen levels between individuals estimate the genetic contribution to be
somewhere between 3% (Thomas et al, 1991) and 50% (Hamsten et al, 1987A).
Fibrinogen also has a positive correlation with most other cardiovascular
risk factors (Ernst 1991), and the question remains whether fibrinogen has a direct
causal relationship with vascular disease, or is merely a marker of the severity of
the disease.
There are several mechanisms by which elevated fibrinogen levels may
contribute to occlusive arterial disease; fibrinogen links to platelet receptors to
promote platelet aggregation (Cook & Ubben, 1990), and platelet aggregability
increases with increasing fibrinogen concentrations (Meade et al, 1985). Fibrinogen
can promote a hypercoagulable state, leading to deposition of thrombus on
atheromatous plaques (Ernst 1991), it may contribute directly to the progress of
atheroma via fibrin deposition in the vessel wall (Smith & Staples, 1981,
Thompson and Smith, 1989), and it increases blood viscosity by its contribution to
plasma viscosity and red cell aggregation (Cook & Ubben, 1990).
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It is possible to understand the potential effects of an elevated fibrinogen on
the course of PAOD from the above outline, and also to postulate on the likely role
of fibrinogen in graft occlusion. The only study reported in the literature that
relates elevated fibrinogen levels to subsequent graft failure, reported a strong
correlation between plasma fibrinogen (measured 6 months post-operatively) and
graft occlusion (Wiseman et al, 1989), as well as between cigarette consumption
and graft occlusion. However there is insufficient evidence to support the case for
routine estimation of plasma fibrinogen in graft surveillance at the current time.
Fibrin degradation products, reflecting fibrin turnover, are perhaps more accurate
indicators of on-going thrombosis, and there is some evidence that they may be
more useful as predictors of graft occlusion (Reid, 1991).
Von Willebrand Factor (vWF)
Von Willebrand Factor (vWF) is a large multimeric glycoprotein present in
platelet a-granules, subendothelium, and plasma (Badimon & Fuster, 1992). It is
synthesized by the vascular endothelium (Jaffe et al, 1973, 1974), the major source
of plasma vWF (Wagner & Bonfanti, 1991), and also the megakaryocyte (Badimon
& Fuster, 1992). vWF has two main functions: it plays a significant role in
platelet-vessel wall interactions (Badimon & Fuster, 1992), and acts as a carrier for
factor VIII (Meyer et al, 1991). The formation of biologically active multimeric
forms of vWF occurs within endothelial cells, which spontaneously release small
multimers into plasma and the endothelial basement membrane (to which the vWF
becomes bound), although the release of large multimers, stored in Weibel-Palade
bodies within the endothelial cells, requires stimulation by inflammatory mediators
(Wagner & Bonfanti, 1991). It is these large multimers that are most effective in
the promotion of platelet adhesion (Meyer et al, 1991), although all sizes of vWF
can carry factor VIII (Wagner & Bonfanti, 1991).
The role of vWF in mediating platelet adhesion involves a conformational
change in the vWF molecule, associated with its binding to the subendothelium.
Although endothelial cells produce vWF that binds to the subendothelium on
secretion, this bound vWF only accounts for 40% of total platelet adhesion, and
normal adhesion requires the presence of additional plasma vWF (Sixma & de
Groote, 1991). Further studies have indicated that platelet adhesion can be
increased beyond that normally observed, in the presence of elevated plasma vWF
levels (Zwaginga et al, 1990).
Adhesion of vWF to blood vessel walls is brought about by a number of
different collagen binding sites on the vWF molecule. Binding to type I and type
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Ill collagen found in the deeper layers of the vessel wall is mediated by at least 2
separate binding sites (Pareti et al, 1987), and occurs on exposure of this collagen,
following vascular injury. Binding to the subendothelium however, involves a
separate domain on the vWF molecule, which is thought to bind to subendothelial
type IV collagen (Sixma & de Groote, 1991) exposed following endothelial injury.
Following adhesion of vWF to the vessel wall, the molecule undergoes a
conformational change that exposes adhesion sites for platelets, which have a
number of binding sites for the vWF molecule (Ruggeri et al, 1983). This vWF-
mediated adhesion of platelets to the vessel wall requires the presence of calcium,
and appears to be of more importance at high shear rates, adhesion at low shear
rates being rapidly mediated by proteins such as fibronectin (Sixma & de Groote,
1991). Although vWF-mediated adhesion is much slower than that of fibronectin, it
is irreversible, and it is this fact that makes vWF the important mediator of platelet
adhesion at high shear rates when platelets are easily washed away from
fibronectin.
Platelet vWF is released by various agonists and then binds to the vWF
receptors on the platelet membrane. This enhances spreading of the initial contact
platelets that have bound to plasma and subendothelial vWF at the site of
endothelial injury, and may act as an intercellular bridge between platelets
(Gralnick et al, 1991), promoting platelet aggregation at the high shear rates
typically encountered in the arterial circulation (Ikeda et al, 1991). The expression
of platelet vWF can be inhibited by aspirin, which inhibits 80% of ADP-induced
platelet vWF expression, however aspirin has no effect on thrombin-induced
platelet vWF expression, although this is inhibited by elevated levels of fibrinogen
(Gralnick, et al, 1991).
The in-vitro role of vWF in platelet adhesion at high shear rates appears to
be supported by the findings of in-vivo studies where occlusive coronary artery
thrombi are produced by a standard injury-stenosis procedure. These occlusive
lesions consist of platelet-fibrin thrombi, and only develop in the presence of
plasma von Willebrand Factor: The formation of such occlusive thrombi was not
observed in von Willebrand Disease pigs deficient in vWF, while restoration of
vWF levels to normal resulted in occlusive thrombus formation at the sites of
arterial injury. (Brinkhous et al, 1991, Nichols et al, 1991).
The implication of these findings is that a high shear rate, such as that
encountered in the arterial circulation, particularly at arterial stenoses, is essential
for vWF to produce occlusive arterial thrombi, and for such thrombi to develop the
vascular injury must involve exposure of the media (Nichols et al, 1991). The
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development of occlusive thrombi can be abolished by the use of a monoclonal
antibody to vWF, but nonocclusive microthrombi are still formed suggesting that
the role of vWF may be in supporting the progression of these microthrombi to
occlusive thrombi (Nichols et al, 1991). In PAOD medial exposure occurs
following endothelial injury (Ross & Glomset, 1976), while areas of high shear
rate are found at the arterial wall, at sites of atherosclerotic stenosis, and in the
microcirculation (Lowe, 1986).
There is evidence that elevation in plasma vWF levels is associated with
PAOD (Smith, 1991, Reid, 1991, Blann, 1993). Some of this elevation is related
to smoking habit (Blann, 1992), and to other risk factors for atherosclerosis, (Blann
et al, 1992, Blann & McCollum, 1992A, 1992B), but some of the elevation of
vWF may be a direct consequence of endothelial damage associated with
atherosclerosis. Although the mechanism of endothelial damage in atherosclerosis
is unclear, there is a correlation between vWF levels and lipid peroxides in
cigarette smokers that suggests one possible mediator of endothelial damage is the
production of oxygen free radicals (Blann, 1991, Smith et al, 1993).
The precise role of vWF in arterial thrombosis and occlusive arterial disease
has yet to be determined despite evidence that this endothelial product is elevated in
the disease. This may solely be a reflection of the endothelial damage associated
with peripheral arterial disease, but it may be that elevated levels of vWF either
lead to an increased risk of developing occlusive thrombi at sites of atheroma, or
contribute directly to the development of arterial (or graft) stenosis.
Plasminogen Activator Inhibitor and Tissue Plasminogen Activator.
Thrombin mediated conversion of fibrinogen to cross-linked fibrin is the
end result of the coagulation pathway. Subsequent fibrinolysis is brought about by
a complex enzyme cascade, that generates localised proteolysis (Kruithof, 1988).
Central to this is the action of plasmin, which is converted from plasminogen by
the action of endothelial cell-derived tissue plasminogen activator (t.P.A.), and
which subsequently cleaves cross-linked fibrin, with the production of FDP's. This
fibrinolytic enzyme system contributes to the precise regulation of haemostasis,
ensuring that fibrin production is neither excessive (with thrombotic sequelae) nor
deficient (with haemorrhagic sequelae). Plasmin activity is specific for excessive
fibrin deposits, as t.P.A. is a poor plasminogen activator in the absence of fibrin
(Kruithof, 1988).
Plasminogen activator inhibitor (P.A.I.), is a fast-acting inhibitor of t.P.A.
found in normal plasma (Kruithof et al, 1984), and released from endothelial cells
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and from stimulated platelets (Kruithof et al, 1986), rapidly complexing with
t.P.A. to reduce its activity in plasma. The binding of P.A.I, to clot-bound t.P.A.
however is much slower (Kruithof et al, 1984), and its main role would appear to
be in the regulation of plasma t.P.A. activity.
Although plasma levels of P.A.I, are highly variable in healthy individuals,
increased P.A.I, activity has been observed in a number of disease states including
cardiovascular and thromboembolic disease (Kruithof et al, 1988). P.A.I, has been
shown to be elevated in survivors of myocardial infarction (Hamsten et al, 1985),
and independently related to reinfarction (Hamsten et al, 1987B). Elevated pre¬
operative P.A.I, levels, and reduced t.P.A. levels have also been shown to be
associated with post-operative DVT formation in a small series of orthopaedic
patients (Paramo et al, 1985).
Some of the wide variation in P.A.I, and t.P.A. levels reported (Kruithof
et al, 1988), may be related to the observation that the plasma levels of these
substances increase with age (Hashimoto et al, 1987). There is also evidence of a
circadian fluctuation in the levels of t.P.A. and P.A.I. (Urano et al, 1990), and in
addition, lipid levels and their dietary modification can influence t.P.A. and P.A.I.
(Mehrabian et al, 1990, Yamada et al, 1990).
Although there is little data on P.A.I, and t.P.A. levels in peripheral arterial
disease, levels of P.A.I, do appear to be elevated in patients with peripheral
vascular disease (Speiser et al, 1990, Reid, 1991, Smith et al, personal
communication), while both P.A.I, and t.P.A. are elevated in patients with
coronary artery disease (Munkvad et al, 1990, Jansson et al, 1991), although this is
disputed by others (Meyers et al, 1991).
Elevated levels of P.A.I, observed in peripheral arterial disease may
predispose to an impairment of fibrinolysis with an associated thrombotic tendency,
which may be of relevance in thrombotic occlusion of both native arteries, and
arterial grafts in patients with occlusive arterial disease, however until further
studies are carried out this must remain as speculation.
Factor VII
This vitamin K dependent plasma glycoprotein is activated by tissue factor,
and is thought to initiate coagulation by the extrinsic pathway, with subsequent
activation of factor X. Recent work has however indicated that there are not
separate extrinsic and intrinsic pathways, as complex interrelationships exist
between the various elements of the coagulation cascade (Messmore, 1981, Prydz,
1992). Nevertheless, population studies have suggested that increased factor VII
62
levels are associated with an increased risk of ischaemic heart disease (Meade et al,
1986, Broadhurst et al, 1991). This may be related to the ability of Factor VII to
initiate the coagulation pathway, with eventual production of fibrin thrombi, and it
has been postulated that increased levels of Factor VII lead to increased coagulation
(Prydz, 1992).
There are few studies on Factor VII levels in peripheral arterial disease,
although an association between acute limb ischaemia or graft occlusion, and
reduced factor VII levels has been demonstrated (Cortellaro et al, 1992). Factor
VII levels are however affected by a number of non-specific stimuli (Meade,
1991), and the role of factor VII in atherosclerotic vascular disease is not yet well
defined.
SUMMARY OF CHAPTER 1
Population studies indicate that the prevalence of symptomatic and
asymptomatic peripheral vascular disease in the older community is between 5 and
12.5% in the United Kingdom, and that the incidence of symptomatic peripheral
arterial disease rises with age. This is of importance in a society with an increasing
elderly population.
Studies of the natural history of symptomatic peripheral vascular disease are
reviewed, and indicate that, in addition to a significantly increased cardiovascular
mortality rate, between one-quarter and one-third of patients will show a
deterioration in their symptoms with time. This highlights the need for careful
patient selection prior to surgery for non limb-threatening disease.
Current methods of investigation and treatment of symptomatic peripheral
vascular disease have been reviewed, with particular reference to infra-inguinal
arterial disease, which represents the majority of symptomatic disease, and in
which reconstructive surgery still has a significant failure rate. The role of
percutaneous recanalisation procedures is also reviewed.
The known causes of infra-inguinal graft failure are described, and the
importance of graft surveillance in the prevention of graft occlusion is discussed.
The pathogenesis of atherosclerosis is briefly reviewed, with reference to
the presumed aetiology of the lesions, and current thinking on the role of lipids in
arterial disease.
The relationship of blood rheology and thrombotic mediators to vascular
disease is reviewed with particular emphasis on blood viscosity, fibrin turnover,
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and the endothelial products von Willebrand Factor Antigen, Tissue Plasminogen
Activator, and Plasminogen Activator Inhibitor. The possible roles of these
variables in the promotion of atherosclerosis, thrombosis, and graft occlusion (and
hence their potential value in pre-operative patient selection) are discussed.
Recent evidence linking neutrophil granulocytes and their activation
products to intermittent claudication and critical ischaemia are also summarised.
AIMS OF THESIS
This thesis was undertaken to address a number of aspects of blood
rheology and levels of potential thrombotic mediators, that have not previously
been investigated in patients with PAOD. Namely:
Is there any relationship between the severity of arterial occlusive disease,
determined directly by angiography, and the disturbances in blood rheology and
levels of potential thrombotic mediators reported to occur in PAOD ? (Chapter 3).
Does the resolution of critical limb ischaemia (either by revascularisation or
by amputation) return rheological and thrombotic parameters to the levels observed
in an age-matched population ? (Chapter 4).
What are the effects of percutaneous transluminal angioplasty (PTA) on
blood rheology and levels of potential thrombotic mediators ? (Chapter 5).
Are pre-operative rheological and haemostatic parameters related to
outcome (graft occlusion or death), following infra-inguinal revascularisation
surgery, and can the pre-operative determination of these parameters assist in the
selection of patients suitable for infra-inguinal revascularisation procedures ?
(Chapter 6).
Does the material employed for infra-inguinal revascularisation affect the
post-operative levels of potential thrombotic mediators ? (Chapter 6).
These were the main issues that this thesis set out to address, although other






This chapter details the subjects, materials and methods, and laboratory
procedures employed in carrying out the studies undertaken in the course of this
thesis.
Patient Selection
All the patients studied were in-patients attending either the Unit for
Peripheral Vascular Surgery, Glasgow Royal Infirmary, which is a specialised
vascular surgery unit serving the Eastern district of Glasgow, and a tertiary referral
centre for surrounding District General Hospitals, or the Level 5 Surgical Unit,
Gartnavel General Hospital, Glasgow, where all 3 consultant general surgeons have
a special interest in vascular surgery. This unit serves the western district of
Glasgow, and also acts as a tertiary referral centre for surrounding District General
Hospitals.
A full clinical history and examination were carried out by myself, and the
findings recorded for each patient, peripheral pulses were documented, and in 90%
of patients, the ankle brachial pressure index (ABPI) was measured prior to blood
sampling. Local Ethical Committee approval for patient participation in the studies
was obtained, and all patients were given a detailed explanation of the methods and
aims of the studies prior to obtaining their consent.
Patients returning for review were seen by myself, in the vascular
laboratories of Gartnavel General Hospital and Glasgow Royal Infirmary, where
clinical examination and venous blood sampling (as described below), was
performed.
The diagnosis of peripheral vascular disease was based on a clinical history
of intermittent claudication or ischaemic rest pain, as defined in the report of the
Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North
American Chapter, International Society for Cardiovascular Surgery (1986). In
addition, an ankle brachial pressure index (ABPI) of less than 0.90 (Laing &
Greenhalgh, 1983), or a fall in ABPI of more than 0.15, following claudication-
inducing exercise (Nicolaides, 1991) were required to confirm the diagnosis. 95%
of all patients studied also underwent either conventional contrast angiography, or
Digital Subtraction Angiography (DSA) as part of their routine assessment.
Critical limb ischaemia, was defined in accordance with the
recommendations of the European Working Group on Critical Limb Ischaemia
(1990), based on an ankle systolic pressure measurement in the affected limb of
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less than or equal to 50 mm Hg, in preference to toe pressure measurement, which
is not routinely performed in our vascular laboratories.
Smoking Habit
A detailed smoking history was obtained for all patients, and blood
carboxyhaemoglobin levels were measured prior to surgery in all patients, and
repeated at each return out-patient visit. Those patients admitting to being current
smokers, or in whom the carboxyhaemoglobin levels exceeded 2.0% (Vesey et al,
1982), were classified as current smokers. Patients who had stopped smoking more
than 5 years ago were classed as non-smokers, while those patients who had
stopped smoking between 1 month and 5 years previously were labelled as recent
smokers. Patients in either of these 2 categories in whom blood
carboxyhaemoglobin levels exceeded 2.0% at return visits were assumed to have
been active smokers for the duration of the studies.
Blood Sampling
A sterile plastic syringe and 19-gauge butterfly needle (Abbott Ireland Ltd.
Rep. of Ireland) were used to collect all blood samples. Blood was sampled without
venous stasis, after puncturing a full ante-cubital fossa arm vein and then releasing
the tourniquet prior to sampling. This method should minimise haemoconcentration
and the elevation in tissue plasminogen activator levels associated with the use of a
tourniquet (Lewis, 1982, Levin et al, 1984).
Sample Handling
Two 4ml samples of blood for the estimation of full blood count, platelets,
and carboxyhaemoglobin were added to tubes containing 0.1ml of liquid
dipotassium EDTA 1.5mg/ml (EDTA, Steyne Laboratories), and an additional 5ml
of blood for the estimation of haemorheological variables was added to tubes
containing dried dipotassium EDTA 1.5mg/ml (Monoject, Sherwood Medical,
U.K.). All these tubes were gently mixed and stored at room temperature (20-
25 °C) for a maximum of 4 hours following collection.
One tube of EDTA blood for full blood count and platelet estimation was
sent to the routine laboratory of the Department of Haematology, Glasgow Royal
Infirmary, within 6 hours of collection, while a further tube of EDTA blood was
sent to the Department of Biochemistry, Glasgow Royal Infirmary, for the
measurement of carboxyhaemoglobin levels.
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Measurement of whole blood viscosity, haematocrit, and red cell
aggregation were performed in the University Department of Medicine, Glasgow
Royal Infirmary, within 6 hours of collection, after mixing of the EDTA sample on
a rotating and gently oscillating oblique wheel mixer, to prevent phase separation.
After the above measurements, the remaining EDTA-anticoagulated blood
was centrifuged at 2,500 g for 10 minutes at room temperature, and 2 samples of
lml of plasma were aspirated with a plastic Pasteur pipette. One sample was snap-
frozen and stored at -70 °C in a stoppered plastic tube , while the remaining sample
was placed in a stoppered plastic tube until plasma viscosity was measured, usually
within 2 hours of separation. Occasionally the specimen was stored at 4°C for up
to 48 hours prior to the measurement of plasma viscosity, as such storage has no
significant effect on this parameter.
A further 5-10 mis of blood were added to a plain glass tube, and
centrifuged at 4°C at 2,500 g for 15 minutes within 4 hours of collection. 2mls of
serum was then sent to the Department of Pathological Biochemistry, Glasgow
Royal Infirmary for estimation of urea, creatinine, albumin, globulin, and total
cholesterol. A further serum sample was stored at -70°C in a stoppered plastic
tube.
In addition, 9mls of blood for the measurement of thrombotic mediators
were added to a plastic tube containing lml of trisodium citrate ( 0.109M ). These
tubes were freshly prepared and stored at 4°C, and were transported in a vacuum
flask containing an ice-pack at 4°C. After addition of blood they were gently
mixed and replaced in the flask at 4°C. The citrated blood was then centrifuged at
4°C for 15 minutes at 2,500 g, within 3 hours of collection, and decanted into
small stoppered plastic tubes, each containing 0.5mls of plasma which were snap
frozen and stored at -70°C for later assay in batches.
LABORATORY METHODS
Introduction
Except where indicated in the following text, all assays were carried out in
the University Department of Medicine Haemostasis and Thrombosis Laboratory,
Glasgow Royal Infirmary, by the laboratory scientific staff. The tests were carried
out using the laboratory's standard methods, and the laboratory's performance of
these tests was satisfactorily assessed, where appropriate, by the National External
Quality Control Assurance Scheme (NEQAS). Unless indicated in the text, all
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assays were carried out within 6 weeks of specimen collection, on samples that
were snap-frozen and stored at -70°C until thawed for assay.
Measurement of Fibrinogen
Clottable fibrinogen was measured on a Coag-A-Mate X2 automated
coagulometer (Organon-Technika, Cambridge, U.K.), by the standard Clauss
assay, using reagents and standards supplied by Organon-Technika, within 1 week
of collection, plasma samples being stored at -70°C prior to assay.
Measurement of Factor VII levels
Factor VII levels were measured by a coagulometric method on an
automated coagulometer (ACL 300, Instrumentation Laboratory (UK.) Ltd.,
Warrington, Cheshire), using reagents supplied by Instrumentation Laboratory
(UK.). The ACL 300 measures factor VII levels by performing a modified
prothrombin time test: the plasma sample is diluted and added to Factor VII-
deficient plasma. Correction of the prolonged clotting time of the Factor VII-
deficient plasma is proportional to the concentration (expressed in terms of activity
%) of Factor VII in the plasma sample being assayed. The exact activity is then
interpolated from a standard calibration curve automatically measured on the
instrument.
Measurement of cross-linked FDP levels
The measurement of cross-linked fibrin degradation products was carried
out using the "Dimertest" enzyme immunoassay kit, supplied by Agen Biomedical
Limited (Agen Ltd., Parsippany, New Jersey, USA).
This kit enables the detection of the degradation products of cross-linked
fibrin by the use of an Enzyme-Linked Immunosorbent Assay (ELISA): Initially
plasma fibrinogen is converted to fibrin by the action of thrombin, and the resulting
fibrin monomers polymerise, forming a soluble gel of fibrin that becomes cross-
linked by thrombin-activated factor XIII, forming an insoluble fibrin clot. The
fibrinolytic enzyme plasmin cleaves both fibrinogen and fibrin, yielding fibrin
degradation products, but only those products from the degradation of cross-linked
fibrin contain d-dimer. The "Dimertest" detects those FDP's that contain the d-
dimer.
The principle of the test involves the use of a monoclonal antibody, DD-
3B6, which recognises d-dimer, and FDP's containing it. The DD-3B6 is bound to
microtitre wells, to which either plasma or standard dilutions of D-dimer are
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added. The wells are then incubated and subsequently rinsed with buffer solution.
Thereafter a Tag monoclonal antibody (DD-4D2), conjugated with horseradish
peroxidase is added to the wells, and this binds to cross-linked FDP that has been
immobilised by the DD-3B6 antibody bound to the wells. After further washing,
addition of substrate leads to the development of colour which is then read by
absorbence spectrometry, and compared with the standard curve. Two
measurements were made of each sample, and an average value obtained for the
specimen.
Elevated levels of cross-linked FDP detected by this method indicate
increased fibrinolysis, and imply an alteration in fibrin turnover.
Measurement of von Willebrand Factor Antigen
Von Willebrand Factor antigen (vWF) levels were measured by an ELISA
technique (Dako, High Wycombe, UK.), within 6 weeks of specimen collection.
The technique involves the use of microtitre wells coated with a monoclonal
antibody to von Willebrand Factor. 100 microlitre aliquots of patients sera are
added to some wells, while standards diluted in a buffer solution are added to
others. After 1 hour of incubation at room temperature, the plates are washed and
peroxide-conjugated detection antibody is added to each well, and incubated for a
further hour. After subsequent addition of a colour reagent, the plates are read by
absorption photometry at 492 nm. and the results of the patient samples are read
against the standard curve plotted for the assay.
Plasminogen Activator Inhibitor (P.A.I.)
Plasma Plasminogen Activator Inhibitor levels were determined by a
commercially available chromogenic substrate assay (KabiVitrum Ltd. Uxbridge,
Middx., UK.).
The assay involves the addition of a fixed amount of tissue Plasminogen
Activator (t.P.A.) in excess to undiluted plasma, where it rapidly forms an inactive
complex with the fast inhibitor P.A.I.-l. Plasminogen is then activated to plasmin
by the residual t.P.A. in the presence of a stimulator. The amount of plasmin
formed is directly proportional to the residual t.P.A. activity, and therefore
inversely proportional to the P.A.I, activity in the plasma sample. Plasmin levels
are then determined by measuring the amidolytic activity of plasmin on a
chromogenic substrate (S-2403), which releases p-nitroaniline, levels of which are
determined using a photometer at 405nm. The absorbence of the sample is then
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compared with the standard curve generated for each test run, and a value for the
level of P.A.I, activity obtained.
Tissue Plasminogen Activator (t.P.A.) levels
Levels of t.P.A. antigen were measured with a commercially available
ELISA method (Biopool TintElize, Biopool AB, Umea, Sweden), utilising a double
antibody principle: Plasma samples were added to 2 adjacent wells, one containing
normal goat IgG (the "N" well), the other containing goat anti-human t.P.A. IgG
(the "A" well), and incubated for 3 hours. Horseradish peroxidase labelled anti-
t.P.A. IgG (conjugate) is then added to the wells, and binds to free antigenic
determinants on the t.P.A. molecules present in the plasma samples. After
incubation any unbound conjugate is washed away, and the amount of peroxidase
activity remaining in the wells is determined by the addition of the substrate
Orthophenylenediamine Dihydrochloride.
The ensuing colour change is the measured photometrically for each well,
and the difference between the "A" and "N" wells calculated. This difference
represents the t.P.A. specific part of the response, and the t.P.A. concentration is
obtained by plotting this value on the standard curve generated for each test run,
standard concentrations of t.P.A. being pre-coated onto each stripwell plate for this
purpose.
Urea, creatinine, albumin and globulin
Serum samples for determination of urea, creatinine, albumin, and globulin
levels were sent to the routine laboratory of the Department of Pathological
Biochemistry, Glasgow Royal Infirmary, where analysis was performed on an
Olympus AU 5200 analyser, using reagents supplied by Olympus and Boehringer
Mannheim (UK. Ltd.).
Total Cholesterol
Serum cholesterol levels were measured on separated plasma samples, using
a Hitachi 717 automatic analyser, and Boehringer Mannheim (UK. Ltd.) reagents,
in the University Department of Pathological Biochemistry, Glasgow Royal
Infirmary.
Carboxyhaemoglobin Measurement
Carboxyhaemoglobin levels were measured on dipotassium EDTA
anticoagulated blood on a Co-Oximeter 282 (Instrumentation Laboratory Ltd.,
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Warrington, Cheshire, UK.), within 6 hours of sampling. All samples were
processed in the Department of Pathological Biochemistry, Glasgow Royal
Infirmary.
Red cell aggregation
Measurement of red cell aggregation was performed by myself and the
laboratory scientific staff on dipotassium EDTA anticoagulated samples of whole
blood. A photometric technique using an automated Myrenne MAI Aggregometer
(Myrenne GMBH, Roetgen, Germany) was employed. This device measures
aggregation in arbitrary units, based on the increasing transmission of light through
a sample of 25/ri of whole blood over a 5 second period of stasis, prior to which
the sample was subjected to a 10 second period of high shear rates of around
600s^' to disrupt any aggregates. The greater the red cell aggregation, the greater
the transmission of light through the sample, and the higher the numeric value
obtained from the aggregometer.
All measurements were performed at room temperature, and at native
haematocrit, as standardising for haematocrit appears to make little difference to
red cell aggregation in clinical situations (MacRury, 1990). Measurements were
repeated twice, and a mean of the 2 readings obtained. If there was a difference of
greater than 0.4 units between the 2 readings, then they were repeated again with a
fresh sample until a consistent result was obtained.
Haematocrit
Haematocrit was measured by the Hawksley microhaematocrit method
(Hawksley & Sons, Lancing, Sussex, UK.) in accordance with the International
Committee for Standardisation in Haematology (ICSH) recommendations (1986),
and measurements were performed by the laboratory scientific staff and myself:
Duplicate samples of well mixed blood anticoagulated with dipotassium
EDTA were drawn up into glass capillary tubes of 1mm diameter, and sealed at
one end. The tubes were placed in the Hawksley microcentrifuge and centrifuged at
13,000g for 5 minutes. The haematocrit was then read as a percentage ratio of the
red cell pack to that of the whole sample, without correction for plasma trapping.
An average of the readings from the 2 samples was taken, rounded to the nearest
percentage point.
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Plasma and whole blood viscosity
Plasma and whole blood viscosity were measured at 37 °C and at high shear
rates (>300s"l) with a Coulter-Harkness semi-automatic capillary viscometer
(Coulter Electronics Ltd., Luton, Beds., UK.). This device measures the time
taken for the plasma or whole blood sample to move through a capillary tube using
a constant head of pressure, thus enabling calculation of the mean velocity.
Viscosity of the liquid can then be calculated from the Hagen-Poiseuille equation
(Ch.l, p.52).
From the measurement of whole blood viscosity and the measurement of
the haematocrit of the specimen, the haematocrit-corrected blood viscosity was
subsequently calculated from a standard formula (Matrai et al, 1987).
Full Blood Count and platelet count
Both the full blood count and platelet count were measured in the
Department of Haematology, Glasgow Royal Infirmary, on a Coulter-S Counter
(Coulter Electronics Ltd., Luton, Beds., UK.), within 6 hours of the sample being
taken.
Ankle Brachial Pressure Index
The ankle brachial pressure indices (ABPI) were measured and calculated in
the vascular laboratory of Gartnavel General Hospital, Glasgow, by the laboratory
technician, and in the Vascular Laboratory of Glasgow Royal Infirmary, either by a
research nurse, or by myself: After a 10 minute period of rest, the brachial,
anterior tibial, and posterior tibial systolic blood pressures were measured with a
standard sphygmomanometer and an SD1 super Dopplex bi-directional Doppler
flow detector with an 8 MHz Doppler probe (Huntleigh Technology pic, Cardiff,
UK.). The ABPI was calculated for both limbs by dividing the highest systolic
ankle pressure in each limb, by the brachial systolic pressure. The highest absolute
systolic pressure for each limb was also documented.
Other vascular laboratory studies employed in this thesis were carried out
by myself in conjunction with a vascular research nurse at the vascular laboratory
of Glasgow Royal Infirmary, or in conjunction with the vascular laboratory
technician at Gartnavel General Hospital, and are documented in detail in the
relevant chapters.
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Data Storage and Analysis
All data gathered in the course of the work undertaken for this thesis was
stored in dBASE III plus files (Ashton-Tate (UK) Ltd., Maidenhead, Berks., UK.)
on an IBM-compatible 386SX microcomputer (Dolan Computers Systems Ltd.,
Carmarthen, Wales), and statistical analyses were carried out by myself using the
CSS.Statistica package (Statsoft, Tulsa, USA.), with the exception of multivariate
analyses which were carried out by Dr. Janet Love, Research assistant, Robertson
Centre for Biostatistics, in conjunction with Dr. G. D. Murray, Director and
Reader in Medical Statistics, Robertson Centre for Biostatistics, University of
Glasgow. All data plots were created by myself using the CSS:Statistica package.
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CHAPTER 3




Studies in hospital patients with peripheral arterial disease have
demonstrated an association between elevated blood viscosity, red cell aggregation,
plasma fibrinogen, and peripheral vascular disease (Dormandy, 1971, Dormandy et
al, 1973A, Ernst & Matrai, 1987, Reid, 1991), while fibrinogen may have a
predictive role in the outcome following reconstructive vascular surgery (Hamer et
al, 1978, Wiseman et al, 1989). In addition, population studies have demonstrated
that the elevation of plasma fibrinogen and other thrombotic mediators is related to
the severity of the disease, as determined by the ankle-brachial pressure index
(ABPI) (Leng & Fowkes, 1991A, Lowe et al, 1993, Smith et al, 1993). In spite of
being a good screening test (Horrocks & Scott, 1991), the resting ABPI is however
an indirect measure of the severity of disease, and gives no clear indication of the
extent of arterial lesions. It is also inaccurate in patients who have heavily calcified
vessels, such as diabetics, in whom an artificially high ABPI is often found
(Krupski & Effeney, 1988, Barnes, 1991).
The aim of this study was therefore to investigate whether or not previously
observed associations between blood rheology, potential thrombotic mediators, and
the presence of peripheral arterial disease were related to the severity of the
occlusive arterial disease when this is determined by the diagnostic standard for the
assessment of peripheral vascular disease (Barnes, 1991), namely angiography. The
relationship between angiographic extent of occlusive arterial disease and blood
rheology and thrombotic mediators, has not previously been studied.
Aims:
1) To compare measures of blood rheology and thrombotic mediators in patients
with peripheral arterial disease, and in an age-matched population sample from the
West of Scotland.
2) To determine the relationship between the angiographic extent of peripheral
arterial disease, red cell aggregation, and blood viscosity, in patients attending a
vascular surgery unit for a variety of revascularisation procedures.
3) To determine the relationship between angiographic extent of peripheral arterial
disease, and a number of potential thrombotic mediators: plasma fibrinogen, cross-
linked fibrin degradation products (FDP), von Willebrand Factor antigen (vWF),
factor VII, Plasminogen Activator Inhibitor (P.A.I.), and tissue Plasminogen
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Activator (t.P.A.). The relationship between t.P.A. and symptomatic peripheral
arterial disease has not previously been reported.
4) To establish the effect of age, sex, and smoking on any association between




219 in-patients attending the vascular surgery units at Glasgow Royal
Infirmary and Gartnavel General Hospital, had venous blood sampled as previously
described, prior to any surgical intervention. These patients were all suffering from
intermittent claudication (Ad Hoc Committee on reporting standards, 1986), which
had been stable for at least 3 months (n=147), or critical limb ischaemia (n=72)
(European Working Group on Critical Limb Ischaemia, 1990).
54 (25%) of the 219 patients had undergone prior revascularisation surgery,
and 9 of these 54 had subsequently undergone major amputation (above or below
knee). There were an additional 2 patients who had undergone primary major
amputation, and 9 patients in whom percutaneous angioplasty had previously been
carried out for claudication. Just over one-quarter of the cases (61 patients, 28%)
had evidence of tissue infection in one or other limb at the time of venepuncture.
The mean age of the patients studied was 66 years with an age range of 36
to 89 years, and there were 138 males and 81 females.
Control values
The control values for the variables studied were derived from data gathered
from 220 subjects aged between 55 and 75 years of age (mean age 65 years), in
local population studies (the first, second, and third W.H.O. MONICA surveys).
These studies were carried out in random samples of the population aged 25-75
years in the Northern section of the Greater Glasgow Health Board area, to
determine the population distribution of cardiovascular risk factors. As part of this
study, venous blood samples were taken from all of the subjects. Sample handling
and storage were as previously described, and all assays were performed by the
staff of the University Haemostasis and Thrombosis Laboratory, Glasgow Royal
Infirmary. The results of the assays for 220 subjects aged between 55-75 years
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were subsequently retrieved, and provide the age-matched population control
values for this study.
Angiographic scoring
All of the 219 patients studied had undergone angiography between 3 days
and 9 months prior to blood sampling, and 193 (88%) had also undergone
measurement of the ankle-brachial pressure index (ABPI). Over 90% of the
patients had undergone Seldinger arteriography, with retrograde aortic cannulation
via the common femoral artery. A small number of patients had undergone
translumbar aortography under general anaesthetic, and in 5 patients with infra-
inguinal arterial disease, Digital Subtraction Angiography (DSA), was required in
addition to obtain adequate imaging of distal run-off.
All of the angiograms were scored by myself, using the scoring system first
described by Bollinger and his co-authors (1981). This scoring system divides the
arterial tree of the lower limb into a number of segments, and assigns a vectorial
score to each segment that is determined by the pattern of occlusions, stenoses, and
plaques within it, and an additive score that reflects the severity of the disease
within the segment (Fig. 3.1, p.79).
For the purposes of this study, the vectorial component of the angiographic
score was ignored, and an additive total for the vascular tree from infra-renal aorta,
to 5 cm beyond the origin of each of the 3 calf vessels, was obtained by adding all
19 segmental scores. The greater the overall total, the greater the extent of the
vascular pathology. Patent pre-existing vascular grafts were assessed as for native
vessels, the underlying by-passed lesions being ignored. For example, if a patient
had undergone aorto-iliac grafting for bilateral common iliac disease, the aorta and
iliac segmental scores would be derived from the angiographic appearance of the
graft and native arteries proximal and distal to the anastomoses, regardless of the
appearance of the underlying native common iliac vessels. Patients in whom a prior
limb amputation had been performed were assessed on the basis of their remaining
vascular tree, and the additive total reflects the extent of arterial disease in the
remaining vessels.
The distribution of angiographic scores in the 219 patients approximated to
the normal distribution (Figure 3.2, p.80), with a mean value of 106 (S.D. 35),
and a range of 26-204. 30 of the 219 angiograms, selected at random, were
subsequently rescored by myself, in a blinded fashion, between 12 and 16 weeks
after the original scoring assessment had been made. These results were then used








Figure 3.1: Diagrammatic representation of arterial segments and scoring chart















Figure 3.2: Distribution of Bollinger angiogram score in 219 patients with
occlusive arterial disease.
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Patient 1st score 2nd score lst-2nd difference^
1 71 81 10 100
2 114 104 -10 100
3 83 93 10 100
4 79 88 -9 81
5 153 161 8 64
6 96 98 2 4
7 68 84 16 256
8 100 93 -7 49
9 78 72 -6 36
10 111 122 11 121
11 99 92 -7 49
12 77 76 1 1
13 85 82 -3 9
14 115 121 6 36
15 76 82 6 36
16 152 154 2 4
17 138 140 2 4
18 93 97 4 16
19 91 86 -5 25
20 73 70 -3 9
21 145 151 6 36
22 118 129 11 121
23 101 112 11 121
24 80 99 19 361
25 100 100 0 0
26 67 61 -6 36
27 105 114 9 81
28 54 63 9 81
29 85 87 2 4
30 74 67 -7 49




coefficient of variation = 5.6/97.7 = 0.057 or 5.7%
percentage error = 2 x 5.6/97.7 = 0.114 = 11%
Table 3.1: Repeatability of angiogram scores in 30 cases.
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calculations (Table 3.1, p.81) show, the coefficient of variation was only 5.7%,
giving a percentage error for the measurement of 11%, indicating that the scoring
system has an acceptable repeatability in my hands.
Statistical Analyses
With the exception of the multivariate analysis, all statistical analyses were
performed by myself as previously described. Multivariate analysis was carried out
by Dr Janet Love, Research Assistant, Robertson Centre for Biostatistics,
University of Glasgow, in conjunction with Dr. G.D. Murray, Reader in Medical
Statistics, and Director, Robertson Centre for Biostatistics.
Multivariate stepwise regression analysis was performed on an IBM-
compatible microcomputer, using the BMDP statistical software package (BMDP
Statistical Software Inc., Cork, Eire), module 2R (Stepwise regression). Variables
entered into the multivariate analysis are listed in table 3.2. For the purposes of the
analysis atrial fibrillation, prior ischaemic heart disease, and prior cerebrovascular
disease, were combined to give a single category of 'other vascular pathology', and
patients were classified as smokers if they had been regular smokers within the past
5 years, and non-smokers if they had stopped smoking before this.
RESULTS
Age, ankle brachial pressure index, and patient characteristics.
Age correlated strongly with the angiographic severity of arterial disease
(Table 3.3, p.84, Figure 3.3, p.85) on univariate analysis. There was also a strong
negative correlation between the average ABPI (derived from the mean of the
highest ABPI reading at each, or the only, ankle), and the angiographic appearance
of the peripheral arterial tree (Figure 3.4, p.86). Age and the ankle brachial
pressure index were also strongly negatively correlated (r= -0.32, p <0.005).
As both the ankle-brachial pressure index and the Bollinger angiogram score
are methods of assessing the severity of arterial disease, the ABPI was excluded
from the multivariate analysis carried out to determine those factors that were
independently related to the Bollinger angiogram score. The presence of critical
limb ischaemia was also excluded from the multivariate analysis, as this term also
represents a response measure, and it was felt inappropriate to include it when
trying to model the underlying disease process.
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VARIABLE DESCRIPTION
Bollinger angiogram score response variable
sex male or female
age in years
other vascular pathology angina, M.I, T.I.A, C.V.A, or A.F
diabetes non-insulin and insulin dependent
hypertension diagnosed and on treatment
hyperlipidaemia previously diagnosed
smoking status current/recent or non-smoker
prior vascular surgery reconstruction or amputation
Presence of infection active sepsis in limbs, e.g. ulcer





cholesterol level fasting prior to surgery
plasma viscosity
whole blood viscosity





cross-linked FDP levels log(FDP)




Table 3.2: Variables entered into the multivariate analysis to determine
the predictors independently related to the angiographic severity of





Mean ABPI 193 -0.61 p < 0.0001
Cross-linked FDP's 213 0.56 p < 0.0001
Age 219 0.46 p < 0.0001
von Willebrand factor 215 0.40 p < 0.0001
Haemoglobin 219 -0.36 p < 0.0001
Haematocrit 208 -0.32 p < 0.0001
Plasma fibrinogen 216 0.30 p < 0.0001
Total cholesterol 205 -0.29 p < 0.0001
Platelet count 219 0.25 p - 0.0004
Factor VII 200 -0.21 p = 0.004
Plasma viscosity 200 0.18 p = 0.009
t.P.A. 195 0.15 p = 0.04
White cell count 219 0.12 p = 0.07
Corrected blood viscosity 190 0.10 p = 0.16
Red cell aggregation 203 -0.08 p = 0.24
Relative blood viscosity 207 - 0.06 p = 0.38
P.A.I. 198 - 0.04 p = 0.56
Table 3.3: Spearman rank order correlations between angiographic severity of
disease (Bollinger angiogram score) and blood rheology and
thrombotic mediators, in patients with symptomatic peripheral
arterial disease. Results are based on univariate analysis.
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BOLLINGER ANGIOGRAPHIC SCORE
Figure 3.3: Correlation between angiographic severity of disease and age of
patient on univariate analysis, (r = 0.46, p < 0.0001).
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Figure 3.4: Correlation between angiographic severity of disease and ankle-
brachial pressure index (ABPI) on univariate analysis,
(r = -0.61, p < 0.0001).
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Multivariate analysis of the patient background information indicated that
the age of the patient (F = 21.07, p < 0.0001), prior vascular surgery (F = 7.51,
p = 0.007), the presence of infection (F = 6.36, p = 0.012), and other vascular
pathology (prior transient ischaemic attack or completed stroke, prior myocardial
infarction, angina, and atrial fibrillation) (F = 7.52, p = 0.007), were all
independently useful in predicting the Bollinger score of the angiographic severity
of peripheral vascular disease. Smoking habit and other factors in the patient
history showed no independent association with angiographic severity of disease.
Viscosity and red cell aggregation
Blood viscosity was significantly higher in the age-matched population
controls than in patients with occlusive arterial disease (Table 3.4, p.88), while the
difference between relative blood viscosity in patients and controls only just
reached statistical significance. The differences in plasma viscosity between
patients and controls was minimal, and failed to reach statistical significance, while
red cell aggregation (measured in Myrenne units), was similar between the two
groups, although haematocrit was significantly lower in patients than in controls
(Table 3.4, p.88).
On univariate analysis (Table 3.3, p.84) there was a weak positive
correlation between the severity of arterial disease, as determined by the Bollinger
angiogram score, and plasma viscosity, with viscosity increasing with increasing
severity of disease. However there was no apparent association between blood
viscosity, or relative blood viscosity, and disease severity, or between red cell
aggregation and angiographic severity of disease on univariate analysis.
There was a strong negative correlation between angiographic disease
severity, haemoglobin (Figure 3.5, p.89), and haematocrit (Figure 3.6, p.90) on
univariate analysis.
Multivariate analysis was performed after adjusting for the significant
factors in the patient background (age, prior vascular surgery, infection, and other
vascular disease), and deleting cases where results were missing. None of the
rheological parameters studied were independently associated with the angiographic
severity of peripheral arterial disease in the patients studied, although haematocrit
showed a non-significant trend towards association (p = 0.08) (Table 3.5, p.91).
Thrombotic mediators
Plasma fibrinogen, vWF, Fibrin Degradation Products (FDP's), and
Plasminogen Activator Inhibitor (P.A.I.) were all significantly elevated in patients
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MANN
TEST CONTROLS CASES WHITNEY
U-TEST
W.C.C 6.2 8.5
(xl(P/l) (5.1-7.9) (7.0-10.4) p < 0.0001
Corrected blood 3.51 3.36
viscosity (mPa.s) (3.24-3.81) (3.14-3.62) p < 0.0001
Fibrinogen (g/1) 2.77 3.60
(2.34-3.29) (3.00-4.61) p < 0.0001
cross-linked 94 165
F.D.P. (ng/ml) (62-144) (101-289) p < 0.0001
von Willebrand 114 143
factor (iu/dl) (85-146) (100-196) P < 0.0001
Plasminogen Activator 93 108
Inhibitor (% pool) (69-112) (83-157) p < 0.0001
Factor VII (% pool) 113 103
(93-135) (85-115) p = 0.0005
Haematocrit (%) 44 43
(41-47) (39-46) p = 0.009
Relative blood 2.57 2.50
viscosity (2.39-2.71) (2.35-2.68) p = 0.05
Plasma Viscosity 1.35 1.34
(mPa.s) (1.29-1.43) (1.29-1.41) p = 0.16
Red cell aggregation 4.25 4.30
(units) (3.30-5.00) (3.40-5.50) p = 0.31
tissue Plasminogen 8.0 8.3
Activator (ng/ml) (5.3-11.0) (6.2-10.7) p = 0.37
Haemoglobin 14.0 13.6
(g/1) (12.0-16.0) (12.3-14.9) n.s
Table 3.4: Levels of blood viscosity and thrombotic mediators in cases and




Figure 3.5: Correlation between angiographic severity of disease and


























Figure 3.6: Correlation between angiographic severity of disease and
haematocrit on univariate analysis, (r = -0.32, p < 0.0001).
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REFER
VARIABLE NUMBER F-STATISTIC TO p VALUE
hyperlipidaemia 213 3.46 F( 1,206) p = 0.06
haematocrit 203 3.01 F(l,196) p = 0.08
factor VII level 198 2.71 F(l, 191) p = 0.10
platelet count 213 2.66 F( 1,206) p = 0.10
hypertension 213 2.17 F(l,206) p = 0.14
relative blood viscosity 187 2.10 F(1,180) p = 0.15
haemoglobin 213 1.76 F(l,206) p = 0.19
white cell count 213 1.32 F( 1,206) p = 0.25
P.A.I, level 194 1.28 F(1,187) p = 0.26
corrected blood viscosity 187 1.08 F(l,180) p = 0.30
warfarin therapy 213 0.85 F(1,206) p = 0.36
sex 213 0.65 F( 1,206) p = 0.42
smoking 213 0.38 F(1,206) p = 0.54
plasma viscosity 198 0.18 F(l, 191) p = 0.67
t.P.A. level 190 0.12 F(1,183) p = 0.73
red cell aggregation 199 0.11 F(1,192) p = 0.74
fibrinogen 210 0.10 F(1,203) p = 0.75
von Willebrand Factor 213 0.08 F( 1,206) p = 0.78
diabetes 213 0.03 F( 1,206) p = 0.86
antiplatelet therapy 213 0.00 F( 1,206) p = 1.00
cholesterol level 202 0.00 F(l,195) p = 1.00
Table 3.5: Relationship between patient characteristics, blood rheology,
potential thrombotic mediators, and the angiographic severity of
disease, on multivariate analysis after adjusting for the effects of
age, infection, prior vascular surgery, other vascular pathology, and
log(FDP).
91
with peripheral arterial disease when compared with the age-matched population
controls (Table 3.4, p.88), although tissue plasminogen activator levels were
similar in both patients and controls. Factor VII levels were measured in patients
not on anticoagulant therapy (n= 172), and were significantly lower in patients than
in controls.
Univariate analysis revealed strong positive correlations (p < 0.005)
between angiographic severity of arterial disease, and fibrinogen (Figure 3.7,
p.94), von Willebrand Factor (Figure 3.8, p.95), and cross-linked fibrin
degradation product (Figure 3.9, p.96), and a weak correlation between tissue
plasminogen activator levels and Bollinger angiogram score (Figure 3.10, p.97).
There was also a weak negative correlation between factor VII levels and the
angiogram score (Figure 3.11, p.98), after exclusion of those patients taking
anticoagulant therapy.
Multivariate analysis was carried out after adjustment for significant factors
in patient characteristics, and deletion of cases with missing data. Prior to
multivariate analysis logarithmic transformation of cross-linked FDP values was
performed to normalise the data distribution of this highly skewed variable.
Only cross-linked FDP's (transformed to log(FDP)) were strongly
independently associated with the angiographic severity of peripheral arterial
disease on multivariate analysis (p < 0.0001), although platelet count, plasma
fibrinogen, Factor VII, and plasma von Willebrand factor levels, showed a non¬
significant trend towards independent association with angiographic severity (Table
3.6, p.93). This gave the final model of variables that played an independently
significant role in predicting the Bollinger score, and after the inclusion of
log(FDP) in the model, other thrombotic mediators did not show any trend towards
a significant independent association with the angiogram score (Table 3.5, p.91).
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REFER
VARIABLE NUMBER F-STATISTIC TO p VALUE
log (FDP) 213 24.67 F( 1,207) p < 0.0001
Platelet count 217 3.55 F(1,211) p = 0.06
Plasma fibrinogen 214 3.32 F( 1,208) p = 0.07
Factor VII 202 3.22 F(l,196) p = 0.07
von Willebrand Factor 217 3.14 F(1,211) p = 0.08
t.P.A. 193 1.27 F(l,187) p = 0.26
P.A.I. 198 0.33 F(1,192) p = 0.57
Table 3.6: Relationship between potential thrombotic mediators and
angiographic severity of disease on multivariate analysis after
adjusting for the effects of significant patient background




Figure 3.7: Correlation between angiographic severity of disease and plasma
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Figure 3.8: Correlation between angiographic severity of disease and plasma von
Willebrand Factor (vWF) on univariate analysis.
(r = 0.40, p < 0.0001).
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BOLLINGER ANGIOGRAPHIC SCORE
Figure 3.9: Correlation between angiographic severity of disease and cross-
linked fibrin degradation products (log(FDP)) on univariate analysis,





Figure 3.10: Correlation between angiographic severity of disease and tissue
plasminogen activator (t.P.A.) on univariate analysis,
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Figure 3.11: Correlation between angiographic severity of disease and factor VII
activity on univariate analysis, (r = -0.21, p = 0.004).
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DISCUSSION
The most striking association observed in this study, on both univariate and
multivariate analyses, was that between increasing angiographic severity of disease,
and increasing age (Figure 3.3, p.85). This finding is in keeping with the results of
population studies that have demonstrated an increasing incidence of symptomatic
and asymptomatic occlusive arterial disease with increasing age (Bloor, 1961,
Kannel et al, 1970, Hughson et al, 1978, Criqui et al, 1985, Fowkes et al, 1991),
and confirms that the extent of peripheral arterial disease increases with increasing
age.
As fibrinogen, plasma viscosity, and levels of some thrombotic mediators
also increase with age (Meade et al, 1979, Lowe et al, 1980), it could be postulated
that the association between Bollinger score and blood rheology and thrombotic
mediators observed here merely reflect the increased age of patients with the most
advanced disease. However comparison of a number of the rheological parameters
and levels of potential thrombotic mediators in patients with occlusive arterial
disease, with age-matched population controls, reveals significant differences
between the two groups, indicating that the altered blood rheology and altered
levels of potential thrombotic mediators in PAOD, are due to more than just the
effects of increasing age.
Blood viscosity & red cell aggregation in cases & controls
The finding of a small but statistically significant reduction in corrected
blood viscosity in cases of peripheral arterial disease when compared with age-
matched population controls, appears to contradict previous studies which have
demonstrated an increase in blood viscosity in association with peripheral arterial
disease (Dormandy et al, 1973A, Lowe et al 1986, Ernst & Matrai, 1987, Lowe et
al, 1993). This study also fails to support the observation that plasma viscosity and
red cell aggregation are elevated in cases of peripheral arterial disease when
compared with controls (Ernst & Matrai, 1987, Reid, 1991). The explanation may
be that the present series includes a significant number of patients with critical leg
ischaemia, who have low levels of haematocrit and plasma albumin, which leads to
a reduction in viscosity and aggregation.
In addition, the results suggest that red cell deformability is increased in
cases of PAOD, as manifest by a small reduction in relative blood viscosity when
compared with controls. This contradicts previous observations that red cell
deformability (measured by filtration) is reduced in patients with peripheral arterial
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disease (Reid et al, 1976, Ehrly & Kohler, 1976), although the difference in
relative blood viscosity between the two groups studied is of a very small
magnitude. This increase in red cell deformability, which accounts for 40% of the
inter-individual variation in blood viscosity (Lowe, 1992), may be contributing to
the reduction in blood viscosity observed in the study population with occlusive
arterial disease.
Some of the aforementioned differences may also be due to the fact that the
control population selected in this study consisted of an age-matched random
population control, rather than the 'normal' controls (selected on the basis of a
negative history of smoking and any cardiac or vascular disease) used in other
studies, where the control values for plasma and whole blood viscosity are slightly
lower than were seen in the control population used here (Lowe et al, 1993). Thus
the median control value in this study reflects blood viscosity in an unfiltered
population which will contain cases of peripheral arterial disease, amongst other
pathologies affecting blood viscosity, as well as being drawn from a population 5 to
10 years older than control populations in other studies (Lowe et al, 1986, Reid,
1991). The observation that the values obtained for plasma viscosity and red cell
aggregation in patients in this study are similar to those from other studies (Reid,
1991), tends to confirm the belief that the results obtained in these studies reflect a
different policy in control selection.
Blood viscosity, red cell aggregation, & disease severity
Despite significant univariate correlations between blood and plasma
viscosity, and the angiographic severity of arterial disease, multivariate analysis
failed to demonstrate any independent association with disease severity. This
indicates that the elevation in plasma viscosity and reduction in blood viscosity
associated with peripheral arterial disease are consequent upon other features that
accompany PAOD: the correlation between angiographic severity of disease and
plasma viscosity being due to the effect of age (Lowe et al, 1980, Reid, 1991), and
the presence of infection, which was independently predictive of disease severity.
The strong negative correlation between disease severity, haemoglobin, and
haematocrit, on univariate analysis, and the trend towards a significant independent
association between haematocrit and Bollinger score on multivariate analysis, is in
contrast to the findings of most studies in patients with peripheral arterial disease,
which associate occlusive arterial disease with increased haematocrit (Lowe et al,
1986).
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The association between low haemoglobin and severe arterial disease may
be similar to the "haematological stress syndrome" reported in patients with PAOD
(Stuart et al, 1981). This syndrome is found in the blood of patients with chronic
inflammatory disease states, and consists of anaemia, platelet activation and
hyperfibrinogenaemia amongst other features. The observation that this response to
chronic inflammatory conditions occurs in occlusive arterial disease, suggests
similarities to these conditions and may indicate that other responses associated
with chronic inflammatory disorders, such as the anaemia of chronic disease
(Rowan, 1985), also occur. This would account for the lower haematocrit observed
in cases of arterial disease, and it is likely that the observed negative correlation
between haemoglobin level and disease severity reflects the presence of the
anaemia of chronic disease in patients with PAOD, in the same way that the
correlation between plasma fibrinogen and disease severity reflects the
haematological stress syndrome. However, as the multivariate analysis indicates,
the associations between haemoglobin, haematocrit, and angiographic severity of
disease, are not independent of the presence of infection and prior vascular
surgery. This suggests that the haematological stress syndrome in severe PAOD
may be a consequence of associated chronic low-grade infection, and perhaps the
presence of synthetic vascular prosthesis, although further studies are required to
determine whether or not this is the case.
Thrombotic mediators in cases & controls
This study has confirmed the findings of previous studies that demonstrate
an increase in potential thrombotic mediators in the presence of peripheral arterial
disease (Dormandy et al, 1973A, Reid, 1991, Lowe et al, 1993): Plasma
fibrinogen, cross-linked FDP's, and von Willebrand Factor have all been shown to
be elevated in cases of peripheral arterial disease, when compared with disease-free
controls (Reid, 1991), although one cause of these alterations may be attributed to
smoking habit (Smith et al, 1993).
The relationship between levels of tissue plasminogen activator (t.P.A.) and
occlusive arterial disease have not previously been reported, although levels of
plasminogen activator inhibitor (P.A.I.) and Factor VII have been found to be
elevated in a small number of patients with peripheral vascular disease (Reid,
1991), and increasing age is known to increase levels of both t.P.A. and P.A.I.
(Hashimoto et al, 1987). The results in this study indicate that levels of t.P.A. in
patients with occlusive arterial disease are similar to those found in an age-matched
population sample, although levels of P.A.I, are significantly greater. This
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elevation in P.A.I, levels in patients with occlusive arterial disease may shift the
fibrinolytic balance towards the inhibition of fibrinolysis, with a corresponding
increase in intravascular thrombus formation leading to vascular occlusion, and an
increased likelihood of thrombus being incorporated into plaques (Duguid, 1946).
It would also be in keeping with the impaired fibrinolysis demonstrated in patients
with other manifestations of vascular disease, such as ischaemic heart disease
(Sakata et al, 1990, Hamsten & Wiman, 1992). The elevated levels of cross-linked
FDP's observed in PAOD, indicating increased lysis of cross-linked fibrin, tend
however to contradict this belief, although the mechanisms that regulate thrombosis
and thrombolysis are of such complexity that the effect of an alteration in the levels
of a single component cannot be realistically predicted.
The finding of a reduction in Factor VII activity in patients with occlusive
arterial disease contradicts a previous study which suggested that Factor VII levels
were increased in the presence of vascular disease (Reid, 1991). The control
population in this current study however, show levels of factor VII activity
comparable with those observed in the cases reported by Reid (1991), suggesting
that age-related elevations in Factor VII activity (Folsom et al, 1991) may have
been responsible for the alteration in Factor VII levels reported in that study. This
belief is supported by the absence of age-matched controls in the study.
Low levels of Factor VII activity have been found in patients with
peripheral arterial disease in other studies (Cortellaro et al, 1992), and the low
factor VII levels observed here may be the consequence of an acute inflammatory
response (Meade, 1991) to limb sepsis, which was present in many of the cases
studied.
Thrombotic mediators & disease severity
The results of univariate analysis in this study provide further evidence that
fibrinogen, FDP's, and vWF increase with increasing severity of arterial disease,
as determined by angiography rather than indirect methods. These correlations,
which have been observed in other similar studies (Reid, 1991, Lowe et al, 1993),
raise the question of whether or not the observed associations between potential
thrombotic mediators and peripheral arterial disease are causal, or merely represent
a haematological response to the underlying chronic disease process (Reizenstein,
1979).
Multivariate analysis suggests that cross-linked FDP levels are
independently associated with the angiographic severity of occlusive arterial
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disease, while there is only a trend towards independent association for plasma
fibrinogen, von Willebrand Factor, and Factor VII levels, which disappears when
log(FDP) is taken into account. In terms of predicting the angiographic severity of
occlusive arterial disease, log(FDP) is therefore the most useful potential
thrombotic mediator. As multivariate analysis indicates, the association between
increasing log(FDP) and increasing severity of occlusive arterial disease is
independent of smoking habit, infection, age, other cardiovascular pathology, and
also prior vascular surgery. This is in keeping with other studies where the elevated
FDP level in peripheral arterial disease has been shown to be independent of other
vascular risk factors (Speiser et al, 1989, Reid, 1991).
Elevated levels of cross-linked FDP's may reflect increased turnover of
fibrin in PAOD, perhaps as a consequence of formation of superadded thrombus on
atherosclerotic plaques (Lindop, 1985). In this way FDP's may be merely an
indicator of the severity of the arterial disease; increased thrombus formation being
more likely in the presence of widespread arterial disease, where there are a greater
number of atherosclerotic plaques. Alternatively the presence of increased levels of
cross-linked FDP's may lead directly to a worsening of disease severity:
There is evidence from pathological studies that there is a continuous
turnover of cross-linked fibrin within the arterial intima (Smith et al, 1990), and
that FDP's are usually found in the advanced lesions of atherosclerosis (Bini et al,
1989). In addition it has been suggested that low molecular weight FDP's stimulate
the release of growth factors from the endothelium (Lorenzet et al, 1992), while
other fragments from the breakdown of cross-linked fibrin are thought to have
mitogenic properties (Thompson et al, 1990).
While these findings derive from animal work, and some concern fibrin
degradation products other than the d-dimer measured in this study, all these
stimulatory FDP's are produced from the degradation of cross-linked fibrin, along
with d-dimer fragments, and will be present in similarly increased concentrations.
It is therefore feasible that the raised FDP's encountered in patients with occlusive
arterial disease contribute to the acceleration of the disease by stimulating the focal
smooth muscle cell proliferation that is a major component of atherosclerosis (Ross
et al, 1984, Ross, 1986). Some FDP's are capable of increasing vascular
permeability and inducing retraction and disorganisation of endothelium (Loscalzo,
1992), which may account for the close relationship between FDP levels and von
Willebrand Factor levels, which may be reflecting the endothelial damage induced
by FDP's.
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No other thrombotic mediators show an independent association with the
angiographic severity of peripheral arterial disease, suggesting that any associations
between occlusive arterial disease and these potential thrombotic mediators are a
consequence of the increased incidence of infection and other cardiovascular
pathology found in patients with the most severe disease, and in the case of t.P.A.,
the increasing age of the patients (Hashimoto et al, 1987). Plasma fibrinogen is
known to be elevated in acute inflammation (Meade, 1991), and will therefore be
elevated in the presence of limb sepsis. Von Willebrand Factor levels are also
increased by a number of non-specific stimuli (Ingerslev, 1990), including chronic
inflammatory conditions (Blann et al, 1992), while Factor VII levels fall in acute
and chronic illness (Meade, 1991).
Despite the lack of any independent association between these potential
thrombotic mediators and the severity of arterial disease, some of them may well
play a role in peripheral arterial disease, either indirectly by increasing thrombin
formation and FDP levels, or by directly contributing to the progression of
peripheral atherosclerosis. Increasing levels of plasma fibrinogen may promote
increased formation of fibrin thrombi, with subsequent occlusion of vessels and a
corresponding increase in the angiographic severity of the disease.
Increased levels of von Willebrand Factor, which is an essential
requirement for the development of occlusive thrombi at sites of arterial injury
(Brinkhous et al, 1991), may lead to increased formation of intravascular thrombi,
with subsequent development of atherosclerotic plaques (Duguid, 1946). Animal
studies have suggested that absence of plasma von Willebrand factor confers
resistance to atherosclerosis (Badimon & Fuster, 1992), and it may follow that
elevated vWf levels are associated with accelerated development of atherosclerosis,
as an increase in plasma vWF can lead to increased platelet adhesion and
aggregation (Zwaginga et al, 1990).
Thus, even if the correlations between potential thrombotic mediators and
the angiographic severity of disease are a consequence of other conditions
commonly associated with peripheral vascular disease, the subsequent alterations in
fibrinogen and von Willebrand Factor levels may contribute to the disease process.
The effect of reversing the disease process by surgical intervention or angioplasty is
studied in subsequent chapters.
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Summary
These findings confirm previous observations that plasma fibrinogen, cross-
linked FDP's, von Willebrand Factor, and P.A.I, levels are all elevated in patients
with peripheral arterial disease, and indicate that the degree of elevation in these
thrombotic mediators correlates with the angiographic severity of the arterial
disease, although only the level of cross-linked FDP's is independently predictive
of the severity of the disease. Elevations in all these thrombotic mediators may
either be consequences of peripheral arterial disease, or may be of aetiological
importance, as a result of their effects on thrombus formation and fibrin turnover,
and the observations support the belief that there is an increase in fibrin turnover
with increasing severity of peripheral arterial disease.
The results also suggest that factor VII levels are reduced in peripheral
arterial disease, in contrast to previously reported findings. This is likely to be a
result of acute and chronic inflammatory responses to peripheral vascular disease.
These studies have determined levels of tissue Plasminogen Activator
(t.P.A.) in patients with symptomatic peripheral arterial disease. This has not
previously been reported, however the results failed to show any significant
elevation in t.P.A. levels in association with arterial disease, and failed to
demonstrate any relationship between t.P.A. and the angiographic severity of
peripheral arterial disease.
Previously reported elevations in plasma and blood viscosity in patients with
peripheral vascular disease were not confirmed by these studies, with a reduction in
blood viscosity, haemoglobin, and haematocrit being observed in contrast. This
may be a result of a haematological stress response to chronic inflammatory
processes resulting from severe peripheral vascular disease.
The observations made confirm that peripheral vascular disease is associated
with marked systemic changes in blood rheology and levels of potential thrombotic
mediators. Subsequent chapters of this thesis will investigate the effects on blood
rheology and potential thrombotic mediators, of reducing the severity of peripheral
arterial disease by surgical intervention.
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CHAPTER 4
The effect of revascularisation surgery on blood rheology and thrombotic
mediators in critical limb ischaemia.
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INTRODUCTION
In the work reported in the previous chapter it was observed that
haematocrit-corrected blood viscosity and relative blood viscosity, together with the
levels of a number of potential thrombotic mediators (plasma fibrinogen, cross-
linked fibrin degradation products, von Willebrand factor, factor VII, and
plasminogen activator inhibitor (P.A.I.)) were altered in patients with peripheral
arterial occlusive disease, and that these alterations were more marked in patients
with angiographic evidence of severe disease. These alterations in potential
thrombotic mediators may act via a number of pathophysiological mechanisms to
further both the development of atherosclerosis and arterial occlusion (Bini et al,
1989, Zwaginga et al, 1990, Badimon & Fuster, 1992), leading to the development
of critical limb ischaemia.
If these alterations in potential thrombotic mediators occur solely as a
consequence of biochemical derangement secondary to tissue ischaemia, then it is
likely that successful revascularisation or amputation will reverse these potentially
harmful alterations in blood rheology and levels of thrombotic mediators. In order
to investigate this possibility, patients with severe peripheral arterial occlusive
disease, meeting the definition of critical limb ischaemia (European Consensus
Document, 1989) have been studied, both before and after surgical intervention to
resolve their critical limb ischaemia. The effects of surgical resolution of limb
ischaemia on thrombotic and rheological parameters in such persons has not
previously been reported.
Aims:
1) To determine the effects of revascularisation or amputation surgery on the
abnormal blood rheology observed in patients with critical limb ischaemia.
2) To determine whether or not levels of the potential thrombotic mediators
plasma fibrinogen, fibrin degradation products (FDP's), von Willebrand factor
(vWF), factor VII, plasminogen activator inhibitor (P.A. I.), and tissue
plasminogen activator (t.P.A.), are altered by such surgical treatment of critical
limb ischaemia.
3) To determine, by means of comparison with an age-matched random
population sample, whether or not surgical resolution of critical limb ischaemia
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results in the normalisation of previously abnormal blood rheology and levels of
potential thrombotic mediators.
4) To determine whether or not the alterations in levels of thrombotic
mediators following revascularisation in patients with critical limb ischaemia, are
affected by the material used in the revascularisation procedure.
MATERIALS AND METHODS
Patients & methods
All the patients studied were in-patients at the vascular surgery units of
Gartnavel General Hospital, and Glasgow Royal Infirmary. The diagnosis of
critical limb ischaemia was made in accordance with the recommendations of the
European Working Group on Critical Limb Ischaemia (1990).
Patients were invited to attend for review 12-16 weeks after surgical
treatment, and resolution of critical limb ischaemia was confirmed by relief of rest
pain, resolution of infection and tissue healing, and an increase in the ankle systolic
pressure to above 50mm Hg. In patients who had undergone amputation, stump
healing and relief of rest pain were taken as confirmatory of resolution of critical
ischaemia.
Ankle systolic pressure was measured as described in chapter 2, and
venous blood was sampled with minimal venous stasis in all patients prior to
surgery for critical limb ischaemia, and again at review 12-16 weeks post¬
operatively. All samples were handled and assayed as described in chapter 2.
Controls
Control values for blood viscosity, red cell aggregation, and thrombotic
mediators were obtained from local population studies (1st, 2nd, and 3rd W.H.O.
Monica studies), as described in chapter 2, and the results for 80 patients aged
between 65 and 75 years (mean age 69yrs.), were used as control values.
Statistics
All statistical analyses were performed by myself on a microcomputer,
using the CSS: Statistica package (Statsoft, Tulsa, USA). Pre and post-operative
results were compared using non-parametric Wilcoxon matched pairs testing, with
pairwise deletion where individual data values were missing, and post-operative
results were compared with population control values by means of the Mann-
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Whitney U-test. Where comparisons were made on the basis of the graft material
used patient characteristics were compared using the Chi-square test to identify any
significant differences between the 2 patient groups.
RESULTS
Patients and outcomes
There were 82 patients enrolled in the study (51 male, 31 female), with a
mean age of 70 years (range 50 - 96 years). 61 patients survived to review at 12 -
16 weeks post-operatively, giving an overall 16-week mortality rate of 26%. 5 of
the 61 survivors were unable to attend for review (3 due to distances involved, 2
refused to attend), but were confirmed to be alive by their General Practitioners.
There was no evidence of recurrence of critical limb ischaemia in the 56
patients who attended for review, the majority having undergone a reconstructive
procedure (Table 4.1, p. 110). The mean age of these 56 patients was 69 years,
with a range of 50 - 89 years, 29 patients had undergone insertion of a synthetic
graft (PTFE or dacron), while in 23 patients autogenous vein had been used. On
the basis of clinical history and estimation of plasma carboxyhaemoglobin levels,
38 of the 56 patients reviewed were current or recent smokers, and 18 had been
non-smokers for more than 5 years. There were no significant differences in
smoking habits between patients in whom vein grafts were used, and those in
whom synthetic grafts were used (E = 0.77, Chi-Square test, 1 degree freedom),
and in addition there were no significant differences in other patient details
between the 2 patient groups (Table 4.2, p. 111).
A number of patients were on warfarin therapy, and the Factor VII
estimations in all those patients on warfarin therapy have been excluded from all
analyses.
Blood rheology
Following resolution of critical limb ischaemia there was a significant fall in
the relative blood viscosity (p = 0.006, Wilcoxon matched pairs), and a trend
towards a significant fall in the corrected blood viscosity (p = 0.07), in the 56
patients available for review, together with significant increases in serum albumin
and globulin (Table 4.3, p. 112). Comparison of post-operative blood rheology in
patients with age-matched population controls (Table 4.4, p. 133), failed to reveal
any significant differences, with the exception of the white cell count, which
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Femoro-femoral crossover graft 2
Table 4.1: Operations carried out in 56 patients with critical limb ischaemia
(excludes 21 patients dying within 3 months of surgery, and 5
patients lost to follow up).
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VEIN SYNTHETIC
GRAFT GRAFT AMPUTATION TOTAL
23 29 4 56
mean age (yrs) 69 69 68 69
prior vascular
surgery 16 20 3 39
active sepsis/
tissue necrosis 11 11 3 25
diabetes 6 5 2 13
current/recent
smoker 14 21 3 38
ex/non-smoker 9 8 1 18
Antiplatelet therapy
pre-operative 5 9 0 14
post-operatively 5 11 0 16
Anticoagulant therapy
pre-operatively 2 2 0 4
post-operatively 2 3 0 5
Table 4.2: Patient details in 56 patients with critical limb ischaemia, excluding





VARIABLE LEVEL LEVEL PAIRS
White Cell Count (xl09/l) 9.6(8.0-12.2) 8.6(7.0-10.2) p< 0.0001
serum albumin (g/1) 38 (32-42) 41 (37-44) p= 0.0001
serum globulin (g/1) 26 (23-29) 28 (26-31) p= 0.0007
relative
blood viscosity 2.50 (2.35-2.66) 2.37 (2.13-2.51) p= 0.006
corrected
blood viscosity (mPa.s) 3.43 (3.22-3.70) 3.27 (3.06-3.58) p= 0.07
Red QgJJ
aggregation (units) 4.1 (3.0-5.5) 3.7 (3.0-4.4) p= 0.12
haematocrit (%) 41 (37 - 45) 42 (38 - 45) p= 0.26
plasma viscosity (mPa.s) 1.38 (1.31-1.50) 1.39 (1.33-1.48) p= 0.72
Table 4.3: Changes in blood rheology following successful surgical treatment











White Cell Count (xl09/l) 6.2 (5.1-7.9) 8.6 (7.0-8.2) p< 0.0001
fibrinogen (g/1) 3.1 (2.7-3.8) 3.8 (3.0-4.9) p= 0.0006
fibrin degradation
products (ng/ml) 220 (115-310) 316 (192-620) p= 0.001
von Willebrand
factor (iu/dl) 120 (90-147) 153 (108-197) p= 0.002
plasminogen activator
inhibitor (% pool) 78 (60-92) 90 (69-121) p= 0.02
tissue plasminogen
activator (ng/ml) 8.4 (5.4-10.7) 6.9 (5.5-9.0) p= 0.06
Red cell
aggregation (units) 4.4 (3.5-5.0) 3.7 (3.0-4.4) p= 0.06
plasma viscosity (mPa.s) 1.36 (1.30-1.44) 1.39 (1.33-1.48) p= 0.07
factor VII (% pool) 113 (93-135) 110 (91-119) p= 0.12
relative
blood viscosity 2.42 (2.24-2.61) 2.37 (2.13-2.51) p= 0.13
haematocrit (%) 44 (41 - 47) 42 (38 - 45) p= 0.26
corrected
blood viscosity (mPa.s) 3.40 (3.12-3.60) 3.27 (3.06-3.58) p= 0.46
Table 4.4: Blood viscosity, red cell aggregation, and levels of thrombotic
mediators following successful surgical treatment for critical limb
ischaemia (56 patients), Compared with values in an age-matched
population. Figures are median values (interquartile range). Factor
VII levels in patients receiving warfarin have been excluded.
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remained elevated in patients following revascularisation surgery. Relative blood
viscosity and red cell aggregation were both lower following surgery, than in an
age-matched population control, but the differences failed to attain statistical
significance.
There were no other significant changes in blood rheology following
correction of critical limb ischaemia, although in patients who had undergone
insertion of an autogenous vein graft there were significant falls in the post¬
operative corrected blood viscosity (p = 0.009), and relative blood viscosity (p =
0.005) (Table 4.5, p. 115) that were not observed in patients undergoing
revascularisation with a synthetic graft (Table 4.6, Figures 4.1, 4.2, p. 116-118),
with post-operative relative blood viscosity (Figure 4.3, p. 119) being significantly
lower than in the population controls (p = 0.03).
Increases in albumin (Figure 4.4, p. 120) and globulin (Figure 4.5, p. 121)
levels were seen in both vein and synthetic groups, as was the post-operative
reduction in white cell count (Figure 4.6, p. 122). Revascularisation procedures
involving the use of a synthetic graft however, failed to alter rheological
parameters post-operatively, with the exception of red cell aggregation, which fell
significantly (p = 0.006) (Figure 4.3), to a level well below that seen in the
control population (p = 0.02).
The presence of pre-operative tissue sepsis or necrosis may affect
rheological parameters pre-operatively. Following successful resolution of critical
limb ischaemia, these features are no longer present. However exclusion of such
cases did not significantly influence the results, and significant falls in relative
blood viscosity and red cell aggregation were still observed following resolution of
critical limb ischaemia in this subgroup of patients (Table 4.7, p. 123).
Thrombotic mediators
Levels of the potential thrombotic mediators plasma fibrinogen, von
Willebrand Factor, and tissue plasminogen activator, all fell significantly following
resolution of critical limb ischaemia (Table 4.8, p. 124). Factor VII levels rose
significantly following surgery (p = 0.008), while there was no significant change
in the levels of cross-linked FDP's following surgery. Levels of most potential
thrombotic mediators remained elevated in comparison with the control population,
with the exception of factor VII and t.P.A. (Table 4.4, p. 113).
Exclusion of patients with pre-operative sepsis or tissue necrosis from the




VARIABLE LEVEL LEVEL PAIRS
von Willebrand
factor (iu/dl) 182 (124-237) 135 (108-197) p= 0.001
relative
blood viscosity 2.44 (2.36-2.52) 2.27 (2.13-2.42) p= 0.005
corrected
blood viscosity (mPa.s) 3.41 (3.21-3.60) 3.13 (2.99-3.41) p= 0.009
fibrinogen (g/1) 4.7 (4.0-5.5) 3.7 (3.0-5.0) p= 0.01
serum albumin (g/1) 37 (32-41) 41 (37-43) p= 0.03
White Cell Count (xl09/l) 8.5 (7.8-11.3) 8.2 (6.5-9.7) p= 0.03
fibrin degradation
products (ng/ml) 296 (215-575) 219 (141-534) p= 0.09
serum globulin (g/1) 25 (20-29) 28 (24-29) p= 0.14
factor VII (% pool) 109 (79-119) 110 (105-118) p= 0.21
tissue plasminogen
activator (ng/ml) 7.8(5.3-13.0) 6.5(5.5-7.7) p= 0.35
haematocrit (%) 41 (37 - 45) 42 (39 - 46) p= 0.42
Red cell
aggregation (units) 3.9 (2.9-5.0) 3.9 (3.3-4.9) p= 0.64
Platelet count (xlO'/l) 287 (235-350) 297 (239-331) p= 0.68
plasminogen activator
inhibitor (% pool) 103 (82-128) 99 (78-119) p= 0.88
plasma viscosity (mPa.s) 1.36 (1.30-1.44) 1.38 (1.31-1.46) p= 0.98
Table 4.5: Changes in blood rheology and potential thrombotic mediators
following successful surgical treatment for critical limb ischaemia in











White Cell Count (xl09/l) 10.9 (8.3-13.9) 9.1 (7.5-11.7) p= 0.001
serum albumin (g/1) 39 (32-43) 41 (37-44) p= 0.002
serum globulin (g/1) 26 (24-29) 29 (26-31) p= 0.003
Red cell
aggregation (units) 4.6 (3.8-6.2) 3.7 (3.0-4.3) p= 0.006
factor VII (% pool) 100 (73-115) 114 (92-119) r—<OOIIcx
tissue plasminogen
activator (ng/ml) 8.5 (7.0-10.0) 7.2 (5.3-9.8) p= 0.01
fibrinogen (g/1) 4.6 (3.4-5.3) 3.7 (3.1-4.8) p= 0.02
plasminogen activator
inhibitor (% pool) 103 (77-133) 85 (60-121) p= 0.06
von Willebrand
factor (iu/dl) 177 (153-203) 164 (109-198) p= 0.07
fibrin degradation
products (ng/ml) 255 (196-463) 401 (252-724) p= 0.09
relative
blood viscosity 2.54 (2.30-2.83) 2.46 (2.25-2.65) p= 0.42
Platelet count (xlO/1) 328 (279-379) 325 (248-389) p= 0.63
corrected
blood viscosity (mPa.s) 3.43 (3.11-3.90) 3.37 (3.09-3.60) p= 0.63
plasma viscosity (mPa.s) 1.37 (1.31-1.48) 1.40 (1.35-1.48) p= 0.66
haematocrit (%) 40 (37 - 45) 40 (38 - 45) p= 0.88
Table 4.6: Changes in blood rheology and potential thrombotic mediators
following successful surgical treatment for critical limb ischaemia in
29 patients undergoing revascularisation surgery with a synthetic





































































Figure 4.2: Changes in haematocrit-corrected blood viscosity following





























































































































































serum albumin (g/1) 38 (32-42) 43 (40-44) p< 0.002
serum globulin (g/1) 25 (23-27) 28 (26-30) p< 0.005
White Cell Count (xl09/l) 9.3 (7.6-11.7) 8.7 (7.0-10.2) p= 0.009
relative
blood viscosity 2.49 (2.34-2.77) 2.34 (1.97-2.48) p= 0.02
Red cell
aggregation (units) 4.2 (3.6-5.5) 3.9 (3.2-4.8) p= 0.03
haematocrit (%) 40 (37 - 45) 42 (37 - 46) p= 0.17
corrected
blood viscosity (mPa.s) 3.41 (3.12-3.67) 3.19 (2.99-3.58) p= 0.25
plasma viscosity (mPa.s) 1.36 (1.30-1.41) 1.38 (1.35-1.43) p= 0.45
Table 4.7: Changes in blood rheology following successful surgical treatment
for critical limb ischaemia in 31 patients without pre-operative





VARIABLE LEVEL LEVEL PAIRS
factor VII (% pool) 106 (79-116) 113 (98-119) p= 0.004
fibrinogen (g/1) 4.7(3.6-5.5) 3.8(3.0-4.9) p< 0.005
von Willebrand
factor (iu/dl) 177 (144-226) 153 (108-197) p< 0.005
tissue plasminogen
activator (ng/ml) 8.5(6.5-11.8) 6.9(5.5-9.0) p= 0.006
plasminogen activator
inhibitor (% pool) 103 (77-130) 90 (69-121) p= 0.12
Platelet count (xl0»/l) 314 (243-368) 303 (244-351) p= 0.38
fibrin degradation
products (ng/ml) 285 (225-510) 316 (192-620) p= 0.76
Table 4.8: Changes in levels of platelets and potential thrombotic mediators
following successful surgical treatment for critical limb ischaemia in
56 patients. Figures are median values (interquartile range). Factor




VARIABLE LEVEL LEVEL PAIRS
fibrinogen (g/1) 4.2 (3.4-5.3) 3.3 (3.0-4.4) p= 0.001
von Willebrand
factor (iu/dl) 175 (118-223) 134 (97-200) p= 0.002
factor VII (% pool) 104 (80-116) 114 (104-122) p= 0.01
tissue plasminogen
activator (ng/ml) 8.8 (6.9-12.0) 7.0 (5.5-9.8) p= 0.07
fibrin degradation
products (ng/ml) 260 (214-519) 409 (202-768) p= 0.16
plasminogen activator
inhibitor {% pool) 90 (76-122) 90 (72-125) p= 0.44
Platelet count (xlO'/l) 289 (232-334) 287 (239-338) p= 0.80
Table 4.9: Changes in thrombotic mediators following successful surgical
treatment for critical limb ischaemia in 31 patients without pre¬
operative infection or tissue necrosis. Figures are median values
(interquartile range).
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the fall in t.P.A. levels on resolution of critical limb ischaemia, which failed to
reach statistical significance after exclusion of sepsis and gangrene (p = 0.07).
Changes in the levels of thrombotic mediators varied with the material
employed for revascularisation: Although both plasma fibrinogen (Fig. 4.7, p. 127)
and vWF (Fig. 4.8, p. 128) levels fell following revascularisation with both vein
and synthetic grafts, there were no significant changes in the levels of factor VII,
t.P.A., and P.A.I, following insertion of a vein graft (Table 4.5, p. 115). There
was however a trend towards a significant fall in the post-operative levels of cross-
linked FDP following insertion of a vein graft (p = 0.09), in contrast to the trend
towards a significant rise observed after insertion of a synthetic graft (p = 0.09)
(Figure 4.9, p. 129).
Insertion of a synthetic graft was also associated with significant falls in
plasma fibrinogen, t.P.A. (Fig. 4.10, p. 130) and P.A.I. (Fig. 4.11, p. 131) levels,
a trend towards a significant fall in vWF levels (p = 0.07), and a rise in factor VII
levels (Fig. 4.12, p. 132), following resolution of critical limb ischaemia (Table
4.6, p. 116). Following revascularisation with a synthetic graft post-operative levels
of cross-linked FDP's were significantly higher than those seen in the population
























































































Figure 4.9: Changes in cross-linked fibrin degradation products following









































Figure 4.10: Changes in tissue plasminogen activator (t.P.A.) following















Figure 4.11: Changes in plasminogen activator inhibitor (P.A.I.) levels following




















Patients & revascularisation procedure
Although this group of patients were not randomly selected, and are heavily
biased towards cases of infra-inguinal disease, they are typical of many patients
with advanced symptomatic occlusive arterial disease, the majority of whom have
infra-inguinal disease (Bloor, 1961, Hertzer et al, 1991), either in isolation or as a
component of multi-level disease (Bell, 1990). An early mortality rate of 26% in
this series is high, but there are few figures available for comparison; the mortality
rate from amputation surgery ranges from 8 to 18% (Harris & Moody, 1990)
depending on the site of amputation, and it is reported that at least 20% of patients
with critical limb ischaemia die within 1 year of diagnosis (Norgren, 1990).
Reliable data for comparison is however limited, and this study is more concerned
with the effects of successful resolution of critical limb ischaemia on blood
rheology and potential thrombotic mediators.
The observation that 39 of the 56 survivors had undergone prior
revascularisation procedures is in keeping with the finding in chapter 3 that a
history of prior vascular surgery is independently associated with the angiographic
severity of peripheral arterial disease. One would expect patients developing critical
limb ischaemia as a consequence of chronic occlusive arterial disease to have
undergone prior revascularisation surgery for symptoms of claudication and critical
limb ischaemia, while the significant number of patients undergoing de novo
vascular reconstruction for critical limb ischaemia in this series is due to both social
factors leading to late presentation, and the individual surgeons decision to defer
surgery in some patients until the development of limb threat.
The 23% incidence of diabetes in the patients studied is approximately 5
times the incidence of diabetes in the general population (Krone & Miiller-Wieland,
1990), and reflects the high incidence of gangrene in these patients (Gutman et al,
1987), while the observation that over two thirds of the patients were current or
recent smokers confirms the strong association between smoking and arterial
disease (Hughson, 1978, Fowkes, 1989).
The use of aspirin as antiplatelet therapy either prior to, or following
surgery, in a number of patients is unlikely to influence the results of this study as
previous work has demonstrated that aspirin therapy has no effect on blood
rheology or thrombotic mediators (Reid, 1991), while the exclusion of factor VII
results from patients on warfarin therapy ensures that pre- and post-operative
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comparisons are accurate. The effect of warfarin on blood rheology and other
thrombotic mediators is not significant (Reid, 1991).
Blood rheology
In this group of patients there were surprisingly few changes in rheological
parameters following resolution of critical limb ischaemia, with only red cell
aggregation and relative blood viscosity (blood viscosity corrected for the effects of
haematocrit and plasma viscosity) showing a significant fall post-operatively.
Comparison of post-operative rheological values with age-matched population
controls indicates that values return to normal following resolution of critical limb
ischaemia.
There is a trend towards a significant elevation in plasma viscosity
following correction of critical limb ischaemia, despite a fall in plasma fibrinogen,
the major determinant of plasma viscosity (Lowe, 1991). This may be a
consequence of increased levels of albumin and serum globulin, which rose
significantly on resolution of critical limb ischaemia, thus offsetting the effect of
the fall in plasma fibrinogen.
Reduced haematocrit and plasma protein levels in patients with critical limb
ischaemia are in contrast to findings in claudicants (Lowe et al, 1986), and suggest
that patients with critical limb ischaemia have a haematological picture more
typical of patients with a chronic disease state (Reizenstein, 1979), with attendant
reductions in serum protein levels. This reduction in serum protein levels may
result in the lowering of plasma viscosity, which has previously been shown to be
elevated in patients with claudication (Lowe et al, 1986, 1993). Thus occlusive
arterial disease leads to an increase in blood and plasma viscosity (Lowe et al,
1993) with increasing severity of disease, until a state of chronic arterial
insufficiency results in critical limb ischaemia. At some point along this
continuum, the elevations in blood and plasma viscosity are offset by the
haematological response to a chronic disease state which lowers plasma proteins
and haematocrit.
The only significant rheological response to the correction of critical limb
ischaemia observed in this study was a fall in relative blood viscosity, although
closer analysis indicated that this fall was only observed in cases where autogenous
vein graft was used. In addition vein grafting was associated with a significant fall
in haematocrit-corrected blood viscosity. This fall in relative blood viscosity (which
is a measure of the cellular contribution to whole blood viscosity) reflects an
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increase in red cell deformability following vein grafting, as has previously been
observed after reconstructive vascular surgery (Irwin et al, 1983).
The significant fall in blood viscosity in association with the use of vein
grafts is occurring in spite of the fact that post-operative levels of the plasma
proteins albumin and globulin are increased, and that the increase in protein levels
is most marked in vein grafts. This fall is therefore not related to alterations in the
major plasma proteins, and in view of the similarity between fibrinogen levels
following vein and synthetic grafting, is not related to fibrinogen either. It may be
that differences in fibrin turnover, as reflected by FDP levels, are at least partly
responsible for the fall in blood viscosity seen following insertion of a vein graft,
and this is discussed in more detail below.
Plasma fibrinogen
The association between elevated plasma fibrinogen and atherosclerotic
vascular disease has been reported by a number of authors (Dormandy et al, 1973a,
Meade et al, 1986, Kannel et al, 1987, Ernst 1991), and there is evidence that the
degree of elevation is related to the severity of the ischaemia (Lowe et al. 1991,
Reid, 1991), as well as the observation that patients with peripheral arterial
occlusive disease and elevated plasma fibrinogen show the most rapid disease
progression (Dormandy et al. 1973B). This study suggests that relief of critical
limb ischaemia reverses some of the elevation in plasma fibrinogen that is
associated with advanced arterial occlusive disease, but that correction of critical
limb ischaemia fails to reduce fibrinogen to the levels encountered in an age-
matched population.
The inability to reduce plasma fibrinogen levels to normal after relief of
critical limb ischaemia may be due to a number of factors: Plasma fibrinogen levels
are elevated in smokers (Meade et al, 1979), and the majority of the patients
studied here were smokers whose smoking habit remaining unchanged following
surgery. Patients with advanced PAOD have widespread arterial involvement and
correction of critical ischaemia in one limb does not eradicate their arterial disease:
it therefore follows that these patients still have elevations in plasma fibrinogen as a
consequence of occlusive arterial disease at other sites. An additional factor in the
persistent elevation of plasma fibrinogen following surgery, may be related to
genetic influences on plasma fibrinogen (Hamsten et al, 1987A, Fowkes et al,
1992, Meade, 1992) which may predispose certain individuals to elevated
fibrinogen levels regardless of the state of their arterial circulation.
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The type of graft material used did not seem to affect fibrinogen levels
following resolution of critical ischaemia, suggesting that after an initial acute
inflammatory response to the insertion of synthetic graft material (Reid, 1991), the
presence of synthetic graft material no longer stimulates increased fibrinogen
production. This may be related to formation of the layer of fibrin (and
occasionally endothelial cells) that completely covers the graft surface in contact
with blood (DeBakey et al, 1964).
The post-operative fall in plasma fibrinogen was not solely due to resolution
of limb sepsis and the excision of necrotic and gangrenous tissue, although
fibrinogen levels were lower in the non-septic, non-necrotic group of patients,
confirming that the presence of sepsis and tissue necrosis leads to elevations in
plasma fibrinogen (Meade, 1992).
These findings indicate that some of the elevation in plasma fibrinogen
associated with critical limb ischaemia can be reversed by revascularisation (or
amputation) of the affected limb, implying that biochemical changes stimulating
fibrinogen synthesis occur in critically ischaemic tissues. This fibrinogen synthesis
is probably hepatic in origin, in response to stimulation of hepatocytes by
interleukin-6 (IL-6) (Cook & Ubben, 1990, Reid, 1991), produced by activated
monocytes (Cruickshank et al, 1990) and it is likely that the fall in plasma
fibrinogen following revascularisation is at least partly a result of the concurrent
reduction in white cell activation that occurs on resolution of critical limb
ischaemia, although further studies of white cell activation are required to clarify
this point.
This fall in plasma fibrinogen following resolution of critical limb ischaemia
has a number of potential clinical benefits: elevated plasma fibrinogen is known to
be an independent risk factor for stroke and myocardial infarction (Ernst, 1991), as
well as cardiovascular mortality (Meade et al, 1986), and also to be associated with
arterial graft occlusion (Wiseman et al, 1989), and the reduction of plasma
fibrinogen levels associated with correction of critical limb ischaemia may reduce
the risk of these events occurring post-operatively.
Fibrin degradation products
Cross-linked fibrin degradation products (FDP's) are the result of lysis of
cross-linked fibrin, and elevated levels of FDP's reflect an increase in fibrin
turnover (Whittaker et al. 1987). Recent studies have suggested that FDP's are
elevated in peripheral arterial disease (Reid, 1991), and that the elevation in FDP's
is related to the severity of occlusive arterial disease (Peltonen et al, 1992,
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Woodburn et al, 1993A). The finding that FDP's are independently associated with
the severity of arterial disease, and the possible relevance of this to the aetiology of
peripheral arterial disease has already been discussed.
Initial analysis of the results obtained in this study indicates that fibrin
turnover is unaffected by successful resolution of critical limb ischaemia, with
levels of FDP's remaining higher than that of an age-matched population. However
graft type has a major effect on FDP levels following resolution of critical limb
ischaemia.
The use of autologous vein to revascularise a critically ischaemic limb
produces a trend towards a significant fall in FDP's, with post-operative levels
comparable to those in the control population, indicating that increased fibrin
turnover is a reversible feature of critical limb ischaemia when the limb is
revascularised with an autogenous vein graft. This reduction in fibrin turnover may
result from a reduction in thrombus formation secondary to stasis (Anderson,
1985), consequent on an improved arterial inflow. Any reduction in thrombus
formation will reduce fibrin turnover, and therefore reduce levels of cross-linked
FDP's.
In contrast, use of synthetic graft materials (PTFE and Dacron) to correct
critical limb ischaemia was associated with a rise in cross-linked FDP levels that
failed to attain statistical significance. A rise in FDP levels at one week following
insertion of a synthetic graft has previously been reported (Reid, 1991), however
the results in this study imply that fibrin turnover is greatly increased for at least 4
months after insertion of a synthetic graft, and this cannot therefore be attributed
solely to surgical trauma, nor can it be related to increases in plasma fibrinogen
levels, which fall significantly over the same time period in the same patients.
This increase in fibrin turnover probably occurs in all patients in whom a
synthetic graft is inserted, regardless of the indication for surgery, and this is
explored in more detail in Chapter 6. Previous studies have shown that the
innermost layer coating the luminal surface of a synthetic graft consists almost
entirely of fibrin (DeBakey et al, 1964), and these new findings suggest that this
must be a dynamic layer that is continually being lysed and reformed. It may be
that this "dynamic equilibrium" between fibrin formation and lysis (Anderson,
1985) that results in increased FDP's in patients revascularised with a synthetic
graft, the increased fibrin turnover preventing accumulation of fibrin within the
graft lumen that could lead ultimately to occlusion.
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von Willebrand Factor
Between 75 and 85 % of circulating vWF is derived from endothelial cells,
where it is synthesised and stored, the remaining plasma von Willebrand factor
being derived from platelet activation (Ingerslev, 1990). Elevated levels of vWF
are therefore largely indicative of endothelial damage, and have been shown to be
elevated following direct arterial injury (Woodburn et al, 1993B). In addition
population studies show elevated vWF in the presence of peripheral arterial disease
(Christe et al, 1984, Blann & McCollum, 1992A, Smith et al, 1993). Although
little is known about the regulation of vWF levels (Ingerslev, 1990), it has been
reported that vWF is elevated in inflammatory conditions (Blann et al, 1992),
although the changes in vWF levels following revascularisation that were observed
in this study were still present when cases with pre-operative sepsis and tissue
necrosis were excluded, suggesting that the changes observed are not just a
consequence of the resolution of infection and its associated inflammatory
response.
Levels of vWF after vein grafting remain higher than in population
controls, and this may be consequent upon increased cigarette consumption in the
patient group. Cigarette smoking is known to elevate vWF levels (Blann, 1992).
The presence of widespread arterial disease elsewhere in the vascular tree, with its
associated endothelial damage promoting increased plasma vWF levels, may also
contribute to the elevated vWF levels in the patient group. The post-operative fall
in vWF may be the result of exclusion from the vascular tree of the diseased
vessels bypassed in the revascularisation surgery. This may eliminate the release of
endothelial cell vWF from these segments into the plasma, and reduce platelet-
endothelial contact and activation, with a reduction in vWF release (Ingerslev,
1990).
Median plasma levels of vWF fall to lower levels following vein grafting
than after synthetic grafting, and this may be related to increased levels of platelet
activation, and hence vWF release (Ingerslev, 1990), in the presence of a synthetic
graft. The increase in fibrin turnover associated with insertion of a synthetic graft
could also lead to release of vWF stored in endothelial cells (Ribes et al, 1987).
These mechanisms may therefore explain why vWF does not fall as markedly after
synthetic grafting to resolve critical limb ischaemia, as it does in situations where
autologous vein has been used, although further work is required to clarify this.
In spite of this graft-related difference in vWF levels following resolution of
critical limb ischaemia, it is apparent that resolution of critical limb ischaemia will
significantly reduce the abnormal elevation in plasma vWF associated with severe
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ischaemia. This reduction in vWF levels may have implications for the subsequent
progression of atherosclerosis in patients with peripheral arterial disease, as a
reduction in vWF levels may reduce platelet-vessel wall interactions, which appear
to be central to the progression of arterial disease (Badimon & Fuster, 1992).
P.A.I, and t.P.A.
Fibrinolysis is controlled in part by the level of activity of plasmin, formed
from its inactive precursor, plasminogen, by the action of tissue-type Plasminogen
Activator (t.P.A.) (Loscalzo, 1992). Activity of t.P.A. is however inhibited by
glycoprotein Plasminogen Activator Inhibitors (P.A.I.) (Kruithof, 1988), and
plasma levels of P.A.I, and t.P.A. therefore exert a major influence on fibrin
turnover.
Resolution of critical limb ischaemia leads to a significant fall in t.P.A.
levels and a less marked fall in P.A.I, levels. P.A.I, however behaves like an
acute-phase protein (Hamsten & Wiman, 1992), and exclusion of cases with pre¬
operative sepsis or necrosis, indicates that while t.P.A. levels still fall after
resolution of critical limb ischaemia, there is no fall in P.A.I, levels. These
findings suggest that conversion of plasminogen to plasmin is reduced following
resolution of critical limb ischaemia, and this may be due to a reduction in arterial
and venous stasis, and consequently thrombus formation, on increasing blood flow
to the affected limb(s).
The fall in tissue-type Plasminogen Activator levels on resolution of critical
limb ischaemia, is independent of the type of graft utilised, although it only attains
statistical significance after synthetic grafting. In contrast, P.A.I, levels show little
change after insertion of a vein graft, while they fall markedly after insertion of a
synthetic graft. This may reflect an increase in plasmin formation (and therefore
fibrin turnover) in association with the use of synthetic grafts to revascularise
critically ischaemic limbs. This would concur with the increase in fibrin turnover
and cross-linked FDP levels already observed in this particular group of patients.
The increased rate of fibrin turnover in synthetic grafts may cause the
associated fall in t.P.A. and P.A.I, levels. An alteration in equilibrium between
t.P.A. and P.A.I, may be more important than their absolute plasma levels, in
terms of their influence on fibrinolysis. What these results do indicate is that
resolution of critical limb ischaemia does not alter this equilibrium significantly if
autologous vein is used, but that alterations occur in the presence of a synthetic
graft. In all cases, resolution of critical limb ischaemia reduces plasma t.P.A.
levels to those seen in an age-matched population.
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Factor VII
Factor VII levels are affected by a number of non-specific stimuli that result
in an inverse relationship between Factor VII and fibrinogen levels (Meade, 1991).
It is therefore not surprising that the fall in fibrinogen after resolution of critical
limb ischaemia is accompanied by a rise in Factor VII levels, that is seen even after
exclusion of pre-operative sepsis and necrosis. It appears that surgical resolution of
critical limb ischaemia results in the return of factor VII levels to normal
population levels, regardless of the material used for revascularisation, although the
magnitude of the rise is smaller after insertion of a vein graft.
There are unlikely to be any significant implications of these changes in
Factor VII. Critical limb ischaemia results in certain inflammatory changes (Lowe,
1990A), that result in Factor VII levels falling below those of an age-matched
population. Resolution of critical limb ischaemia reverses these changes, with
Factor VII levels returning to normal, and it is unlikely that these changes have a
major effect on the overall thrombotic tendency, which is affected to a greater
extent by the marked changes in other potential thrombotic mediators occurring in
association with surgical treatment of critical ischaemia.
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Summary
The work reported in this study indicates that several abnormalities of blood
rheology and potential thrombotic mediators found in association with critical limb
ischaemia, can be reversed by resolution of the limb ischaemia. However only a
minority of these variables are returned to a level that corresponds to that seen in
an age-matched population.
1 in 4 of the patients undergoing treatment for critical limb ischaemia are
dead within 4 months of surgery. This observation has implications for patient
selection and requires further study.
Relative blood viscosity, an index of red cell deformability, is reduced
following resolution of critical limb ischaemia, and this has been observed in a
prior study (Irwin et al, 1983). This reduction is not seen in patients revascularised
with a synthetic graft.
Blood and plasma viscosity are essentially unaltered after resolution of
critical limb ischaemia despite a large fall in plasma fibrinogen, and it is postulated
that the effect of this fall is offset by the increase in other plasma protein levels
which follows surgery.
This fall in plasma fibrinogen implies that critical limb ischaemia leads to
an increase in fibrinogen synthesis that is partly reversible. This could be related to
hepatic stimulation by products of activated monocytes. The persisting elevation in
fibrinogen following revascularisation may reflect a genetic predisposition to high
fibrinogen in patients who develop critical limb ischaemia, or generalised
atherosclerosis.
Cross-linked fibrin degradation product levels are unchanged following
revascularisation with autologous vein, but are greatly increased following insertion
of a synthetic graft, and this is likely to reflect the continuous turnover of the
fibrinous layer lining these grafts.
von Willebrand factor levels fall with revascularisation, but fail to return to
population levels, possibly because the widespread nature of peripheral arterial
disease results in the continued contact between blood and damaged endothelium.
Levels of vWF are higher after revascularisation with synthetic grafts and this may
reflect increased platelet activation and degranulation in the presence of such grafts.
Further studies of markers of platelet activation need to be carried out in such
patients.
The regulators of fibrinolysis, t.P.A. and P.A.I., are reduced following
revascularisation surgery, although insertion of a synthetic graft reduces P.A.I, to a
greater extent, suggesting that the balance between activation and inhibition of
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plasminogen is shifted in favour of activation. This observation would be in
keeping with the postulated increase in fibrin turnover accompanying the insertion
of a synthetic graft.
Factor VII levels rise after revascularisation and this is probably due to the
tendency of Factor VII to behave as a "negative acute-phase reactant". This return
to normal population levels is unlikely to have a significant effect on an
individual's thrombotic tendency following revascularisation.
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CHAPTER 5
The effect of percutaneous angioplasty on blood rheology and
thrombotic mediators in peripheral arterial disease
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INTRODUCTION
Percutaneous transluminal angioplasty (PTA) is now an established method
of treating arterial stenoses in both peripheral and coronary arterial disease, and the
results of PTA in peripheral arterial disease have been extensively reviewed (Dake
& Katzen, 1990), although meaningful comparison between different series is
hampered by the lack of uniform reporting methods (Rutherford & Becker, 1991).
The lesions most suited to percutaneous angioplasty have also been identified (Dake
& Katzen, 1990, Al-Kutoubi, 1992), the cost benefits of the procedure have been
emphasised (Doubilet & Abrahams, 1984), and the clinical indications for
percutaneous angioplasty have been at least partly defined (Campbell, 1986,
Whyman et al, 1991).
Studies of the direct effects of percutaneous angioplasty have been limited
to pathophysiological studies of the mechanism of angioplasty (Castenada-Zuniga et
al, 1980, Zarins et al, 1982, Kinney et al, 1984) that suggest that the process is one
of controlled injury produced by dilatation, followed by a healing process that
results in a smooth-walled lumen (Dake & Katzen, 1990). The effects of
angioplasty on blood rheology and thrombotic mediators, which are associated with
peripheral arterial disease (Lowe, 1986, Lowe, 1992, Leng & Fowkes, 1991B,
Woodburn et al, 1993A), has not been studied. This chapter examines the effects of
percutaneous angioplasty on blood rheology and potential thrombotic mediators,
and also compares arterial and venous levels of these variables.
Aims:
1) To determine whether or not measures of blood rheology, fibrin turnover
(cross-linked FDP's), von Willebrand Factor (vWF), Plasminogen Activator
Inhibitor (P.A.I.), and tissue Plasminogen Activator (t.P.A.) are the same in
venous blood, and peri-lesional arterial blood, in patients undergoing percutaneous
transluminal angioplasty for intermittent claudication.
2) To determine the immediate local effects of percutaneous angioplasty on
arterial blood rheology, fibrin turnover (as determined by levels of cross-linked
FDP's), markers of endothelial damage (plasma vWF), and fibrinolysis
(determined by levels of t.P.A. and P.A.I.), in patients with intermittent
claudication.
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3) To examine the longer-term effects of percutaneous angioplasty on blood
rheology and thrombotic mediators in patients with claudication, by comparison of
venous blood samples prior to, and 4 months after, percutaneous angioplasty.
These changes will be compared with a control group of patients with peripheral
arterial disease undergoing arteriography alone.
4) To determine whether or not any relationship exists between pre-angioplasty




Forty-three (43) patients undergoing percutaneous transluminal angioplasty
of symptomatic stenoses (35 cases), or short occlusions (8 cases), in either iliac or
femoropopliteal vessels, were recruited. All patients were attending the peripheral
vascular surgery unit at Glasgow Royal Infirmary, and underwent a full physical
examination prior to entry into the study. Diagnosis of peripheral vascular disease
was based on a fall in the ankle-brachial pressure index (ABPI) of more than 0.15,
following a standard treadmill exercise test (2km/hr at an incline of 10 until either
the onset of symptoms, or a maximum of 200 metres), carried out by myself or a
vascular research nurse, and a Seldinger arteriogram showing a stenosis of greater
than 50% at a site appropriate to the symptoms. Informed consent for participation
in the study was obtained from all patients, and approval obtained from the hospital
ethical committee.
Fasting venous blood samples were obtained by myself, with minimal
stasis, from the antecubital vein in all patients, 2 to 4 hours prior to angioplasty,
and again 16 weeks later at review in the vascular laboratory. The review samples
were all taken prior to the patient undergoing a further treadmill exercise test,
using the criteria described above, with measurement of ankle-brachial pressure
indices (ABPI) prior to and following the test. Samples were obtained, handled,
and assayed as described in chapter 2.
All angioplasties were carried out by Dr. A.W. Reid, consultant vascular
radiologist, using commercially available angioplasty balloon catheters.
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Comparison of venous & arterial blood
In 15 of the 43 patients additional 14ml samples of arterial blood were
obtained through a size 5 french angiography catheter, at the site of the arterial
lesion (8 downstream of an iliac stenosis, 7 upstream from a superficial femoral
lesion), by the radiologist, prior to angioplasty being carried out, and a further
sample obtained in the vicinity of the lesion immediately following deflation of the
angioplasty balloon. 5mls of each sample of blood were added to tubes containing
dried dipotassium EDTA 1.5mg/ml (Monoject, Sherwood Medical, U.K.), for
estimation of rheological parameters as previously described, while the remaining
9mls were added to a plastic tube containing 1ml of trisodium citrate (0.109M),
and subsequently handled and assayed for cross-linked FDP's, von Willebrand
Factor, Plasminogen Activator Inhibitor (P.A.I.) and tissue Plasminogen Activator
(t.P.A.), as described in chapter 2.
Controls
In 10 control patients (7 male and 3 female) with angiographically proven
peripheral arterial disease and symptoms of intermittent claudication, who were
undergoing arteriography by the Seldinger technique, venous blood samples were
obtained, stored, and assayed in the manner previously described. The mean age of
the control patients was 68 years (range 49-80), and 50% were on antiplatelet
therapy pre- and post-angiography. All samples were obtained prior to
angiography, and sampling was repeated 12-16 weeks later. At this time clinical
examination and measurement of ABPI's was carried out in all patients to ensure
that there had been no significant deterioration in the patients peripheral arterial
disease following angiography. Samples were subsequently handled and assayed as
previously described.
Statistics
All results were stored as described in chapter 2, and all statistical analyses
were carried out by myself. Results were compared using non-parametric methods,
with pairwise deletion where data values were missing.
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RESULTS
Results of percutaneous angioplasty
It was not possible to carry out angioplasty in 1 of the 43 patients due to
inability to traverse a short occlusion with a percutaneous guidewire, and this
"technical failure" was therefore excluded from further analysis. A further patient
was diagnosed as suffering from gastric adenocarcinoma, after a successful PTA
but prior to review, and was therefore also excluded.
41 patients therefore completed the study, 24 males and 17 females, with a
mean age of 63 years (range 38-77). 25 of these patients had undergone iliac
angioplasty, and 16 superficial femoral angioplasty (Table 5.1, p. 148). The
smoking habits of all the patients in the study remained unchanged over the 4
month follow up period, non-smoking being confirmed by plasma
carboxyhaemoglobin estimation (Chapter 2). There were 4 patients who
commenced antiplatelet therapy following angioplasty, in addition to 13 patients
who remained on antiplatelet therapy throughout the period of the study.
One 70 year old female patient died following surgery for a femoral false
aneurysm after successful angioplasty, and in the remaining patients there were 36
cases in which angioplasty improved the ABPI (figures 5.1-5.2, p. 149-150), and
increased the mean treadmill walking distance from 120 metres (range 40-200m) to
155 metres (range 30-200m), and 4 patients (10%), in whom both clinical and
laboratory assessment at 3 months confirmed restenosis or occlusion of the
angioplastied lesion (Table 5.1), treadmill distance remaining at a mean level of 94
metres post-angioplasty (97 metres pre-angioplasty). In all 40 of these patients
however, radiological assessment immediately post-angioplasty confirmed technical
success, while clinical patency was confirmed on examination prior to hospital
discharge, 24 hours following the angioplasty.
Comparison of blood rheology measures prior to and 16 weeks after
successful angioplasty (Table 5.2, p. 151), showed no significant changes in blood
rheology following successful percutaneous angioplasty, and a similar stability was
observed in the control patients undergoing angiography alone, although there was
a significant rise in red cell aggregation observed in control cases (Table 5.3,
p. 152).
In the control patients there were no significant differences in the levels of
any of the potential thrombotic mediators (fibrinogen, FDP's, vWF, Factor VII,
t.P.A, and P.A.I.), when pre-angiography and post-angiography results were
compared (Table 5.3). Following successful angioplasty there was a significant
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GOOD
OUTCOME RESTENOSIS DIED TOTALS
Indication
Claudication 36 3 1 40
Critical limb
ischaemia 1 - - 1
Site of PTA
Iliac 21 3 1 25
< 5cm stenosis 17 1 - 17
> 5cm stenosis 4 - - 4
occlusion <5cm - 2 1 3
SFA/popliteal 15 1 - 16
< 5cm stenosis 8 1 - 9
> 5cm stenosis 2 - - 2
occlusion <5cm 5 5
Risk Factors
Continued smoking 23 1 - 24
Ex-smokers 14 2 1 17
Antiplatelet therapy 17 3 - 20
Diabetes Mellitus 2 1 - 3










































































VARIABLE PRE-PTA POST-PTA PAIRS
fibrin degradation
products (ng/ml) 100 (64-134) 140 (99-179) p < 0.04
haematocrit (%) 45 (42-48) 45 (42-48) p = 0.06
Platelet count (x10^/1) 259 (214-287) 269 (226-327) p = 0.08
factor VII (% pool) 120 (104-128) 128 (110-139) p = 0.15
fibrinogen (g/1) 3.5 (2.9-3.8) 3.4 (3.1-4.3) p = 0.45
corrected
blood viscosity (mPa.s) 3.30 (3.14-3.36) 3.31 (3.12-3.46) p = 0.50
plasminogen activator
inhibitor (% pool) 103 (86-159) 116 (75-159) p = 0.46
White cell Count (x 10^/1) 8.6 (6.8-9.8) 8.0 (6.9-9.4) p = 0.51
relative
blood viscosity 2.50 (2.38-2.58) 2.44 (2.32-2.54) p = 0.52
von Willebrand
factor (iu/dl) 124 (102-157) 124 (93-153) p = 0.64
plasma viscosity (mPa.s) 1.32 (1.28-1.40) 1.36 (1.30-1.39) p = 0.66
tissue plasminogen
activator (ng/ml) 7.8 (5.3-10.0) 8.3 (6.0-10.7) p = 0.66
Red cell
aggregation (units) 4.2 (3.6-4.9) 4.2 (3.5-5.1) p = 0.80
Table 5.2: Changes in blood rheology and thrombotic mediators following
successful percutaneous angioplasty in 36 patients. Figures are







aggregation (units) 4.6 (3.7-5.4) 5.7 (4.6-6.2) p = 0.04
Corrected
blood viscosity (mPa.s) 3.30 (3.19-3.33) 3.26 (3.04-3.58) p = 0.12
haematocrit (%) 44 (42-46) 40 (37-46) p = 0.18
fibrin degradation
products (ng/ml) 288 (165-639) 258 (135-592) p = 0.20
plasma viscosity (mPa.s) 1.37 (1.34-1.44) 1.37 (1.27-1.39) p = 0.21
factor VII (% pool) 113 (101-128) 118 (98-130) p = 0.34
fibrinogen (g/1) 4.0 (3.5-4.4) 3.7 (3.5-4.6) p = 0.39
Platelet count (x 10^/1) 248 (234-305) 240 (233-287) p = 0.58
White cell Count (x10^/1) 8.5 (6.4-9.4) 8.2 (7.0-9.6) p = 0.58
relative
blood viscosity 2.40 (2.33-2.48) 2.47 (2.35-2.63) p = 0.78
tissue plasminogen
activator (ng/ml) 8.8 (6.5-9.5) 8.0 (6.9-9.6) p = 0.80
von Willebrand
factor (iu/dl) 124 (93-162) 121 (107-132) p = 0.91
plasminogen activator
inhibitor (% pool) 119 (87-136) 114 (84-122) p = 1.00
Table 5.3: Blood rheology and thrombotic mediators pre and post-angiography
in 10 control patients. Figures are medians (interquartile range).
152
increase in fibrin turnover, as determined by levels of cross-linked fibrin
degradation products, when compared with pre-operative levels (p < 0.04). Levels
of other variables measured were similar both pre- and post-angioplasty (Table 5.2)
in these patients.
Comparison of pre-angioplasty blood rheology and levels of thrombotic
mediators in the 2 outcome groups (successful PTA versus restenosis/occlusion)
failed to reveal any significant differences in the 2 outcome groups (Table 5.4,
p. 154), although on comparison of pre- and post-operative FDP levels it appears
that successful angioplasty is associated with alterations in fibrin turnover that are
not observed in cases where angioplasty fails (Fig. 5.3, p. 156). However as there
were only 4 failures these conclusions must be limited.
Rheology & thrombotic mediators in arterial & venous blood
Arterial and venous samples were available for comparison in 15 patients
(mean age 63 years, range 38-75 yrs.), 10 male and 5 female. In 2 of these cases
there was evidence of significant haemodilution (presumably as a result of flushing
the angiography catheter with heparinised saline), and the intra-arterial samples
from these patients were therefore excluded from subsequent analyses. One
additional sample was found to contain clots, and was also discarded, leaving 12
samples for comparison of arterial and venous levels of blood rheology, cross-
linked FDP's, von Willebrand factor, t.P.A., and P.A.I. 6 of these arterial samples
were obtained downstream of an iliac lesion, and 6 upstream of a superficial
femoral lesion.
Arterial blood rheology was almost identical to venous blood rheology in all
samples, with no significant differences in any of the parameters, and both cross-
linked FDP levels, and P.A.I, levels were also similar (Table 5.5, p. 157). von
Willebrand factor levels (Figure 5.4, p. 158), and tissue Plasminogen Activator
(t.P.A.) levels (Figure 5.5, p. 159) were however significantly lower in arterial
blood than in venous blood, although correlations between arterial and venous
levels were above 0.5 for all measurements except vWF and relative blood
viscosity (Table 5.5).
Changes in arterial blood after angioplasty
Pre- and post-angioplasty arterial samples were compared in 12 of the 15
patients, 3 patients being excluded on the grounds of differences in pre- and post-
angioplasty haematocrit suggesting haemodilution (2 cases), or due to a clotted




VARIABLE PTA PTA U-TEST
haematocrit (%) 45 (42-48) 41 (40-41) p = 0.10
von Willebrand
factor (iu/dl) 124 (102-157) 179 (135-179) p = 0.14
relative
blood viscosity 2.50 (2.38-2.58) 2.35 (2.31-2.39) p = 0.18
plasma viscosity (mPa.s) 1.32 (1.28-1.40) 1.40 (1.39-1.42) p = 0.23
Platelet count (xl09/l) 259 (214-287) 315 (248-315) p = 0.25
fibrin degradation
products (ng/ml) 100 (64-134) 127 (108-127) p = 0.39
White cell Count (xl09/l) 8.6 (6.8-9.8) 9.2 (7.6-9.2) p = 0.43
tissue plasminogen
activator (ng/ml) 7.8 (5.3-10.0) 3.9 (3.7-14.5) p = 0.55
factor VII (% pool) 120 (104-128) 137 (128-148) p = 0.56
cell
aggregation (units) 4.2 (3.6-4.9) 4.7 (3.2-4.7) p = 0.65
fibrinogen (g/1) 3.5 (2.9-3.8) 3.6 (3.1-3.6) p = 0.70
corrected
blood viscosity (mPa.s) 3.30 (3.14-3.36) 3.30 (3.28-3.32) p = 0.85
plasminogen activator
inhibitor (% pool) 103 (86-159) 96 (58-201) p = 0.85
Table 5.4: Comparison of levels of baseline rheology and thrombotic mediators
in successful (36 cases) and failed (4 cases) percutaneous
transluminal angioplasty. Figures are median (interquartile range).
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In these cases there were no significant changes in arterial blood rheology
or Plasminogen Activator Inhibitor (P.A.I.) levels immediately following
angioplasty (Table 5.6, p. 160). There was a trend towards a significant rise in the
levels of cross-linked FDP's immediately following angioplasty (Figure 5.6,
p. 161), that was more apparent in venous samples taken 16 weeks after angioplasty
(Fig. 5.7, p. 162), together with a significant rise in vWF levels (Figure 5.8,
p. 163), although this was not maintained in the post-angioplasty venous samples
(Fig. 5.9, p. 164). There was also a significant fall in tissue Plasminogen Activator
(t.P.A.) levels (Figure 5.10, p. 165) in arterial blood immediately following
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Figure 5.3: Plot of pre-angioplasty fibrin degradation product level against post-









































p = 0.003 R = 0.36
p = o.Ol R = 0.90
p = 0.22 R = 0.96
p = 0.24 R = 0.81
p = 0.37 R = 0.45
p = 0.50 R = 0.78
p = 0.53 R = 0.48
p = 0.59 R = 0.79
p = 1.00 R = 0.60
Table 5.5: Comparison of blood rheology and thrombotic mediators in venous
and peri-lesional arterial blood, in 12 patients undergoing PTA.
Figures are medians (interquartile range). Spearman rank order






Figure 5.4: Arterial and venous levels of von Willebrand Factor (vWF) in 11





Figure 5.5: Arterial and venous levels of tissue Plasminogen Activator (t.P.A.)





VARIABLE PRE-PTA POST-PTA PAIRS
von Willebrand
factor (iu/dl) 68 (58-100) 88 (74-132) p = 0.01
tissue plasminogen
activator (g/1) 6.9 (4.8-7.8) 4.5 (2.9-5.4) p = 0.02
fibrin degradation
products (ng/ml) 100 (81-174) 108 (90-154) p = 0.06
relative
blood viscosity 2.40 (2.34-2.42) 2.49 (2.37-2.55) p = 0.13
plasma viscosity (mPa.s) 1.29 (1.26-1.37) 1.28 (1.24-1.34) p = 0.14
cell
aggregation (units) 4.4 (3.6-5.0) 2.6 (1.9-4.1) p = 0.34
haematocrit (%) 44 (42-44) 44 (41-44) p = 0.40
plasminogen activator
inhibitor (% pool) 80 (60-88) 76 (63-86) p = 0.64
corrected
blood viscosity (mPa.s) 3.20 (3.02-3.28) 3.27 (3.02-3.31) p = 0.84
Table 5.6: Comparison of blood rheology and thrombotic mediators in pre and
post-angioplasty arterial blood, in 12 patients undergoing PTA.










Figure 5.6: Pre- and post-angioplasty levels of cross-linked fibrin degradation
products in arterial blood in 11 patients undergoing PTA. p = 0.06,
Wilcoxon matched pairs test.
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F.D.P. LEVEL (ng/ml)
Vv. PRE art. PRE art. POST W. 16WKS
SAMPLE
Figure 5.7: Serial changes following angioplasty: Plasma fibrin degradation
product levels in 9 cases (Vv. = venous blood, art. = arterial, Pre =






Figure 5.8: Pre- and post-angioplasty levels of von Willebrand Factor (vWF) in





Vv. PRE art. PRE art. POST vV. 16WKS
SAMPLE
Figure 5.9: Serial changes following angioplasty: Plasma von Willebrand Factor
levels in 9 cases (Vv.= venous blood, art. = arterial, Pre =






Figure 5.10: Pre- and post-angioplasty levels of tissue Plasminogen Activator
(t.P.A.) in arterial blood in 12 patients undergoing PTA. p = 0.02,




Vv. PRE art. PRE art. POST vV. 16WKS
SAMPLE
Figure 5.11: Serial changes following angioplasty: Tissue Plasminogen Activator
levels in 9 cases (Vv.= venous blood, art. = arterial, Pre =
pre-angioplasty, post = post-angioplasty).
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DISCUSSION
The patients described in this study were not randomly selected but are a
representative sample of cases selected for angioplasty at one vascular surgery
centre. 90% of the patients had both clinical and Doppler evidence of successful
angioplasty at 4 months, in keeping with other reports (Cambria et al, 1987,
Michaels, 1990), although when a diagnosis of failure is made on the basis of non¬
invasive vascular laboratory studies, rather than on angiographic appearances, it is
impossible to be certain that symptoms are attributable to restenosis of the
angioplastied lesion, rather than arising from other significant arterial lesions. In
this series failure was more common in iliac lesions (Table 5.1), in which
angioplasty is recognised to have a lower success rate (Al-Kutoubi, 1992).
The relatively low early failure rate of angioplasty in this series, coupled
with the previously expressed doubts about the source of recurrent symptoms in the
patients studied, makes it difficult to draw any definite conclusions on the role of
blood rheology and thrombotic mediators in restenosis following angioplasty. To
address this issue in appropriate detail will require large numbers of patients and
invasive angiographic follow up. However this was not the primary aim of this
study, which has concentrated on the effects of successful angioplasty on blood
rheology and thrombotic parameters, as the success of angioplasty can be assessed
non-invasively by improvement in ABPI and walking distance.
Arterial & venous comparisons
Altered blood viscosity in patients with peripheral arterial disease, has been
demonstrated in a number of studies (Dormandy et al, 1973A, Lowe, 1986), and it
has been suggested that local alterations in rheological parameters may have a role
in the distribution of the lesions of atherosclerosis (Schwartz et al, 1989).
Pathological studies in patients with peripheral arterial disease have implicated
fibrin deposition in the development of the arterial lesions (Duguid, 1949, Smith &
Staples, 1981), and in addition there is evidence implicating increased fibrin
turnover in the disease process, elevated levels of cross-linked fibrin degradation
products (FDP's) having been demonstrated in patients with symptomatic
peripheral arterial disease (Reid, 1991, Al-Zahrani et al, 1992).
These findings have however all been made in venous blood samples, taken
from the antecubital vein, and in view of the focal nature of the lesions of
atherosclerosis, the situation in arterial blood may be different. These results
however indicate that venous sampling represents an accurate reflection of the
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composition of arterial blood in patients with symptomatic peripheral arterial
disease, with good correlations between arterial and venous levels of most
mediators. The major exception to this observation is with respect to von
Willebrand factor levels, which, despite a poor correlation between arterial and
venous levels, appear to be consistently lower in arterial blood. The reason for this
difference is not known, but may reflect decreased production from a damaged
arterial endothelium at sites of stenosis, or binding of vWF to exposed
subendothelium at these sites.
In addition, tissue Plasminogen Activator (t.P.A.) levels are significantly
lower in peri-lesional arterial blood than in venous blood, although complete data
was only available in 8 cases. This may also be due to impaired production of
t.P.A. by damaged endothelium in the vicinity of arterial stenoses, as t.P.A. is
mainly synthesised by endothelial cells (Hashimoto et al, 1987). However levels of
P.A.I., also synthesised by endothelial cells (Kruithof, 1988), would be expected
to be similarly reduced in this situation, but this was not observed. The implication
of this is that the equilibrium between t.P.A. and P.A.I, in peri-lesional arterial
blood is not the same as it is in venous blood, with the balance being shifted in
favour of a reduction in fibrinolytic activity in peri-lesional arterial blood. This
may be a contributory factor in the development of atherosclerotic plaques and
arterial stenosis, which have been shown to contain fibrin (Duguid, 1949, Smith &
Staples, 1981).
The similarity between arterial and venous levels of cross-linked FDP levels
indicates that any contribution that altered fibrin turnover makes to peripheral
arterial disease, and in particular to the progression of atherosclerotic plaques
(Duguid, 1949, Smith & Staples, 1981), is not made by local alterations in fibrin
turnover at the sites of development of symptomatic stenoses. The elevated levels
of FDP that have been documented in peripheral arterial disease (Reid, 1991, Al-
Zahrani et al, 1992, Peltonen et al, 1992)), appear therefore to reflect a systemic
alteration in fibrin turnover.
These results do little to support any suggestion of significant local
alterations in haemostatic and rheological parameters at the sites of symptomatic
lesions in patients with peripheral arterial disease, and confirm that venous blood
sampling provides an accurate reflection of the composition of arterial blood in
such patients, although it consistently overestimates the concentration of the
endothelial products vWF and t.P.A. present in arterial blood samples taken from
the vicinity of a symptomatic stenosis.
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Effects of angioplasty on arterial & venous blood
The stability of arterial Theological parameters immediately following
angioplasty is unremarkable: the changes in blood rheology associated with
peripheral arterial disease occur in association with chronic arterial insufficiency,
and are partly due to a chronic increase in inflammatory products such as
fibrinogen (Reid, 1991). In the absence of inflammatory changes arterial rheology
will remain unchanged in the early post-angioplasty period.
The observed rise in vWF immediately following angioplasty is in keeping
with the endothelial damage produced by balloon angioplasty. This consists of cell
injury and loss (Block et al, 1980, 1981), brought about by splitting of the intima,
and medial stretching, that accompanies inflation of the angioplasty balloon
(Castenada-Zuniga et al, 1980), presumably resulting in release of vWF at the site
of vascular injury (Wagner & Bonfanti, 1991). This release of vWF appears to be a
transient phenomenon however, as venous levels in the same patients are
unchanged from their pre-angioplasty levels 4 months later, and remain unchanged
pre-and post-angioplasty in the larger group of patients. Analysis of pre-operative
vWF levels by outcome, suggests that there is a tendency for angioplasty to fail in
patients with higher initial vWF levels. This may indicate that failures occur in
those patients with the most severe disease, as vWF levels are higher in more
severe disease (Chapter 3), however in view of the small number of cases involved
it is not possible to draw any meaningful conclusions from this observation.
The fall in t.P.A. levels immediately following angioplasty is not
maintained in venous blood 4 months later, and may be a transient local response
to fibrin formation at the site of arterial injury. Prior animal models of arterial
injury have demonstrated a similar fall in t.P.A. after arterial injury (Clowes et al,
1990). Tissue-type Plasminogen activator (t.P.A.) binds to fibrin, significantly
improving its catalytic efficiency (Kruithof, 1988), and in this way accelerating the
lysis of fibrin. It is presumably this binding of t.P.A. to fibrin deposited at the
angioplasty site (Block et al, 1980) that results in the observed fall in t.P.A. levels
in arterial blood immediately following angioplasty.
This binding of t.P.A. to fibrin stimulates plasmin production (Kruithof,
1988), leading to fibrinolysis, which may account for the small increase in arterial
cross-linked FDP levels observed following angioplasty. This rise in FDP's
following angioplasty was only minimal, however, perhaps because the post-
angioplasty arterial sampling was performed immediately following the procedure,
while local fibrin turnover may increase gradually after angioplasty. This belief is
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supported by the observation that 16 weeks after angioplasty, FDP's are elevated
further from their pre-angioplasty level.
An increase in the lysis of cross-linked fibrin is probably an essential
response to the fibrin deposition that has been demonstrated to occur at sites of
angioplasty (Block et al, 1980) if arterial occlusion and restenosis is to be avoided,
and this study suggests that following successful angioplasty, in addition to the rise
in arterial FDP's immediately following angioplasty, there is a sustained rise in
venous FDP's that persists for at least 4 months. Closer examination of pre- and
post-angioplasty levels of FDP's however, confirms that the rise in FDP's
following successful PTA is not a uniform observation, and a number of cases
demonstrate a reduction in FDP levels following successful angioplasty.
It is not possible to interpret the observation that cases of restenosis show
minimal alteration in fibrin turnover after PTA because the numbers involved are
too small, and longer follow-up of a larger number of cases would be required to
further investigate this. It is however conceivable that FDP's rise following
angioplasty as a consequence of an increase in fibrin turnover at the site of
angioplasty, secondary to residual arterial damage and delayed restoration of
endothelial cover. In these circumstances an increase in fibrin turnover would be
required to maintain patency of the damaged arterial segment. It has previously
been observed that incomplete restoration of the arterial lumen following
angioplasty results in high shear deposition of platelets at the site of angioplasty
(Chesebro et al, 1987). This leads to formation of platelet-fibrin thrombi, which
can lead to restenosis and occlusion (Faxon et al, 1987. Harker, 1987). Lysis of
such platelet-fibrin thrombi (resulting in an increase in FDP's) would however
reduce the likelihood of restenosis and occlusion in such a situation.
When, in contrast, fibrin turnover decreases markedly in the 4 months
following angioplasty, this may be because angioplasty has completely restored the
arterial lumen with minimal arterial damage, and consequently rapid endothelial
regeneration, leading to a reduction in fibrin turnover and FDP levels.
It is also possible that the rise in FDP's observed following angioplasty is
the result of worsening of arterial disease in the 4 months following angioplasty, as
there is a strong association between the severity of arterial disease, and FDP levels
in patients with symptomatic peripheral vascular disease (Reid, 1991, Woodburn et
al, 1993A). The effect of angioplasty on the progression of arterial disease has not
yet been studied, but there is some animal work indicating that disease progression
is more rapid distal to a 50% stenosis, than it is to more severe stenoses
(Bomberger et al, 1981).
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Because angioplasty often fails to fully restore the arterial lumen to its
original diameter, with the original plaque remaining while the non-diseased
portion of the arterial wall is stretched to widen the lumen (Zarins et al, 1982), the
residual effect of angioplasty is often to leave a minor degree of stenosis present in
the recanalised vessel. The presence of these minimal residual stenoses may
accelerate disease progression downstream of the site of angioplasty, with
consequent increased fibrin turnover and incorporation into plaques (Smith et al,
1992) reflected by an increase in FDP levels.
The lack of any significant alterations in thrombotic mediators in patients
undergoing angiography alone confirms the fact that the observations made in this
study are a consequence of undertaking percutaneous angioplasty in patients with
peripheral arterial disease. The observations made confirm that percutaneous
angioplasty has little effect on many thrombotic and rheological parameters
associated with peripheral arterial disease, an observation that may in part be due to
the fact that patients undergoing angioplasty have less extensive disease than
patients undergoing surgery. However the observation that fibrin turnover (as
reflected by levels of cross-linked FDP's) is significantly increased immediately
after angioplasty, and that this increase is maintained for at least 4 months
following the procedure, merits further investigation, as this increase in FDP's may
be associated with an increase in the severity of peripheral arterial disease.
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Summary
These studies have demonstrated that the measurement of venous blood
rheology and most thrombotic mediators show a strong correlation with, and
provide an accurate reflection of, peri-lesional arterial values, in patients with
symptomatic peripheral arterial disease. Investigators should however bear in mind
that venous levels of von Willebrand Factor antigen are significantly higher than
peri-lesional arterial levels, and that there is only a weak correlation between the
venous and arterial levels.
Percutaneous transluminal angioplasty produces transient alterations in a
number of potential thrombotic mediators, that are probably a direct effect of the
arterial injury produced by the procedure, but these soon return to baseline levels
with the exception of fibrin turnover, as determined by crosss-linked FDP levels,
which remain altered for at least 4 months following angioplasty. The magnitude
and nature of these alterations may be related to progression of arterial disease
following angioplasty and further studies are required to investigate these
observations.
These findings are of particular importance in view of the expansion in the
number of patients undergoing angioplasty, a procedure which has never been
subjected to any rigourous investigation of its long term effects, and the trend
towards offering angioplasty to those patients with mild claudication who would
previously have been treated by conservative measures alone. Further long term
studies of the biochemical effects of angioplasty are required to identity aspects of








Symptomatic peripheral arterial disease commonly results from superficial
femoral artery disease (Bloor, 1961), with surgical bypass of occluded superficial
femoral arteries being required to relieve claudication and critical limb ischaemia.
While the results of proximal revascularisation procedures are excellent (Reid &
Pollock, 1991), the outcome following femoropopliteal and femoro-distal grafting
is less encouraging (Whittemore et al, 1990, McCollum et al, 1991B).
There are a number of factors that affect the outcome of infra-inguinal
bypass grafting, including the quality of run-off vessels, the graft material utilised
(Rutherford, 1990, Tordoir et al, 1993) and the diameter and quality of the bypass
conduit (Wengerter et al, 1990). Intrinsic patient hypercoagulability may also
contribute to graft failure (Rutherford, 1990). Alterations in blood rheology and
levels of potential thrombotic mediators in patients with peripheral arterial disease,
may increase thrombogenicity and therefore influence the outcome following
revascularisation surgery.
Elevations in blood viscosity have been shown to reduce blood flow along
vessels (Dormandy, 1971), while elevated plasma fibrinogen 6 months after
surgery predicts femoropopliteal vein graft occlusion (Wiseman et al, 1989).
Animal studies have indicated that plasma von Willebrand factor is an essential
requirement for the development of occlusive thrombi at sites of arterial injury
(Brinkhous et al, 1991), and that low levels of vWF protect against the
development of atherosclerosis (Badimon & Fuster, 1992). There are therefore a
number of potential roles for these and other thrombotic mediators in infra-inguinal
bypass graft failure.
Altered levels of thrombotic mediators are of particular interest because
they may be more amenable to pharmacological manipulation than the other factors
contributing to graft failure. Any relationship between potential thrombotic
mediators and the outcome following infra-inguinal bypass grafting offers a means
of improving pre-operative patient selection for such surgery, and identifying
situations where adjuvant pharmacological therapy may improve the results of
surgery.
Although infra-inguinal graft occlusion is readily detected by clinical
means, identification of the failing graft, in which intervention may prevent
occlusion, is of greater importance (DeWeese & Green, 1990). Colour duplex
scanning and other non-invasive vascular laboratory techniques (Wyatt et al, 1991,
Idu et al, 1992), offer alternatives to angiography for the early identification of
174
"at risk" infra-inguinal grafts (Harris, 1991, Renton et al, 1991, Hatsukami, 1992,
Davies et al, 1993), and the use of these non-invasive techniques in a graft
surveillance program enables accurate assessment of the results of revascularisation
surgery. This information can be used to relate clinical events to any post-operative
changes that may occur in rheological and thrombotic parameters. The
haemorheological responses to infra-inguinal grafting have not been previously
reported.
Aims:
1) To develop a predictive index for poor outcome (death or graft occlusion)
following infra-inguinal bypass grafting, based on pre-operative blood rheology,
levels of thrombotic mediators, and clinical and radiological information.
2) To establish, by means of serial measurements, the effects of successful
infra-inguinal revascularisation surgery on the abnormal blood rheology and levels
of potential thrombotic mediators previously observed in patients with peripheral
arterial disease, and to investigate the effects of the material used for bypass
grafting on these responses.
3) To determine the pattern of post-operative changes in blood rheology and
thrombotic mediators in vein grafts developing stenoses, and to compare these
changes with the changes occurring in vein grafts remaining free of stenoses.
4) To investigate the value of non-invasive imaging and assessment techniques
in identifying infra-inguinal grafts that require further assessment by angiography.
MATERIALS AND METHODS
Patients
186 consecutive infra-inguinal bypass grafts in 165 patients attending the
Unit for Peripheral Vascular Surgery, Glasgow Royal Infirmary, and the Vascular
Surgery Unit, Gartnavel General Hospital, were recruited into this study prior to
undergoing surgery, and followed up for up to 1 year post-operatively. Venous
blood samples were obtained without stasis prior to surgery, and at 3, 6, and 12
months post-operatively, or until the graft was shown to be occluded, whichever
was the shorter period. A full history and examination was obtained from each
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patient, and informed consent for participation in the study was obtained. The
study was approved by the relevant hospital's ethical committee.
On post-operative visits graft status was assessed by clinical examination in
addition to the vascular laboratory methods described below, and the time of graft
occlusion determined by clinical history. Patient mortality was confirmed from
hospital records, and the patients' own general practitioner where appropriate.
Graft surveillance
All patients whose grafts were patent at discharge from hospital attended for
graft surveillance at 3, 6, and 12 months post-operatively. Patients attending
Gartnavel General Hospital underwent clinical examination and measurement of
resting ankle-brachial pressure indices at each visit, as described in chapter 2, and
colour duplex scanning of the graft was carried out by myself in conjunction with
Mrs. Roz Carter, Vascular Laboratory Technician, using an Acuson 128 Scanner
(Acuson Corporation (U.K.), Stevenage, Herts.). Duplex scans were performed at
each surveillance visit, and in grafts where the duplex scan was suggestive of
significant stenosis, or where symptoms of claudication or rest pain had returned,
patients underwent arteriography for definitive diagnosis. Significant stenosis on
colour duplex scanning was based on the appearance of turbulence on the colour
duplex image (Figure 6.1, p. 177), together with either an increase in blood
velocity of more than 50%, or any decrease in velocity to below 40cm/sec. (Green
et al, 1990).
Patients whose surgery had been carried out in Glasgow Royal Infirmary
also underwent assessment as described above, colour duplex scans being
performed by Dr. Alan Reid, Consultant Radiologist, using an ATL Ultramark 9
(HDI) scanner (Advanced Technology Laboratories, San Francisco, USA). In
addition grafts were directly insonnated using a hand held 4 or 8Mhz probe
attached to a Scimed PVL 50 portable vascular laboratory (Scimed, Bristol, UK).
Pulse volume recordings and Doppler velocity tracings were obtained from the
proximal and distal ends of the graft, using the Scimed PVL 50, and proximal and
distal impedance measurements were calculated for the limb (Wyatt et al, 1991).
These measurements were carried out by myself in conjunction with the research
nurses in the Fraser Vascular Laboratory, Glasgow Royal Infirmary, and all
patients in whom frequencies greater than 4Khz were detected on graft insonnation,
or who had a duplex scan suggestive of graft stenosis, or an impedance value above
0.5, underwent intra-arterial digital subtraction angiography to determine whether
or not there was evidence of graft stenosis or run-off deterioration.
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Figure 6.1: Duplex scans of above-knee femoropopliteal vein graft at 3 and 6
months post-insertion, there is evidence of graft stenosis in the later
scan.
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Measurement of the impedance value for a limb involves the computer
assisted analysis of pulsatile pressure and flow signals: Measurement of Doppler
flow velocity was made proximal to the graft origin using a 4 or 8 MHz Doppler
probe, 12 to 15 velocity waveforms were obtained and the mean value stored in the
PVL 50. A pneumatic cuff was then placed around the upper thigh, and linked to a
pulse volume recorder contained within the PVL 50. A number of pulse volume
waveforms were recorded and the mean stored in the PVL 50. An on-board
computer was used to calculate an impedance score for the limb using Fourier
transfer analysis of the 2 averaged waveforms (Wyatt et al, 1991). The process was
repeated at the lower end of the graft (Figure 6.2, p. 179). An impedance value of
greater than 0.49 has previously been shown to be of value in detecting "at risk"
grafts (Davies et al, 1993).
All patients in whom graft stenosis was proven on angiography were
referred back to the consultant who had undertaken their initial surgery for
consideration for further intervention to correct the stenosis.
Laboratory methods
Blood sampling was performed with minimum venous stasis, using a 19-
gauge butterfly needle. Sample handling for all specimens was as described in
chapter 2, citrated blood samples being transported to the laboratory in a vacuum
o
flask at 4 Celsius, and the various assays carried out as described in Chapter 2.
Smoking status was confirmed by clinical history and estimation of plasma
carboxyhaemoglobin levels, as described in chapter 2. Carboxyhaemoglobin levels
were measured prior to surgery and at each subsequent sampling time.
Statistical analyses
Univariate and multivariate analysis of pre-operative patient characteristics,
blood rheology, and thrombotic mediators, were carried out by Dr Janet Love,
Research Assistant, Robertson Centre for Biostatistics, University of Glasgow, in
conjunction with Dr. G.D. Murray, Reader in Medical Statistics and Director,
Robertson Centre for Biostatistics. Univariate analysis was performed by log rank
testing (Peto et al, 1977) on an IBM-compatible microcomputer, using the BMDP
statistical software package, module 1L, and multivariate analysis performed using
Cox proportional hazards models (Module 2L) (BMDP Statistical Software Inc.,
Cork, Eire). For univariate analyses of continuous variables, patients were divided
into 2 groups: those patients who had a value above the median value for the entire
























Figure 6.2: Impedance tracings obtained from a below knee femoropopliteal vein
graft using the SciMed PVL 50 portable vascular laboratory.
179
distribution of values of FDP's, this variable was analysed after logarithmic
transformation.
All other statistical analyses were carried out by myself with the
CSS:Statistica package (Statsoft, Tulsa, USA), using non-parametric methods.
RESULTS
Graft and patient survival
There were 186 consecutive infra-inguinal bypass grafts performed on 165
patients. The mean age of patients at the time of surgery was 66 years (range 36-89
years), with a median of 67 years (interquartile range 60-72 yrs.). 15 patients
underwent bilateral grafting during the period of the study, and a further 6 patients
underwent redo bypass grafting after occlusion of a graft inserted during the study
period. With the exception of 14 grafts, all operations were carried out as non¬
urgent procedures. Sixteen patients (10%) died with patent grafts during the period
of the study (9 with vein grafts, 7 with synthetic), all but 3 deaths occurring within
3 months of operation, and 6 within 30 days of surgery. 8 patients (50%) died
following a documented cardiac event, 2 from post-operative respiratory failure, 1
following massive pulmonary thromboembolism, and the cause of death was not
stated in 5 patients. Forty-seven (47) grafts occluded within 1 year of surgery,
giving a total of 63 grafts that were classed as having a poor outcome.
Almost half the grafts were performed in patients who had undergone prior
vascular surgery, and in 70 cases (38%) surgery was carried out to relieve critical
limb ischaemia (European Working Group on Critical Limb Ischaemia, 1990).
Fifty percent of grafts were performed in current smokers (93 grafts), while 51
grafts (27%) were carried out in patients who had been non-smokers for at least 5
years (Table 6.1, p. 181). Fifty percent (93) of the grafts were carried out in
patients with evidence of other cardiovascular morbidity in addition to their
peripheral vascular disease (angina, previous myocardial infarction, atrial
fibrillation, transient ischaemic attacks or completed stroke). The severity of
peripheral arterial disease in the study group, as determined by the Bollinger
angiogram score (Chapter 3), was normally distributed (Figure 6.3, p. 182).
Patients with ischaemic ulceration and gangrene of digits were classified as having










Current smoker 55 38 8.61 (1) p = 0.01
prior vascular surgery 41 51 1.04 (1) n.s.
ischaemic heart disease 31 41 1.31 (1) n.s.
critical limb ischaemia 35 35 0.11(1) n.s.
Male sex 60 60 0.25 (1) n.s.
antiplatelet therapy 25 38 2.90 (1) p = 0.10
limb sepsis/gangrene 26 26 0.06 (1) n.s.
non-smoker ( > 5 yrs) 21 30 1.48 (1) n.s.
treated hypertension 18 27 1.69 (1) n.s.
recent smoker 14 28 6.56 (1) p - 0.05
cerebrovascular disease 10 17 1.66 (1) n.s.
diabetes mellitus 11 15 0.36 (1) n.s.
Atrial fibrillation 8 11 0.34 (1) n.s.
treated hyperlipidaemia 4 5 0.07 (1) n.s.
warfarin therapy 3 4 0.10 (1) n.s.




Figure 6.3: Distribution of Bollinger angiogram scores in patients undergoing
infra-inguinal bypass grafting.
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Synthetic grafts were removed from 2 patients while still patent, both as a
consequence of graft infection, and these grafts have been excluded from
subsequent analyses. There were therefore 184 grafts that made up the study group:
90 vein grafts and 94 synthetic grafts. Synthetic grafts consisted of 6mm. diameter
PTFE (Gore-tex, W.L. Gore & Associates (UK) Ltd, Woking, Surrey. Impra-flex,
Impra (UK) Ltd, Ascot, Berks.), or 8mm. gelatin coated knitted dacron grafts
(Gelsoft, Vascutek Ltd, Inchinnan, Renfrewshire, UK.). A number of synthetic
grafts also had a vein patch (Taylor et al, 1992) or cuff (Tyrrell & Wolfe, 1991)
interposed at the distal anastomosis.
With the exception of 2 patients unable to attend for follow up, all grafts
have been followed up for a mean of 310 days, with all but 30 of the grafts
followed up for a full year. Patency of the 2 grafts lost to follow up has been
confirmed by the patient's own General Practitioner. Table 6.2 (p. 184) gives
details of the types of graft used and the site of distal anastomosis, while the
cumulative patency rates for vein and synthetic grafts in the 1st post-operative year
are shown in figure 6.4 (p. 185). Patient characteristics were similar in both vein
and synthetic groups, with the exception of smoking habit, which was greater in
patients undergoing vein grafting (Table 6.1).
Patient characteristics and outcome
On univariate log rank testing a number of terms were found to be related
to the time of primary endpoint, defined as death or graft occlusion within 1 year
of surgery (Table 6.3, p. 186). Female sex (Fig. 6.5, p. 187), age over 67 years
(Fig. 6.6, p. 188), presence of limb sepsis or tissue necrosis (Fig. 6.7, p. 188),
emergency revascularisation (Fig. 6.8, p. 190), single vessel run off (Fig. 6.9,
p. 191), a graft to distal popliteal or calf vessels (Fig. 6.10, p. 192), a systolic
ankle pressure of less than 71mm Hg (Fig 6.11, p. 193), and an angiogram severity
score (as described in chapter 3) of over 107 (Fig. 6.12, p. 194) were all
significantly related to death and graft occlusion within 1 year of surgery. There
was no association between a poor outcome and graft material or current smoking
habit, although the post-operative use of antiplatelet therapy (aspirin or
dipyridamole), showed a trend towards a significant association with increased
cumulative primary patency (Table 6.3, p. 186, Fig. 6.13, p. 195).
Subsequent multivariate analysis of the patient characteristics, carried out on
the 130 cases in whom all data was complete, indicated that a low systolic ankle
pressure (Chi^ statistic 16.64, p < 0.0001), presence of limb sepsis or tissue
necrosis (Chi^ 7.80, p < 0.01), prior vascular surgery (Chi^ 5.11, p = 0.02),
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ANASTOMOSIS PATENT OCCLUDED(%) TOTAL
Proximal popliteal
reversed vein 46 (5) 8 (15%) 54
in-situ vein — — —
PTFE 37 (3) 11 (23%) 48
PTFE & vein cuff 3 — 3
Dacron 8 2 (20%) 10
Distal popliteal
Reversed vein 11(2) — 11
in-situ vein 3 (1) 3 (50%) 6
PTFE 6 (1) 5 (45%) 11
PTFE & vein cuff 4 — 4
Dacron 1 — 1
Crural vessel
Reversed vein 1 1 (50%) 2
in-situ vein 9 (1) 8 (47%) 17
PTFE 4 (1) 6 (60%) 10
PTFE & vein cuff 4 (2) 3 (43%) 7
Dacron —
Table 6.2: Outcome by site of distal anastomosis and material used in 184 infra-
inguinal bypass grafts. Based on a mean follow-up period of 310
days. Figures in brackets in 'patent' column indicate number of




















N STATISTIC TO p VALUE
No. calf vessels (0-3) 184 38.3 Chiz 3) p < 0.0001
Infected limb (Y/N) 184 28.79 Chi2 1) p < 0.0001
Anastomosis (AK/BK/calf) 184 25.54 Chi2 2) p < 0.0001
Systolic ankle pressure 136 23.77 Chi2 1) P < 0.0001
Elective (Y/N) 184 9.20 Chi2 1) p < 0.01
Sex 184 7.20 Chi2 1) p < 0.01
Bollinger score 173 5.92 Chi2 1) p = 0.02
Age (years) 184 5.01 Chi2 1) p = 0.03
Post-op. aspirin 184 3.38 Chi2 1) p = 0.07
Post-op warfarin 184 2.67 Chi2 1) p = 0.10
Diabetes (Y/N) 184 2.35 Chi2 1) p = 0.13
Pre-op. warfarin 184 1.92 Chi2 1) p = 0.17
Smoking (current/ex or non) 184 1.14 Chi2 1) p = 0.28
Pre-op. aspirin 184 1.00 Chi2 1) p = 0.32
other cardiovascular (Y/N) 184 0.72 Chi2 1) p = 0.40
Hyperlipidaemia (Y/N) 184 0.61 Chi2 1) p = 0.43
Graft (vein/synthetic) 184 0.31 Chi2 1) p = 0.58
Prior vascular ops. (Y/N) 184 0.21 Chi2 1) p = 0.65
Hypertension (Y/N) 184 0.01 Chi2 1) p = 0.90
Table 6.3: Results of univariate survival analyses of patient characteristics in
184 grafts. Primary endpoint defined as death or graft occlusion.



























Figure 6.5: Cumulative graft and patient survival by sex, based on univariate log
























Figure 6.6: Cumulative graft and patient survival by age, based on univariate log
rank analysis. "Young" refers to cases with an age below the median




















Figure 6.7: Cumulative graft and patient survival for patients with and without
















Figure 6.8: Cumulative graft and patient survival as determined by whether or
not surgery was carried out as an elective procedure, based on




0 9 6 5 5 2
1 49 26 20 18 11
2 55 46 44 37 31
3 70 59 57 44 36
Figure 6.9: Cumulative graft and patient survival by number of run-off vessels










Above knee 115 97 91 73 59
Below knee 33 25 22 18 14
Calf 36 16 14 13 7
Figure 6.10: Cumulative graft and patient survival by site of distal anastomosis,
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Figure 6.11: Pre-operative systolic ankle pressure values by outcome, together
with cumulative graft and patient survival. "High" refers to cases
with a pre-operative systolic ankle pressure above the median value























































Figure 6.12: Pre-operative Bollinger angiogram scores by outcome, together with
cumulative graft and patient survival. "High" refers to cases with a
Bollinger score above the median value of 107, "low" to patients

























Figure 6.13: Cumulative graft and patient survival by antiplatelet therapy, based
on univariate log rank analysis.
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female sex (Chi^ 4.93, p = 0.03), and emergency infra-inguinal bypass grafting
(Chi^ 4.78, p = 0.03), were all independently predictive of subsequent death and
graft occlusion in the 1 year following revascularisation surgery.
Blood rheology and outcome
Rheological parameters were not significantly related to graft occlusion or
death on univariate analysis (Table 6.4, p. 197), with the exception of lower red
cell aggregation (Myrenne) which showed a trend towards a significant association
with poor outcome following surgery. Both reduced haematocrit (Fig. 6.14,
p. 198), and haemoglobin (Fig. 6.15, p. 199) were related to graft occlusion and
death on univariate analysis, as were elevated platelet (Fig 6.16, p.200) and white
cell counts (Fig. 6.17, p.201).
Multivariate analysis indicated that an elevated platelet count was the only
haemorrheological variable that improved on a predictive model based solely on
patient background details (Table 6.5, p.202).
Thrombotic mediators and outcome
Increased pre-operative plasma fibrinogen (Fig. 6.18, p.203), increased von
Willebrand Factor (Fig. 6.19, p.204), increased fibrin turnover (Cross-linked
FDP's (log(FDP)), Fig. 6.20, p.205), and decreased factor VII activity (Fig.
6.21), were all related to post-operative graft occlusion and patient death on
univariate analysis while pre-operative t.P.A. and P.A.I, activity (Table 6.4) were
unrelated to the subsequent post-operative course.
On multivariate analysis, only elevated pre-operative plasma von
Willebrand Factor was independentiy predictive of subsequent graft occlusion and
patient death when tested within a model based on patient background information
(Table 6.5). When this was then added to the model it was found that prior
vascular surgery, and emergency revascularisation surgery were no longer
significant terms in the model, and pre-operative plasma von Willebrand Factor
level (Chi^ statistic 14.14, p < 0.001), systolic ankle pressure (Chi^ 8.30, p <
0.01), presence of infection or tissue necrosis (Chi^ 6.33, p = 0.01), and female
sex (Chi^ 5.01, p = 0.03), were the only terms independently related to graft and
patient survival. Tables 6.6 and 6.7 summarise the results of testing all other







vWF 184 27.45 Chi2 (1) P < 0.0001
Haemoglobin 184 17.86 Chi2 (1) P < 0.0001
Platelets 184 13.81 Chi2 (1) P < 0.001
Haematocrit 171 13.78 Chi2 (1) P < 0.001
Fibrinogen 183 12.37 Chi2 (1) P < 0.001
Log(FDP) 182 11.96 Chi2 (1) P < 0.001
Factor VII 178 9.30 Chi2 (1) P < 0.01
Cholesterol 175 6.16 Chi2 (1) P = 0.01
W.C.C. 184 3.94 Chi2 (1) P < 0.05
Red cell aggregation 166 3.37 Chi2 (1) P = 0.07
Plasma viscosity 172 2.11 Chi2 (1) P = 0.15
Relative blood viscosity 156 1.27 Chi2 (1) P - 0.26
t.P.A. 164 0.97 Chi2 (1) P = 0.32
P.A.I. 168 0.65 Chi2 (1) P = 0.42
Blood viscosity 156 0.23 Chi2 (1) P = 0.63
Table 6.4: Associations between pre-operative rheology and thrombotic
mediators, and poor outcome (death or graft occlusion) following
infra-inguinal bypass grafting (184 grafts). Univariate analysis with

























Figure 6.14: Pre-operative haematocrit values by outcome, together with
cumulative graft and patient survival. High values are cases with a
pre-operative haematocrit above the median value of 42, low have















Figure 6.15: Pre-operative haemoglobin by outcome, together with cumulative
graft and patient survival. High values are above the median pre¬





















Figure 6.16: Pre-operative platelet count by outcome, together with cumulative
graft and patient survival. High values are above the median pre¬









































Figure 6.17: Pre-operative white cell count by outcome, together with cumulative
graft and patient survival. High values refer to pre-operative white
cell count above the median value of 8.3 x KP/l. Low are cases







vWF 130 7.88 Chi2 (1) P < 0.01
Platelets 130 4.09 Chi2 (1) P = 0.04
t.P.A. 118 3.22 Chi2 (1) P = 0.07
Hct. 120 2.19 Chi2(l) P = 0.14
Factor VII 126 1.48 Chi2 (1) P = 0.22
Red cell aggregation 119 1.25 Chi2 (1) P = 0.26
Relative blood viscosity 114 0.56 Chi2 (1) P = 0.45
Cholesterol 125 0.56 Chi2 (1) P = 0.46
w.c.c. 130 0.42 Chi2 (1) P = 0.52
Plasma viscosity 125 0.28 Chi2 (1) P = 0.59
Fibrinogen 129 0.06 Chi2 (1) P = 0.81
Log(FDP) 130 0.05 Chi2 (1) P = 0.82
P.A.I. 120 0.03 Chi2 (1) P = 0.86
Blood viscosity 114 0.01 Chi2 (1) P = 0.92
Haemoglobin 130 0.00 Chi2 (1) P = 0.97
Table 6.5: Associations between pre-operative rheology and thrombotic
mediators, and poor outcome (death or graft occlusion) following
infra-inguinal bypass grafting (184 grafts). Multivariate analysis by
Cox's proportional hazards model, after adjusting for patient
background information (sex, systolic ankle pressure, limb infection,






































Figure 6.18: Pre-operative plasma fibrinogen levels by outcome, together with
cumulative graft and patient survival. High refers to pre-operative





























Figure 6.19: Pre-operative von Willebrand Factor levels by outcome, together
with cumulative graft and patient survival. High values are those
above the median pre-operative vWF level of 141 iu/dl, low are








































Figure 6.20: Pre-operative cross-linked FDP's by outcome, together with
cumulative graft and patient survival by log(FDP). High values are
those above the median pre-operative value for log(FDP) of 5.223,
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Figure 6.21: Pre-operative Factor VII levels by outcome, together with
cumulative graft and patient survival. High values refer to Factor
VII levels above the pre-operative median level of 106%. Low refers







Diabetes (Y/N) 130 3.03 Chi2 (1) P = 0.08
Anastomosis (AK/BK/calf) 130 2.38 Chi2 (2) P = 0.30
Post-op warfarin 130 2.11 Chi2 (1) P = 0.15
Prior vascular ops. (Y/N) 130 1.81 Chi2 (1) P = 0.18
Pre-op. warfarin 130 1.57 Chi2 (1) P = 0.21
Post-op. aspirin 130 1.33 Chi2 (1) P = 0.25
Hyperlipidaemia (Y/N) 130 1.03 Chi2 (1) P = 0.31
Elective (Y/N) 130 0.68 Chi2 (1) P = 0.41
Bollinger score 130 0.20 Chi2 (1) P = 0.65
Pre-op. aspirin 130 0.18 Chi2 (1) P = 0.67
No. calf vessels (0-3) 130 0.06 Chi2 (3) P = 0.81
Hypertension (Y/N) 130 0.05 Chi2 (1) P = 0.83
Age 130 0.04 Chi2 (1) P = 0.84
Smoking (current/ex or non) 130 0.03 Chi2 (1) P - 0.87
other cardiovascular (Y/N) 130 0.00 Chi2 (1) P - 0.95
Graft (vein/synthetic) 130 0.00 Chi2 (1) P = 0.99
Table 6.6: Significance of patient characteristics on multivariate survival
analysis after correcting for the effects of von Willebrand Factor,







Platelets 130 2.77 Chi2 (1) p = 0.10
Red cell aggregation 119 2.25 Chi2 (1) p = 0.13
t.P.A. 118 1.98 Chi2 (1) p = 0.16
Log(FDP) 130 1.66 Chi2 (1) p = 0.20
Haematocrit 120 0.63 Chi2 (1) p = 0.43
Plasma viscosity 125 0.56 Chi2 (1) p = 0.45
Relative blood viscosity 114 0.45 Chi2 (1) p = 0.50
Factor VII 126 0.40 Chi2 (1) p = 0.53
Blood viscosity 114 0.37 Chi2 (1) p = 0.54
Fibrinogen 129 0.22 Chi2 (1) p = 0.64
P.A.I. 120 0.13 Chi2 (1) p = 0.71
Cholesterol 125 0.07 Chi2 (1) p = 0.80
W.C.C. 130 0.03 Chi2 (1) p = 0.86
Haemoglobin 130 0.00 Chi2 (1) p =0.99
Table 6.7: Significance of blood rheology and thrombotic mediators on
multivariate survival analysis after correcting for the effects of von
Willebrand Factor, systolic ankle pressure, sex, and limb sepsis.
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The coefficients from this final Cox proportional hazards model were then
scaled and rounded to give a risk scoring system as follows:
Score = vWF - (2.5 x ankle pressure) + (115 x sex) + (127 x infection)
(where Sex = 1 if male, 2 if female, and infection = 0 if absent, 1 if present)
whereby the higher the risk score, the greater the incidence of death or graft
occlusion. Confidence intervals for the relative hazards associated with varying
values of the covariates in the final model are shown in Table 6.8 (p.210), and
Figure 6.22 (p.211) illustrates Cox model survival curves for differing risk scores.
Graft surveillance: duplex scanning
There were 159 grafts patent at discharge from hospital, however 16 grafts
(12 synthetic and 4 vein grafts) occluded prior to the first post-operative duplex
scan, 5 patients died during this period, and 2 grafts were lost to follow up. There
were therefore 136 grafts (68 synthetic and 68 vein grafts) that entered the program
of duplex scanning at 3, 6, and 12 months post-operatively, and a total of 312
duplex examinations have been performed in the course of the study.
Duplex scanning identified 12 vein grafts (18% of those entering
surveillance) as being at risk, and in which stenosis (8 grafts) or arteriovenous
fistulae (1 graft) were confirmed by angiography. There were 3 grafts that
occluded prior to angiography. 2 further vein grafts occluded following a 'normal'
duplex scan, while 2 arteriovenous fistulae and a distal in-situ vein graft stenosis
were detected in grafts reported as normal on duplex scanning. Overall there were
7 false negative examinations, and 4 false positive examinations in the 68 vein
grafts undergoing surveillance (Table 6.9, p.212), giving a sensitivity of 0.63, and
a specificity of 0.97 for the use of colour duplex scanning in vein graft
surveillance.
In the 68 synthetic grafts undergoing surveillance, there were positive
duplex scan findings in 2 of 8 grafts that subsequently occluded, consisting of
evidence of popliteal stenosis beyond the graft in one case, and a kink in the graft
in the other. In a further graft, thrombus identified within the lumen at the 6
monthly visit (Figure 6.23, p.213), was seen to be resolved at 12 months post¬
operatively, and there were 3 false positive duplex scans. With a total of 157 scans
being performed on synthetic grafts during the study, this gives a sensitivity of
0.33, and a specificity of 0.98 for the use of colour duplex scanning in the post¬
operative surveillance of synthetic grafts.
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RELATIVE POINT
VARIABLE HAZARD FOR ESTIMATE 95% C.I.
Systolic
ankle pressure L.Q vs U.Q 2.44 1.27-4.66
Sex Female v male 2.11 1.09-4.10
Infection yes v no 2.29 1.20-4.37
vWF (iu/dl) U.Q vs L.Q 1.78 1.34-2.37
Table 6.8: Confidence interval for relative hazards for varying values of
covariates in the final model, where L.Q is the lower quartile and
U.Q the upper quartile.
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03 6 9 12
TIME (months)
NUMBERS AT RISK
130 103 95 82 65
Figure 6.22: Cox model survival curves for infra-inguinal bypass grafts based on
the risk assessment score described in the text.
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SCAN APPEARANCE NUMBER OF GRAFTS
Duplex & D.S.A. positives 12
proximal graft stenosis 7
mid graft stenosis 1
arteriovenous fistula 1
mid-graft stenosis 2*
low flow along graft 1*
Duplex positive/D.S.A. negative 4
Duplex negative/D.S.A. positive 7
arteriovenous fistulae 2
run off deterioration 2
distal graft stenosis 1
grafts occluded 2*
Duplex negative/no D.S.A. 132
indicates grafts in which occlusion occurred prior to angiographic
confirmation of non-invasive surveillance results.
Table 6.9: Results of duplex scanning in 68 vein grafts over a 1 year period.
All positive scans confirmed by angiography. False negatives
identified by angiography performed on grafts identified as "at risk"
by other surveillance methods.
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Figure 6.23: Intra-arterial D.S.A. demonstrating thrombus accumulation at the
lower end of an above-knee synthetic femoropopliteal bypass graft.
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Graft surveillance: Doppler and impedance
There were 49 grafts (28 vein and 21 synthetic) that underwent Doppler
insonnation and impedance measurement in addition to colour duplex scanning, and
19 grafts were identified as at risk (Table 6.10, p.215). All grafts confirmed to be
"at risk" by angiography had an impedance value above 0.55, with the exception of
one graft that occluded prior to angiography (Fig. 6.24, p.216). However this graft
had high frequencies on direct insonnation with a 4Khz Doppler probe, and was
classed as "at risk" on the basis of this finding.
The sensitivity of impedance measurement in the identification of "at risk"
infra-inguinal grafts (vein and synthetic) is therefore 0.95, rising to 1.0 with the
addition of direct graft insonnation with a continuous wave Doppler probe, while
the specificity of the investigation is 0.91.
Graft material and blood rheology
The median values of rheological parameters in synthetic and vein grafts
that remained patent and free from stenosis and run-off deterioration, were plotted
against each other to highlight any differences in the haemorrheological response to
revascularisation. Haematocrit-corrected blood viscosity (Fig. 6.25, p.217), plasma
viscosity (Fig 6.26, p.218), and relative blood viscosity (Fig. 6.27, p.219),
followed a similar pattern in both vein and synthetic grafts with median values
remaining static, or falling gradually, in the year following surgery, although
following insertion of a vein graft plasma viscosity rose transiently before returning
to baseline values. Red cell aggregation (Myrenne) fell significantly 3 months
following insertion of a synthetic graft (Fig. 6.28, p.220), but thereafter levels
were similar in vein and synthetic grafts.
Both white cell count and platelet count were unchanged following
revascularisation surgery, with graft material having no effect on the median values
over the first post-operative year.
Graft material and thrombotic mediators
Most potential thrombotic mediators were unaffected by the material used as
the bypass conduit: Alterations in plasma fibrinogen (Fig 6.29, p.221) following
revascularisation were affected by graft type initially, but median values were
similar to pre-operative levels by 6 months post-operatively. Levels of von
Willebrand Factor (Fig. 6.30, p.222) fell gradually following revascularisation
with either synthetic or vein grafts. Plasminogen Activator Inhibitor (Fig. 6.31,
p.223), and Factor VII activity (Fig. 6.32, p.224), remained unchanged following
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IMPEDANCE FINDINGS NUMBER OF GRAFTS
Impedance & D.S.A. positive 18
run off deterioration 5
grafts occluded 3*
proximal graft stenosis 3
other graft stenosis 3
arteriovenous fistula 3
distal graft stenosis 1
Impedance positive/D.S.A. negative 12
Impedance negative/insonnation positive 1
graft occluded 1 *
Impedance negative/negative or no D.S.A. 126
indicates grafts in which occlusion occurred prior to angiographic
confirmation of impedance and graft insonnation results.
Table 6.10: Results of impedance measurement in 49 grafts over a 1 year period.
All positive findings based on an impedance value over 0.55 and
confirmed by angiography. False negatives identified by








Figure 6.24: Impedance values in grafts remaining patent, and in grafts with








PRE-OP. SPECIMEN IS t=0
Figure 6.25: Serial changes in median blood viscosity following vein and








PRE-OP. SPECIMEN IS t=0
Figure 6.26: Serial changes in median plasma viscosity following vein and


































PRE-OP. SPECIMEN IS +=0
Figure 6.27: Serial changes in median relative blood viscosity following vein and








PRE-OP. SPECIMEN IS t=0
Figure 6.28: Serial changes in median red cell aggregation levels following vein

















PRE-OP. SPECIMEN IS +=0
Figure 6.29: Serial changes in median plasma fibrinogen following vein and



































PRE-OP. SPECIMEN IS t=0
Figure 6.30: Serial changes in median von Willebrand Factor levels following
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PRE-OP. SPECIMEN IS +=0
Figure 6.32: Serial changes in median Factor VII levels following vein and
synthetic infra-inguinal bypass grafting.
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revascularisation, regardless of the graft material used, while tissue Plasminogen
Activator (Fig 6.33, p.226), showed a minimal increase following synthetic
grafting, remaining unchanged following successful vein grafting.
Post-operative fibrin turnover was greatly affected by the graft material
employed in the revascularisation surgery (Fig 6.34, p.227). In the year following
insertion of a successful vein graft, the median level of FDP's was slightly reduced
over the year, while insertion of a synthetic graft resulted in a marked elevation in
FDP's that was apparent 3 months after surgery, and persisted unchanged over the
following 9 months.
Post-operative changes and vein graft stenosis
There were 11 vein grafts that were shown to have developed stenoses
within the graft in the 6 months following surgery, and in these 11 cases
rheological and thrombotic parameters were unchanged from their pre-operative
levels at the 3 month assessment (all p > 0.2, Wilcoxon matched pairs testing),
while in the 46 vein grafts with no evidence of stenosis, run off deterioration, or
arteriovenous communications, white cell count ( p < 0.01), plasma fibrinogen
(p < 0.02), and von Willebrand Factor (p < 0.02) levels, had all fallen
significantly 3 months following revascularisation (all Wilcoxon matched pairs
testing) (Table 6.11, p.228). However when pre-operative values of these variables
are plotted against their values at 3 months post-operatively, there are no
significant differences in response between stenosed and normal vein grafts, with
the exception of von Willebrand Factor levels (Figure 6.35, p.229). The
differences between pre- and post-operative levels of white cell count and
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VARIABLE PRE-OP. POST-OP. PAIRS
No stenosis
W.C.C.(xl09/l) 8.4 (6.9-9.6) 7.2 (6.5-9.0) p < 0.02
Fibrinogen (g/1) 3.6 (3.0-4.3) 3.3 (2.5-3.7) p = 0.02
vWF (iu/dl) 120 (97-181) 106 (80-151) p = 0.02
Stenosis
W.C.C.(xl09/l) 8.5 (7.2-9.3) 7.2 (6.4-9.0) p = 0.29
Fibrinogen (g/1) 3.6 (2.8-4.7) 3.2 (2.8-4.2) p = 0.93
vWF (iu/dl) 122 (78-180) 148 (125-164) p = 0.40
Table 6.11: Pre- and post-operative white cell count (W.C.C.), plasma
fibrinogen, and von Willebrand Factor (vWF) levels in 46 patent
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Figure 6.35: Change in von Willebrand Factor levels 3 months after bypass
grafting in patent and stenosed vein grafts.
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DISCUSSION
Graft and patient survival
The cumulative primary patency rates for this series of consecutive
femoropopliteal and femoro-distal grafts, are similar to results reported from other
centres (Evans et al, 1981, Hobson et al, 1985, Wiseman et al, 1989, Bergamini et
al, 1991, McCollum et al, 1991B), with a patency rate of around 80% for vein
grafts, and just below 70% for synthetic grafts. Although some authors claim
significantly better results (Leather et al, 1988, Taylor & Porter, 1991, Taylor et
al, 1992) these are often based on retrospective studies, and meaningful comparison
with results from other centres are hampered by the lack of uniform patient
selection and reporting standards (Rutherford & Becker, 1991).
The angiographic disease severity in this study was normally distributed.
The results support the data that vein grafts perform better than synthetic grafts, in
particular when the anastomosis is to distal popliteal or calf vessels (reviewed by
Kempczinski et al, 1990). There were no significant differences in patient
characteristics between the 2 graft types in this study to account for the difference
in outcome, with an increased number of current smokers in the vein grafts being
the solitary significant difference between the 2 groups. Further sub-analyses by
type of synthetic material employed are unfortunately rendered of little value by the
small numbers in each group.
A 1 year mortality rate of 10% for this group of patients, over one-third of
whom were classified as critical limb ischaemia, confirms the high mortality rate
consequent on associated cardiac and cerebrovascular disease in patients with
PAOD (Norgren, 1990, Dormandy, 1991, Dormandy & Murray, 1991). The 30-
day post-operative mortality rate of 6 patients in 186 procedures (3%) is higher
than rates quoted by other authors (Harris et al, 1986, Mannick et al, 1991,
Cheshire et al, 1992), probably as a consequence of the higher percentage of
patients with critical limb ischaemia in this series. Most of the patients dying
outwith this 30-day period died within 3 months of successful revascularisation and
are therefore unlikely to have obtained significant benefit from the procedure prior
to death.
Graft surveillance
Recognition of the need for surveillance of infra-inguinal vein grafts has
existed for many years (Breslau & DeWeese, 1965), with up to 30% of such grafts
developing asymptomatic fibrous strictures (Szilagyi et al, 1973). In the vein grafts
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studied here, 14 (21%) were thought to have developed significant stenoses on non¬
invasive vascular laboratory tests, 9 of which were confirmed by angiography, and
these figures are in keeping with other reported series (reviewed by Varty et al,
1993). Most of these grafts have subsequently undergone successful intervention to
maintain graft patency, and this tends to confirm the value of a surveillance
program in improving the long-term patency of vein grafts (Harris, 1992).
Surveillance of synthetic grafts rarely identified any correctable lesion that led to
subsequent graft occlusion, and it seems unlikely that long term patency of infra-
inguinal synthetic grafts can be improved by graft surveillance.
The surveillance program confirmed the sensitivity of impedance analysis in
the identification of 'at risk' grafts (Wyatt et al, 1991), and the addition of a simple
graft insonnation technique improved sensitivity even further. Both these
techniques require less capital outlay, and may be easier to learn, than colour
duplex scanning, which was again shown to be deficient in the detection of run-off
deterioration (Harris, 1992), and was a less sensitive screening technique than has
been reported elsewhere (Renton et al, 1991). Both the lack of sensitivity and the
surprising inability of colour duplex scanning to identify arteriovenous fistulae in
in-situ vein grafts were at least partly due to operator inexperience in the initial
stages of the surveillance program, although it would appear that duplex scanning
is an unreliable method of assessing run-off vessels in the calf.
The accuracy of the figures for vein graft stenosis derived from these
observations is obviously open to question, as only grafts with positive findings on
review subsequently underwent direct imaging with angiography or intra-arterial
digital subtraction angiography. The incidence of stenosis in grafts with normal
findings at surveillance remains unknown in the absence of angiography, and the
true false negative rate cannot be calculated. However, grafts have been followed
up for up to 1 year post-operatively, and no vein grafts have occluded in the
presence of negative surveillance findings. All vein graft occlusions occurred
within 6 months of surgery, and it must be assumed that any undetected vein graft
stenoses would have declared themselves by graft occlusion within the study
period. This assumption rests on the belief that all haemodynamically significant
vein graft stenoses ultimately progress to graft occlusion, and this may not be so
(DeWeese & Green, 1991). It could be that the incidence of vein graft stenosis in
this series is greater than claimed, if a number of "benign stenoses" are escaping
detection by non-invasive imaging techniques, although the importance of such
strictures is unlikely to be significant in terms of graft outcome.
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Two other important conclusions to draw from this surveillance program are
the need for graft surveillance to be carried out early in the post-operative course,
as a large number of grafts occlude prior to their first surveillance visit at 3
months, and the importance of early angiography following a positive vascular
laboratory assessment, as prolonged delay will inevitably lead to occlusion before
intervention can be undertaken. Although many of the early graft occlusions
occurred in synthetic grafts, there were a number of occlusions in vein grafts that
may have been preventable with earlier surveillance and prompt detection of
stenoses or flow anomalies.
In summary these studies confirm that post-operative surveillance of infra-
inguinal vein grafts leads to increased identification of lesions that may
compromise long term patency, thus enabling intervention to prolong patency. This
work also suggests that impedance analysis offers a surveillance technique that
appears to be more reliable than duplex scanning (Davies et al, 1993), requires less
capital outlay, and which, with the addition of a simple Doppler insonnation test,
has a sensitivity of 100%. An ideal surveillance program would however include
early assessment of grafts prior to hospital discharge, in addition to vascular
laboratory assessment at 3, 6, and 12 months post-operatively, with rapid
angiography following a positive surveillance visit. These measures should
significantly improve the 1-year patency rate for infra-inguinal vein grafts.
Patient characteristics and outcome
A large number of patient and graft characteristics have been shown to
affect the outcome of infra-inguinal bypass grafting (Buda et al, 1976, Harris et al,
1987, Rutherford et al, 1988, Tordoir et al, 1993), and this is confirmed on
univariate analysis in this study. Many of these variables undoubtedly contribute to
graft occlusion for mechanical reasons, with high Bollinger angiogram scores, a
low ankle systolic pressure, grafts to below knee vessels, and to single run off
vessels, all being measures of the extent of arterial disease, and factors clearly
identified as contributing to graft failures (Rutherford et al, 1988, Budd et al,
1990), although not previously associated with post-operative death.
Post-operative mortality was responsible for less than 30% of cases of poor
outcome, mortality being attributed to cardiac causes in 50% of cases, a similar
rate to that reported elsewhere (Dormandy, 1991), and the association between
patient characteristics and mortality is presumably weaker than the association with
graft occlusion. There is however evidence that advanced vascular disease is
associated with a higher mortality than claudication alone (Norgren, 1990,
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Dormandy & Murray, 1991), and other studies have suggested that a low ante¬
brachial pressure index is associated with subsequent mortality in patients with
peripheral arterial occlusive disease (Dormandy, 1991). The inclusion of post¬
operative deaths with graft occlusion in the poor outcome category is justified in
view of the fact that all but 3 of the deaths occurred within 3 months of surgery,
indicating that any benefit from revascularisation was short lived.
Multivariate regression analysis indicated that ankle systolic pressure was
the determinant of disease severity with most influence on subsequent outcome,
although prior vascular surgery, and emergency revascularisation procedures were
also independently associated with poor outcome in an initial model based on
patient characteristics alone, their influence on outcome disappearing when
thrombotic mediators were added to the outcome model. Thus the assessment of
disease severity with the greatest predictive value for the outcome following infra-
inguinal revascularisation was the systolic ankle pressure, which is one of the
simplest techniques available!
The association between age and poor outcome on univariate analysis could
be predicted from the observations in Chapter 3 that disease severity increases with
age. Concomitant cardiac disease and post-operative mortality also increase with
age (Franco et al, 1990), while the association of female sex with a poor outcome
may be a consequence of increased graft occlusion secondary to the smaller vessel
diameter in women. Age and female sex remain significant predictors of outcome
in multivariate analysis, together with the presence of limb sepsis or tissue
necrosis, which in addition to reflecting poor distal circulation, may influence
outcome by their tendency to elevate inflammatory reactants and thrombotic
mediators such as fibrinogen (Cook & Ubben, 1990, Meade, 1992), therefore
increasing the rate of graft occlusion.
Neither smoking habit, nor graft material were significantly related to
outcome in this study, in contrast to findings in other series (Wiseman et al, 1989,
Budd et al, 1990, Tordoir et al, 1993). The influence of graft material however
appeared to be confined to grafts to infragenicular vessels (Rutherford et al, 1988),
which accounted for a minority of cases in this study, and although no significant
difference was observed in terms of outcome, graft patency was greater for vein
grafts at all levels of anastomosis. The lack of any smoking-related effect on
outcome may be consequent upon small numbers of non-smokers, although other
studies have also failed to find a significant relationship between smoking habit and
graft patency (Budd et al, 1990).
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In summary, although several previously identified risk factors for graft
occlusion were found to be significantly associated with a poor outcome following
infra-inguinal bypass grafting on univariate analysis in this study, the only factors
that remained significantly associated with poor outcome following multivariate
analysis were female sex, the presence of limb sepsis, advanced age, and a low
ankle systolic pressure in the affected limb. Some of these factors may be
detrimental to the outcome of infra-inguinal revascularisation surgery by virtue of
their tendency to increase levels of potentially harmful thrombotic mediators such
as fibrinogen, and further studies investigating the effects of reducing plasma
fibrinogen levels in these patients are required.
Blood rheology and outcome
There did not appear to be any relationship between blood rheology and the
outcome of revascularisation surgery in this study, despite the presence of various
mechanisms by which abnormal blood rheology could contribute to graft occlusion
(Lowe, 1986, Lowe, 1992, Koenig & Ernst, 1992). Reduced haematocrit and low
haemoglobin were related to a poor outcome on univariate analysis, but not when
other variables were taken into consideration, while an elevated platelet count
appeared to be independently associated with a poor outcome until potential
thrombotic mediators were also considered in the predictive model.
The link between elevated platelet count and a poor outcome was reinforced
by the observation that post-operative antiplatelet therapy (aspirin) is associated
with a good outcome. This observation failed to reach statistical significance, but is
similar to the findings of other studies that have examined the effects of antiplatelet
therapy on infra-inguinal graft patency (McCollum et al, 1991A). Although these
studies have failed to prove conclusively that post-operative aspirin therapy
improves graft patency there is however evidence that antiplatelet therapy reduces
vascular mortality in patients with a history of cardiac and cerebrovascular disease
(Antiplatelet trialists collaboration, 1988), as well as in peripheral vascular disease
(McCollum et al, 1991A).
The univariate associations of low haematocrit and haemoglobin, and
elevated white cell count, with a poor post-operative outcome may reflect the effect
of limb sepsis and tissue necrosis on these variables: Infection and tissue necrosis
promote a leucocytosis (Walter & Israel, 1987D), while the low haemoglobin and
haematocrit reflect the haematological stress response (Reizenstein, 1979) to
chronic sepsis. The value of an elevated pre-operative white cell count as a
predictor of femoropopliteal graft failure has recently been confirmed (Thomas et
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al, 1993). If these increases in white cell count are associated with increased levels
of white cell activation products, which have been shown to be both toxic to
vascular endothelium (Sacks et al, 1978, Smedly et al, 1986) and to have a
vasoconstrictive action on atherosclerotic vessels (Lopez et al, 1989, Miigge et al,
1991), then this could be the means by which limb sepsis and tissue necrosis
promote a poor outcome following revascularisation surgery, and this merits
further investigation.
Thrombotic mediators and outcome
The observation that levels of potential thrombotic mediators are related to
poor outcome following revascularisation surgery has not been reported previously,
with the exception of the association between elevated fibrinogen and subsequent
outcome following revascularisation (Hamer et al, 1973, Harris et al, 1988,
Wiseman et al, 1989). The association of elevated fibrinogen with graft occlusion
may reflect a mechanism by which other risk factors, such as smoking, act to bring
about graft occlusion (Wiseman et al, 1989), a belief supported by the observation
that elevated fibrinogen is not independently associated with poor outcome in this
study.
The elevation in fibrinogen in poor outcome cases in this study may partly
reflect its correlation with disease extent, and is partly a consequence of infection,
which is known to increase fibrinogen levels (Cook & Ubben, 1990), probably via
the production of interleukin-6 by monocytes (Ritchie et al, 1982, Reid, 1991).
The highly significant independent association of pre-operative limb sepsis with a
poor post-operative outcome that was observed in these studies, may be a result of
the associated elevation in plasma fibrinogen which may predispose to thrombosis
by increasing atheroma (Smith et al, 1990, 1992), increasing fibrin formation
(Meade, 1992), and increasing platelet aggregation (Meade, 1992). All of these
mechanisms could ultimately lead to either graft occlusion, or cardiac events
secondary to coronary artery occlusion, and current evidence indicates that plasma
fibrinogen may play a significant role in both these events (Wiseman et al, 1989,
Meade, 1992).
The association of elevated FDP's with a poor outcome on univariate
analysis is partly a measure of the relationship between disease severity and
outcome following revascularisation surgery. It has previously been demonstrated
that FDP levels are independently predictive of the angiographic severity of arterial
disease (Chapter 3), and it may be that the association between elevated FDP levels
and poor outcome observed in this study is a consequence of the associations
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between markers of increased disease severity and a poor outcome. In this respect
FDP's may be merely another indicator of the extent of arterial disease, although
their predictive capacity would appear to be of little significance alongside systolic
ankle pressure in the final model.
Low factor VII levels were also associated with a poor outcome on
univariate analysis, a finding previously observed in a multicentre study which
showed associations between low factor VII levels, and both graft occlusion and
myocardial infarction on univariate analysis (Cortellaro et al, 1992). In this study
the associations also disappeared on multivariate analysis, and it is likely that any
association between factor VII levels and graft outcome may be a consequence of
infection reducing factor VII levels (Meade, 1991).
von Willebrand Factor is a plasma glycoprotein that has been shown to be
an essential requirement for the development of occlusive thrombi at sites of
arterial injury (Brinkhous et al, 1991), and an association between elevated vWF
levels and poor outcome following infra-inguinal grafting may indeed be causal:
vWF is important in platelet adhesion to subendothelium at sites of vessel injury,
and the mechanism of platelet adhesion and activation is dependent on the presence
of vWF, such that if vWF is absent, mural thrombi will not form at sites of injury
(reviewed by Badimon & Fuster, 1992).
Elevated levels of vWF may therefore lead to increased platelet adhesion
and thrombus formation within diseased native vessels, perhaps promoting graft
occlusion by compromising inflow and outflow vessels. Anastomotic sites may also
be prone to increased thrombus formation, as these are areas where endothelial
injury occurs at the time of surgery, and also sites of increased shear rates due to
the anatomical arrangement of the end-to-side anastomosis. Increased shear rates at
sites of arterial injury are thought to contribute to increased platelet deposition
(Badimon & Fuster, 1992), and this may be more marked in the presence of
increased plasma vWF.
Elevated pre-operative vWF levels may therefore theoretically lead to an
increased rate of occlusive intravascular thrombus, with subsequent graft occlusion
or cardiac mortality, and the findings in this study of an independent association
between elevated vWF levels and poor post-operative outcome (both death and
graft occlusion) would support this belief.
This association between elevated vWF levels and poor outcome following
infra-inguinal revascularisation may be amenable to pharmacological manipulation
to maintain graft patency: Although post-operative antiplatelet agents may be of
some benefit in peripheral arterial disease (Antiplatelet Trialists Collaboration,
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1988, McCollum et al, 1991A), presumably as a consequence of the role of
platelets in thrombus formation (reviewed by Smith, 1991), it may be that in the
presence of abnormally high vWF levels, platelet adherence and aggregation (and
subsequent thrombus formation) occur without the requirement for Thromboxane
A2 release. This would account for the limited effects of antiplatelet therapy on
post-operative graft patency, as aspirin therapy has no effect on vWF levels (Reid,
1991). An alternative approach, aimed at reducing vWF levels, may therefore be
required to improve graft patency. Such an approach could involve the use of
monoclonal antibodies to vWF, currently used in experimental models to
investigate the role of vWF in thrombogenesis (Badimon & Fuster, 1992), and
further studies are required to assess the value of this form of therapeutic
intervention.
In the absence of any currently available pharmacological means of
improving the outcome of infra-inguinal bypass grafting apart from antiplatelet
therapy, an alternative is to improve the results of such surgery by improving pre¬
operative patient selection. The use of a risk scoring system that considers
thrombotic mediators in addition to patient characteristics (Budd et al, 1990), may
offer a more accurate method of assessing the suitability of an individual for infra-
inguinal revascularisation procedures, although the scoring system developed from
these studies requires further prospective validation before it can be used to assist
in patient selection.
In summary, a number of potential thrombotic mediators were elevated pre-
operatively in cases of infra-inguinal bypass grafting with a poor outcome, and
these elevations may promote increased thrombus formation. Only elevated von
Willebrand Factor levels were independently related to poor outcome, and this may
be a consequence of its role in platelet aggregation and thrombus formation.
Increased levels of fibrinogen and fibrin turnover may be the means by which other
independently predictive risk factors, such as limb sepsis and disease severity,
contribute to graft occlusion and death.
These findings offer the potential for future pharmacological therapy, but at
present the use of a pre-operative risk scoring system incorporating vWF offers the
best means of improving the results of infra-inguinal revascularisation surgery by
identifying patients unlikely to benefit from attempts at reconstructive surgery.
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Graft material & blood rheology
There appear to be few major changes in rheological variables in the first
year following successful infra-inguinal revascularisation surgery. This suggests
that the alterations in blood rheology that are observed in patients with PAOD, is
not a consequence of tissue ischaemia alone, as successful revascularisation fails to
reverse the changes in blood rheology.
The graft material employed does not appear to influence blood rheology
over the first post-operative year, with the pre-operative differences in the 2 graft
material groups being maintained at subsequent sampling, and median values
remaining almost constant over the period of the study.
Graft material and thrombotic mediators
Most potential thrombotic mediators are unaffected by the graft material
employed, and show little change from their pre-operative levels in the year
following revascularisation, despite transient alterations in the early post-operative
period that are probably related to the resolution of limb sepsis, and the acute phase
response that accompanies surgery.
This relative stability in levels of thrombotic mediators following surgery
indicates that successful infra-inguinal revascularisation does little to reverse the
potentially thrombogenic abnormalities observed in patients with PAOD. This may
be a consequence of post-operative improvements in thrombotic parameters being
offset by progression of arterial disease following revascularisation, or a reflection
of a genetic influence on the levels of some variables such as fibrinogen
(Humphries et al, 1987, Fowkes et al, 1992), which maintains potential thrombotic
mediators at an abnormally high level.
Synthetic infra-inguinal grafting appears to result in a prolonged increase in
fibrin turnover, and elevated FDP's are found for at least 12 months, indicating
that the fibrin layer found within synthetic grafts (DeBakey et al, 1964) is a
dynamic layer that is constantly being remodelled and altered. This is further
supported by the observation that t.P.A. levels rise, and P.A.I, levels fall, in the
period following synthetic grafting. Overall this indicates a shift in favour of
fibrinolysis, and this is probably required to lyse the fibrin that is continuously
deposited within the graft. Subsequent lysis of this fibrin will prevent occlusion and
further studies will be required to determine whether or not the level of fibrin
turnover in synthetic grafts is related to long-term patency.
It is notable that analysis of the small number of vein grafts in whom
stenoses were detected by the surveillance program, indicates that plasma
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fibrinogen and von Willebrand Factor levels remained elevated following
revascularisation, in contrast to cases where the vein graft remained patent and free
from stenoses in the initial post-operative year. As already discussed, vWF is
required for platelet adhesion and thrombus formation (Smith, 1991, Badimon &
Fuster, 1992), while fibrinogen has been identified in atherosclerotic plaques (Bini
et al, 1989), and although the pathogenesis of vein graft stenosis is unclear (Varty
et al, 1993), the observations made in these studies may be of relevance to the
aetiology of vein graft stenosis. In view of the small numbers of cases studied, and
the limitations of the graft surveillance program, more detailed investigation is
however required to determine the significance of these observations.
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Summary
Elevated levels of von Willebrand Factor, a glycoprotein with a role in
platelet-vessel wall interaction, have been shown to be independently associated
with a poor outcome following infra-inguinal revascularisation, and a risk scoring
system which takes this and other pre-operative patient characteristics into
consideration has been developed to assist in pre-operative patient selection.
Elevation in vWF levels may play a role in the pathogenesis of infra-
inguinal graft occlusion through its effects on platelet aggregation, while the effects
of other patient characteristics that are independently associated with outcome
(ankle pressure, sex, infection) may be mediated in part by elevated levels of other
potential thrombotic mediators such as fibrinogen.
Blood rheology and thrombotic mediators are not significantly altered
following successful revascularisation surgery, although there is some evidence
from these studies that the response to surgery may be influenced by the graft
material employed, and by the development of post-operative vein graft stenoses.
Further studies are required to clarify whether or not these observations are causal
in nature.
The use of a non-invasive graft surveillance program has been confirmed to
be of value in the detection of vein graft stenosis, and should be commenced early
in the post-operative course. The use of computer-assisted impedance measurement
offers a reliable and inexpensive alternative to colour duplex scanning in vein graft
surveillance, and this finding has not previously been reported in a prospective
study. These studies however, failed to identify any technique that was of value in





Blood Rheology and disease severity
The absence of any significant change in plasma viscosity and red cell
aggregation in cases with peripheral arterial occlusive disease, reported in this
thesis, together with the significant reduction in blood viscosity and relative blood
viscosity, contradict previously reported findings in patients with symptomatic
peripheral arterial occlusive disease (Dormandy et al, 1973A, Ernst & Matrai,
1987, Reid, 1991). This may reflect the nature of the control population selected
for comparison, which was a random population sample, rather than an age-
matched group of disease-free patients, but is more likely to be related to the
severity of the PAOD in the patient group studied.
Previous studies of blood rheology in arterial disease have concentrated on
patients with mild to moderate claudication (Dormandy et al, 1973A), implying a
skewed distribution of disease severity in favour of mild disease. This contrasts
with the Gaussian distribution of angiographically assessed disease severity in the
patient population studied in this thesis, all of whom had disease severe enough to
merit consideration for reconstructive surgery, that is, moderate to severe
claudication, or rest pain and critical limb ischaemia. The studies in patients with
critical limb ischaemia (Chapter 4) indicate that severe arterial disease is associated
with a reduction in plasma proteins, and while it is possible that plasma viscosity is
increased in patients with mild arterial disease, the effects of advanced PAOD
appear to favour a reduction in plasma proteins, the net effect being that there is no
significant difference between the median plasma viscosity in the patients studied,
and that in age-matched population controls.
The findings of a reduced blood viscosity in addition to other features of a
haematological stress response (Reizenstein, 1979) to chronic peripheral arterial
occlusive disease suggest that the rheological changes observed in PAOD are a
consequence of the biochemical and haematological responses to the disease state,
while the observations made in previous studies reflect the effects of an increase in
fibrinogen on blood and plasma viscosity (Reid, 1991). In more advanced PAOD
the effects of fibrinogen on viscosity are offset by the changes in plasma proteins
that accompanies the haematological stress response.
The belief that the rheological changes found in association with PAOD are
a response to the disease process is further supported by the lack of any
independent associations between rheological parameters and angiographic severity
of disease in the patients studied, and by the observation that revascularisation of a
critically ischaemic limb results in a normalisation of rheological parameters
(Chapter 4).
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There is now an increasing body of evidence that reversible tissue ischaemia
is associated with a number of biochemical events leading to cellular damage and
an inflammatory response (Shearman et al, 1988, Hickey et al, 1990, Adiseshiah et
al, 1992, Hickey et al, 1993) and these may precipitate alterations in blood
rheology as a consequence of the release of inflammatory mediators. Many of these
events are thought to be mediated by neutrophil products (Romson et al, 1983,
Neumann et al, 1990, Welbourn et al, 1991), and levels of the monocyte product
IL-6 are elevated in cases of peripheral arterial disease (Reid, 1991). It is therefore
important to investigate white cell activation in future clinical studies in peripheral
arterial disease by measuring markers of neutrophil activation (e.g. elastase) and
monocyte activation (e.g. interleukin-6), and determining the relationship between
these products, blood rheology, and arterial disease.
Thrombotic mediators and disease severity
This thesis has demonstrated that levels of cross-linked fibrin degradation
products (FDP's) are independently associated with the angiographic severity of
occlusive arterial disease, and that plasma fibrinogen and von Willebrand Factor
(vWF) show a trend towards significant independent association on multivariate
analysis. These associations between potential thrombotic mediators, and a direct
assessment of disease severity, have not been reported previously.
The confirmation that levels of potential thrombotic mediators are elevated
in comparison with age-matched population controls, provides further evidence that
the biochemical environment in patients with occlusive arterial disease is capable of
promoting increased thrombus formation. The presence of increased fibrin turnover
reflects increased thrombus formation that may result in an increase in
atherosclerosis (Thompson et al, 1990, Lorenzet et al, 1992), while the
accompanying elevations in plasma fibrinogen and vWF will further increase
thrombus formation (Brinkhous et al, 1991), with the elevation in P.A.I, levels
resulting in inhibition of fibrinolysis. Despite failing to show independent
correlation with disease severity, elevations in fibrinogen and vWF may be one
means by which age and limb sepsis influence the severity of arterial disease, with
advancing age increasing fibrinogen levels (Meade, 1992), while vWF has some of
the characteristics of an acute-phase reactant (Smith, 1991).
The existence of a prothrombotic environment in patients with occlusive
arterial disease is maintained after resolution of critical limb ischaemia (Chapter 4),
indicating that associations between potential thrombotic mediators and disease
severity are not a solely a consequence of tissue ischaemia. The post-
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revascularisation fall in plasma fibrinogen, vWF, and t.P.A. levels, results from
the resolution of limb sepsis, as these mediators are increased in inflammatory
conditions (Smith, 1991, Meade, 1992), but their failure to return to normal
population levels implies that additional factors influence plasma levels of these
potential thrombotic mediators. These are probably related to cigarette smoking
(Wiseman et al, 1989, Reid, 1991, Blann, 1991, 1992) and in the case of
fibrinogen, an additional genetic effect (Thomas et al, 1991, Fowkes et al, 1992),
although further studies into fibrinogen genotype are required. The persisting
prothrombotic state following revascularisation surgery has not previously been
reported and has important implications for the longer-term results of surgery.
Studies into the use of pharmacological therapies aimed at lowering levels of
potential thrombotic mediators (Meade, 1992) in patients with PAOD, are therefore
required.
Percutaneous angioplasty
This procedure has become the mainstay of treatment in claudication, and
has also been recommended in critical limb ischaemia (Lu et al, 1982). The studies
undertaken for this thesis confirm that in appropriate cases the short-term success
rate of angioplasty is excellent. The comparison of venous and peri-lesional arterial
samples refutes the suggestion (Schwartz et al, 1989) that local alterations in
haemorrheological parameters are responsible for the development of
atherosclerotic lesions at specific sites, and this has not previously been reported.
In view of the tendency for patients undergoing angioplasty to have less
severe arterial disease than patients undergoing reconstructive surgery, it is not
surprising that angioplasty produces few changes in rheological parameters, which
remain similar to those encountered in age-matched controls both prior to and
following angioplasty. This suggests that the biochemical changes associated with a
chronic disease state are not found in the presence of the less severe arterial
occlusive lesions typically selected for angioplasty, and is further evidence that
rheological alterations in claudicants are secondary to biochemical changes that
accompany advanced PAOD.
The immediate effects of angioplasty on intra-arterial thrombotic mediators
mirror the pathophysiological changes that have been demonstrated to result from
balloon angioplasty (Block et al, 1980, 1981, Castaneda-Zuniga et al, 1980, Brady
& Warren, 1991), with changes in thrombotic mediators that reflect endothelial
damage and fibrin deposition at the site of angioplasty. These changes are however
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transient, and successful angioplasty produces no long term alterations in levels of
thrombotic mediators, with the sole exception of cross-linked FDP's.
The persisting elevation in fibrin turnover (FDP's) that accompanies
successful angioplasty may be required to prevent thrombus formation at the site of
angioplasty leading to restenosis. This is supported by the observation that fibrin
turnover remains unchanged in cases with evidence of restenosis following
angioplasty, although only a small number of patients fell into this category.
Alternatively, in view of the independent association of FDP's with the
angiographic severity of disease, the increase in FDP levels following angioplasty
may indicate progression of arterial disease (Fowkes et al, 1993) as a consequence
of successful angioplasty. There is experimental evidence that subcritical stenoses
enhance distal arterial disease (Bomberger et al, 1981), and the endothelial injury
and fibrin formation occurring at sites of angioplasty, may result in such a stenosis,
which could promote distal disease progression. A more likely explanation of this
finding however, is that successful angioplasty restores normal flow to the arterial
tree distal to a stenosis. This will increase contact between atherosclerotic distal
vessels and blood, with a subsequent increase in fibrin turnover as fibrin is
deposited in the vicinity of atheromatous plaques.
Recent evidence suggests that elevations in FDP levels are also predictive of
subsequent coronary events (Fowkes et al, 1993), although this is not proven to be
a causal association. It remains to be seen whether or not the increase in FDP
levels following angioplasty increases the coronary risk in patients with PAOD.
These potentially detrimental effects of angioplasty, and the possible role of
fibrin turnover in restenosis following angioplasty, require to be studied in more
detail in a much larger patient population, with a longer period of follow-up,
ideally with angiographic studies to determine outcome more accurately.
Infra-inguinal bypass grafting
These studies have confirmed that the results of femoropopliteal and
femoro-distal grafting are poorer than for more proximal procedures, and that up to
one-quarter of vein grafts will develop stenoses within 6 months of surgery. These
findings confirm the value of a graft surveillance program (Harris, 1992). Analysis
of the results of duplex scanning and impedance measurement indicate that both
techniques will adequately detect graft stenoses, with impedance measurement
having the added advantage of assessing distal run-off in addition to the graft itself.
The adoption of a graft surveillance program based on either of these techniques,
with angiography reserved for grafts identified as "at risk" on initial screening, will
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enable pre-emptive treatment of graft stenoses, thus improving the long-term graft
patency without the risks and expense of routine angiographic imaging in all infra-
inguinal grafts.
Having demonstrated a strong association between potential thrombotic
mediators and disease severity, the results in this thesis have also indicated that
many thrombotic mediators have a role in graft occlusion and post-operative death.
Of particular relevance is the strong independent association of elevated vWF with
graft occlusion and death. The influence of other patient characteristics such as age,
and limb sepsis on poor outcome are possibly a consequence of the increased levels
of fibrinogen and other potential thrombotic mediators which accompany these
conditions, and which were elevated in cases with a poor outcome.
The link between vWF and graft occlusion may be causal, with evidence
from animal studies that vWF is an essential requirement for the development of
occlusive thrombi, having a major role in platelet-endothelial adhesion at high
shear rates (Badimon & Fuster, 1992). High shear rates are typically encountered
at vascular anastomoses. It is therefore possible that graft failure is a consequence
of increased vWF levels which are present prior to surgery, and which may
increase further in response to surgery (Smith, 1991). The effects of increased
vWF levels on intravascular thrombus formation have not been directly studied,
although circumstantial evidence of an increased thrombotic tendency in association
with elevated vWF does exist (Zwaginga et al, 1990). The clinical effects of
reducing vWF levels on graft patency would provide more substantial proof of the
role of vWF in graft occlusion, and such studies should be performed.
Before these studies can be performed however, a suitable method of
reducing plasma vWF must be found. The effects of currently available
antithrombotic agents on vWF levels have not been studied, with the exception of
low dose warfarin (Reid, 1991), although post-operative anticoagulation appears to
improve post-operative survival following femoropopliteal bypass grafting
(Kretschmer et al, 1988), and merits further investigation in this situation, as does
the use of low-molecular weight heparins. An alternative approach would be to use
monoclonal antibodies against vWF, which are effective in reducing vWF levels in
experimental animal models (reviewed by Badimon & Fuster, 1992), and studies
aimed at assessing the effects of these and other antithrombotic agents on both
thrombotic mediators and graft survival, are required. Such studies of graft
survival as have already been performed, have been hampered by the differences in
descriptive criteria employed in different studies, which utilise subjective
assessments of disease severity (Rutherford & Becker, 1991). If future studies
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involve the pre-operative determination of levels of thrombotic mediators this may
provide objective assessment of disease severity, with a more reliable comparison
between different series.
The development of a predictive risk index for the pre-operative assessment
of patients being considered for infra-inguinal revascularisation, has the potential to
improve on current assessment techniques, most of which are based on mechanical
considerations alone (Parvin et al, 1985, Beard et al, 1989, Bell, 1991, Thompson
et al, 1992), ignoring the potential contribution of the composition of the blood that
will be required to flow through the graft, despite some evidence that altered levels
of thrombotic mediators are associated with graft occlusion (Hamer et al, 1973,
Wiseman et al, 1989). This thesis has considered the information routinely obtained
pre-operatively in patients with PAOD, and on which the decision to operate is
made. Multivariate analysis indicates that determination of pre-operative vWF
levels provides important additional information, increasing the pre-operative
ability to predict subsequent outcome in patients being considered for infra-inguinal
revascularisation. The use of such a risk scoring system should therefore improve
pre-operative patient selection, and reduce the number of early graft failures that
leading to subsequent amputation, although it requires further validation before
being adopted in routine clinical practice.
There was, in addition, evidence that prolonged post-operative elevations in
vWF and perhaps also white cell count, were related to the development of vein
graft stenosis in the patients studied, and this preliminary finding merits further
investigation with a larger number of patients. More detailed assessment of white
cell activation, involving determination of white cell activation markers such as
neutrophil elastase, and interleukin-6, would perhaps provide further information in
this situation.
Prolonged determination of levels of potential thrombotic mediators
following successful infra-inguinal grafting indicated that some of the alterations
associated with PAOD were only partly reversed by revascularisation, again
implying that tissue ischaemia is not the sole cause of the abnormalities seen. In
addition it is apparent that a significant increase in fibrin turnover persists
following insertion of a synthetic graft. This indicates a dynamic deposition of
fibrin within such a graft that is not seen with the use of autogenous vein, and in
view of the potential of FDP's to enhance the development of atherosclerosis
(Thompson et al, 1990, Lorenzet et al, 1992), together with their association with
the progression of peripheral arterial disease, and with coronary events (Fowkes et
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al, 1993) the use of such grafts, when autogenous vein is available, must be called
into question.
Summary
This thesis has demonstrated that increased levels of the potential
thrombotic mediators fibrinogen and vWF, together with increased fibrin turnover
(as determined by levels of cross-linked fibrin degradation product levels) are
related to the presence and severity of peripheral arterial occlusive disease.
Revascularisation surgery fails to return the levels of these thrombotic mediators to
normal population values, and elevated pre-operative von Willebrand Factor levels
are predictive of post-operative graft occlusion and death. This association may be
causal through an effect on intravascular thrombus formation and further studies
are required to determine whether or not reducing the levels of potential thrombotic
mediators will improve graft and patient survival. In addition a predictive risk
index has been developed to assist in the identification of patients unlikely to
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INTRODUCTION
A number of authors have related abnormalities of blood and plasma viscosity, fibrin
degradation products (FDP), and markers of endothelial damage (von Willebrand Factor,
vWF) in venous blood to peripheral and coronary arterial disease in man (1,2,3,4,5,6). Altered
levels of these variables have also been accorded prognostic significance in some reports, and
some may have a role in the pathogenesis of the lesions of atherosclerosis (7,8,9).
Although venous sampled for estimation of these haemostatic and rheological variables are
collected for such studies, it has never been shown that the results obtained from venous
sampling accurately represent the haemostatic and rheological state encountered in arterial
blood. In order to confirm that results obtained from venous sampling in patients with
peripheral arterial disease, reflect the composition of the blood in their diseased arterial tree,
we have compared blood viscosity, FDP levels, and vWF levels in peripheral venous blood
samples, with those in arterial blood sampled from the vicinity of symptomatic arterial
stenoses, in 14 patients undergoing percutaneous angioplasty.
MATERIALS AND METHODS
Fasting venous samples were obtained, without stasis, from the ante-cubital veins of 15
patients (mean age 63yrs, S.D.Ilyrs) with symptomatic peripheral arterial disease, using a 19-
gauge needle. Diagnosis of peripheral vascular disease was based on an ankle-brachial
pressure index (ABPI) of less than 0.85, together with a fall in the ABPI on walking, and a
Seldinger arteriogram showing a stenosis of greater than 50% at a site appropriate to the
symptoms. Arterial samples were obtained between 2 and 4 hours later at angioplasty, when
samples of arterial blood were taken through a size 5 french angiography catheter, at the site
Key words: blood viscosity, fibrin degradation products, von Willebrand factor,
peripheral arterial disease
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of the arterial lesion (8 downstream of an iliac stenosis, 7 upstream from a superficial femoral
lesion), prior to any interventional procedure being undertaken. Both arterial and venous
samples were handled in an identical manner prior to being assayed.
Plasma and whole blood viscosity were measured at 37°C and high shear rates ( >300s"^ )
within 4 hours of sampling, in samples anticoagulated with Ko EDTA (Monoject, Sherwood
Medical, U.K.), using a Coulter capillary viscometer (Coulter Electronics, Luton, Beds.
U.K.). Haematocrit was estimated by the Hawksley micro-centifuge method (Hawksley and
Son Ltd., Lancing, W.Sussex, U.K.), and from these values the haematocrit-corrected blood
viscosity was calculated (10).
Cross-linked FDP levels were measured using a commercially available ELISA test (Agen
Ltd. Parsippany, New Jersey, U.S.A.), and von Willebrand factor estimation was carried out
by ELISA (Dako, High Wycombe, U.K.). Both assays were performed on plasma obtained
from 9ml blood anticoagulated with 1ml of 3.2% trisodium citrate, and centrifuged at 4
degrees centigrade for 15 mins. Plasma was stored at -70°C until assay, and both venous and
arterial samples were assayed in the same batch to minimise inter-assay variation.
Control values for all variables were obtained from samples of venous blood obtained for this
purpose from an age matched local population study.
All assays on arterial and venous samples were compared by Wilcoxon matched pairs test
using the CCS:Statistica package (Statsoft, Tulsa, USA) on microcomputer.
RESULTS
In 2 of the 15 patients there was evidence of significant haemodilution in the arterial samples
(as a result of flushing the angioplasty catheter with heparinised saline), with a greater than
25% fall in haematocrit between the 2 samples, and these patients were therefore excluded
from further analysis. In the remaining 13 patients (Table 1) there were no significant
differences in either plasma or whole blood viscosity between the venous samples, and the
peri-lesional arterial sample, nor between arterial and venous levels of cross-linked F.D.P.
However venous levels of von Willebrand Factor were significantly higher than in
corresponding arterial samples (p=<0.05 Wilcoxon matched pairs test). There were no
significant differences between the results obtained from superficial femoral or iliac samples.
TABLE 1
Comparison of arterial and venous samples in 13 patients with symptomatic peripheral
arterial disease. Results are given as median values (interquartile range).
Mean venous level
Variable in population Venous Arterial
Plasma Viscosity (mPa.s) 1.32 1.30(1.27-1.38) 1.28 (1.24-1.37)
Whole blood
viscosity (mPa.s) 3.38 3.31 (3.11-3.56) 3.25 (3.06-3.40)
Haematocrit 44.2 45 (42-48) 44 (43-45)
Corrected
blood viscosity (mPa.s) 3.41 3.31 (3.21-3.59) 3.29 (3.19-3.34)
F.D.P.s (ng/ml) 83 101 (82-126) 100 (78-149)
vWF (i.u./dl) 109 123 (113-147) 76 (56-101)
Vol. 13, No. 4 RHEOLOGY AND ARTERIAL DISEASE 517
DISCUSSION
Altered blood viscosity in patients with peripheral arterial disease, has been demonstrated in a
number of studies (1,2,3), and some authors have suggested that local alterations in
rheological parameters may have a role in the distribution of the lesions of atherosclerosis
(11). Pathological studies in patients with peripheral arterial disease have implicated fibrin
deposition in the development of the arterial lesions (7,9), and in addition there is evidence
implicating increased fibrin turnover in the disease process, elevated levels of cross-linked
fibrin degradation products (F.D.P.) having been demonstrated in patients with symptomatic
peripheral arterial disease (6,12).
These findings have however all been made in venous blood samples, taken from the ante-
cubital vein, and in view of the focal nature of the lesions of atherosclerosis, the situation in
arterial blood may be different. Our results however indicate that venous sampling represents
an accurate reflection of the composition of arterial blood in patients with symptomatic
peripheral arterial disease, with the exception of von Willebrand Factor antigen levels, which
appear to be consistently slightly lower in arterial blood. The reason for this difference is not
known, but may reflect decreased production from a damaged arterial endothelium at sites of
stenosis.
The lack of any significant difference in blood and plasma viscosity between arterial and
venous samples confirms that the elevated viscosity encountered in venous blood in patients
with advanced peripheral arterial disease is present in arterial blood also, where, in the
presence of arterial stenoses, it is likely to make a significant contribution to altered flow
dynamics.
The similarity between arterial and venous levels of cross-linked F.D.P. levels indicates that
any contribution that altered fibrin turnover makes to peripheral arterial disease, and in
particular to the progression of atherosclerotic plaques (7,9), is not made by local alterations
in fibrin turnover at the sites of development of symptomatic stenoses. The elevated levels of
F.D.P. levels that have been documented in peripheral arterial disease (6,12,14), appear to
reflect a systemic alteration in fibrin turnover.
In summary our results refute any suggestion of local alterations in haemostatic and
Theological parameters at the sites of symptomatic lesions in patients with peripheral arterial
disease, and confirm that venous blood sampling provides an accurate reflection of the
composition of arterial blood in such patients, although it consistently overestimates the
concentration of vWF antigen present in arterial blood samples taken from the vicinity of a
symptomatic stenosis. Further studies are required to study the nature of this arterio-venous
difference.
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